



US007473762B2

(12) **United States Patent**  
**Foster et al.**

(10) **Patent No.:** **US 7,473,762 B2**  
(45) **Date of Patent:** **Jan. 6, 2009**

(54) **PROTEINS AND POLYPEPTIDES FROM  
COAGULASLASE-NEGATIVE  
STAPHYLOCOCCI**

(75) Inventors: **Timothy J. Foster**, Templeogue (IE);  
**Kirk McCrea**, Houston, TX (US);  
**Magnus A. O. Hook**, Houston, TX (US);  
**Stacy Davis**, Houston, TX (US);  
**Deirdre Nieldhin**, The Coombe (IE);  
**Orla Hartford**, Duleek (IE)

(73) Assignees: **The Provost Fellows and Scholars of  
the College of the Holy and Undivided  
Trinity of Queen Elizabeth Near  
Dublin**, Dublin (IE); **The Texas A&M  
University System**, College Station, TX  
(US)

(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 627 days.

(21) Appl. No.: **10/689,082**

(22) Filed: **Oct. 21, 2003**

(65) **Prior Publication Data**

US 2004/0142348 A1 Jul. 22, 2004

**Related U.S. Application Data**

(62) Division of application No. 09/386,962, filed on Aug.  
31, 1999, now Pat. No. 6,635,473.

(60) Provisional application No. 60/117,119, filed on Jan.  
25, 1999, provisional application No. 60/098,443,  
filed on Aug. 31, 1998.

(51) **Int. Cl.**  
**C07K 14/00** (2006.01)  
**C12N 15/00** (2006.01)

(52) **U.S. Cl.** ..... **530/350**; 435/69.1; 536/23.7

(58) **Field of Classification Search** ..... None  
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,380,370 B1 4/2002 Doucette-Stamm et al.

FOREIGN PATENT DOCUMENTS

WO WO 97/48727 \* 12/1997

\* cited by examiner


*Primary Examiner*—Sean R McGarry

(74) *Attorney, Agent, or Firm*—B. Aaron Schulman; Stites &  
Harbison PLLC

(57) **ABSTRACT**

Proteins and polypeptides from coagulase-negative staphylo-  
coccal bacteria such as *S. epidermidis*, including proteins  
designated SdrF, SdrG and SdrH, and their effective frag-  
ments such as their respective A domains, are provided which  
are useful in the prevention and treatment of infection caused  
by coagulase-negative staphylococcal bacteria such as *S. epi-  
dermidis*. The SdrF, SdrG and SdrH proteins are cell-wall  
associated proteins that specifically bind host proteins and  
which each have a highly conserved motif of which the con-  
sensus sequence is TYTFTDYVD (SEQ ID NO: 16). The  
proteins and polypeptides may be useful in generating antibod-  
ies for the diagnosis and treatment of coagulase-negative  
staphylococcal infections.

**14 Claims, 28 Drawing Sheets**



S.EPIDERMIDIS STRAIN K28 SdrG

**FIG. 1**

## CODING SEQUENCE FOR SdrF - INCLUDES FLANKING SEQUENCES

tattggataaaattatgcttataaagattttacataaaaaatgtaaatgcaatttacaagta  
Y W I N Y A Y K V F T - K C K C N L Q V  
aatattcaaatatttccttgtaaaatatttttaactggagggtatagtagtaaaaaag  
N I Q I I S L - N I Y F N W R Y S M K K  
agaagacaaggaccaattacaagagagtggtttctatccaacaaggtaaacaaagtac  
R R Q G P I N K R V D F L S N K V N K Y  
tcgattaggaagttcacagtaggtacagcttcaataactcgtgggtacgtaaatgttt  
S I R K F T V G T A S I L V G A T L M F  
ggtgccgcagacaatgaggctaaaggctgaagacaatcaatagaaatcagcttcaaaa  
G A A D N E A K A A E D N Q L E S A S K  
gaagaacagaaggtagtgcgtgataatgaaactcaaaacttaactcaagtcgatttagac  
E E Q K G S R D N E N S K L N Q V D L D  
aacggatcacatagttctgagaaaacaacaatgtaaacactgcaactgaagtaaaaaaa  
N G S H S S E K T T N V N N A T E V K K  
gttgagcaccacgacaagtgacgtatcttaagcctaaagctaatgaagcagtagtgacg  
V E A P T T S D V S K P K A N E A V V T  
aatgagtaactaaacaaaacaagcaccactgttaatgaggaatcaatagct  
N E S T K P K T T E A P T V N E S I A

FIG. 2

gaaaccccaaacctcaactacacaacaagaattcgactgagaagaataatccatcttta  
E T P K T S T T Q Q D S T E K N N P S L  
aaagataatttaaatcctcaacgacatctaaagaagtaaacagacagacaatctct  
K D N L N S S T T S K E S K T D E H S  
actaagcaagctcaaatgtactaataaatcaaatcttagacacaaatgactctccaact  
T K Q A Q M S T N K S N L D T N D S P T  
caaagtgaaaaacttcatcacaagcaataacgacagtacagataatcagtcagcacct  
Q S E K T S S Q A N N D S T D N Q S A P  
tctaaacaattagattcaaaaaccatcagaacaaaagtatatataaaacaaaatttaatgat  
S K Q L D S K P S E Q K V Y K T K F N D  
gaacctactcaagatgttgaaacacagacaactaaattaaacaccttctgtttcaaca  
E P T Q D V E H T T T K L K T P S V S T  
gatagttcagtcaatgataagcaagattacacacgaagtgctgtagctagtttaggtgtt  
D S S V N D K Q D Y T R S A V A S L G V  
gattctaatgaacagaagcaattacaatgcagttagagacaatttagatttaaagct  
D S N E T E A I T N A V R D N L D L K A  
gcatctagagaacaaatcaatgaagcaatcattgctgaagcactaaaaaagacttttct  
A S R E Q I N E A I I A E A L K K D F S  
aacctgattatgggtgcgatacgccatttagctctaaacagatctcaatcaaaaaattca  
N P D Y G V D T P L A L N R S Q S K N S

FIG. 2(cont'd)

ccacataagagtgcaagtcaccgcatgaatttaatgagtttagctgctgagccctaatagt  
P H K S A S P R M N L M S L A A E P N S  
ggtaaaaatgtgaatgataaaagttaaaatcaaaaaccctacgcttccacttaataagagt  
G K N V N D K V K I T N P T L S L N K S  
aataatcacgctaataacgtaataatggccaacaagtaacgaacaatttaatttaaagca  
N N H A N N V I W P T S N E Q F N L K A  
aattatgaattagatgacagcataaaagaggagagatactttactatataagtaggtcag  
N Y E L D D S I K E G D T F T I K Y G Q  
tataatgacgggtggttagaacttcctgcaataaaaactcaactacgtagtaaggat  
Y I R P G G L E L P A I K T Q L R S K D  
ggctctattgtagctaattggttatatgataaaaactacaatacgcgacttatacat  
G S I V A N G V Y D K T T N T T Y T F

*FIG. 2(cont'd)*

actaactatgttgatcaataatcaaaaataattacaggtagtttggatttgaatttggacgcct  
T N Y V D Q Y Q N I T G S F D L I A T P  
aagaggaaacagcaattaaggataatcagaattatcctatggaaagtgacgattggctaac  
K R E T A I K D N Q N Y P M E V T I A N  
gaagtagtcaaaaagacttcattgtggattatggtaataaaaaggacaatacaactaca  
E V V K K D F I V D Y G N K K D N T T T  
gcagcggtagcaaatgtggataatgtaataataaacaatacgaagtgttatttctaaac  
A A V A N V D N V N N K H N E V V Y L N  
caataaaccctaaataatgctaaataatttctcaacagtaaaaaatgggtgaattt  
Q N N Q N P K Y A K Y F S T V K N G E F  
ataccaggtgaagtgaagtctacgaagtacggatccaatgcgattgtagatagcttc  
I P G E V K V Y E V T D T N A M V D S F  
aatcctgatttaaatagttctaatgtaaaagatgtgacaagtcaatttgcacctaaagta  
N P D L N S S N V K D V T S Q F A P K V  
agtgcagatggtagagttgatataatcaatttggctagaagtatggcaaatggtaaaaag  
S A D G T R V D I N F A R S M A N G K K  
tataattgtaactcaagcagtgagaccaacgggaactggaaatgtttataccgaatatgg  
Y I V T Q A V R P T G T G N V Y T E Y W  
ttaacaagagatggtagtaccatacaaatgattttaccgtggaaacgaagtctacaacg  
L T R D G T T N T N D F Y R G T K S T T

FIG. 2(cont'd)

gtgacttatctcaatgggttcttcaacagcacaggggataatcctacatatagttctagggt  
 V T Y L N G S S T A Q G D N P T Y S L G  
 gactatgtatggtagataaaaaataaaacgggttcaagatgatgagaaaggttta  
 D Y V W L D K N K N G V Q D D E K G L  
 gcagggtttatgttactcttaagacagtaacaatagagaattacaacgtgtaactact  
 A G V Y V T L K D S N N R E L Q R V T T  
 gatcaatctggacattatcaatttgataatttacaanaatggaacgtacacagtcgagttt  
 D Q S G H Y Q F D N L Q N G T Y T V E F  
 gcgattcctgataattatacgcattctccgcaataattctacaatgatgcaatagat  
 A I P D N Y T P S P A N N S T N D A I D  
 tcagatggtaacgtgatggttacacgtaagtagttgttgccaaggaaacaattaataat  
 S D G E R D G T R K V V A K G T I N N  
 gctgataatagactgtagatactggcttttatttaactcctaatacaatgctcggagat  
 A D N M T V D T G F Y L T P K Y N V G D  
 tatgtatgggaagatacaaaaataaagatgggtatccaagatgacaatgaaaagggaatttct  
 Y V W E D T N K D G I Q D D N E K G I S  
 ggtgtaaaagtaacgttaaaaaataaaaatggagatactattggcaacaacgacaacagat  
 G V K V T L K N K N G D T I G T T T D  
 tcaaatggtaaatatgaattcacaggtttagagaacggggattacacaatagaatttgag  
 S N G K Y E F T G L E N G D Y T I E F E

FIG. 2(cont'd)

acgccggaaggctacacaccgactaaacaaactcgggaagtgacgaaaggtaaatca  
T P E G Y T P T K Q N S G S D E G K D S  
aacggtacgaaacaacagtcacagtcacaagatgcagataataaacaatagactcaggt  
N G T K T T V T V K D A D N K T I D S G  
ttotacaagccaacataataacttaggtgactatgtatgggaagatacaataaagatggt  
F Y K P T Y N L G D Y V W E D T N K D G  
attcaagacgacagtgaaaaaggatttctggggttaaagtgacggttaaagaataaaat  
I Q D D S E K G I S G V K V T L K D K N  
ggaatgccattgggacaacgacaacagcagcaagtggtcattatcaatttaaaggatta  
G N A I G T T T D A S G H Y Q F K G L  
gaaaatggaagctacacagttgagtttgagacaccatcaggttatcacaccgacaaagcg  
E N G S Y T V E F E T P S G Y T P T K A

*FIG. 2(cont'd)*



aattcagggtcaagataaactgtagattccaacgggtataacaacaacagggtatcattaac  
N S G Q D I T V D S N G I T T G I I N  
ggagctgataatctacaattgatagtggtttctacaacaacccaataatagtgctgga  
G A D N L T I D S G F Y K T P K Y S V G  
gattatgtatgggaagatacaaaaataaagatgggtatccaagatgacaatgaaaagggaatt  
D Y V W E D T N K D G I Q D D N E K G I  
tctgggttaaagtaacgttaaaggatgaaaaggaaataataatgacactacaacaact  
S G V K V T L K D E K G N I I S T T T  
gatgaaaatgggaagtatcaatttgataattagatagtggttaattacattatcattttt  
D E N G K Y Q F D N L D S G N Y I I H F  
gagaaaccggaaggcatgactcaaacactacagcaaatcttgaaatgatgataaagat  
E K P E G M T Q T T A N S G N D D E K D  
gctgatgggaagatgttcgttactgattactgacatgactgactttagtatagataat  
A D G E D V R V T I T D H D D F S I D N  
ggttatttgacgatgattcagacagtgactcagacgagatagtgattcagactcagac  
G Y F D D S D S D S D A D S D S D S D  
agtactcggacgcagacagcattctgacgcagacagtgactcagacgagatagtgat  
S D S D A D S D S D A D S D S D A D S D  
tctgactcagacagcactcagacgagatagtgattccgattcagacagcagcactcggat  
S D S D S D A D S D S D S D S D S D

FIG. 2(cont'd)

tcagatagtgattcggatgcagacagcgcgactcggattctgacagtgattctgacgcgacagac  
S D S D S D A D S D S D S D S D S D S D S D A D  
agtactcagattcagacagtgactcggattcagacagcgcgattcggattcggattcagac  
S D S D S D S D S D S D S D S D S D S D S D  
agtactcggattcagacagtgactcagactccgacagtgattcggattcagatagcagac  
S D S D S D S D S D S D S D S D S D S D S D  
tccgacgcagatagtgattcggacgcagacagtgactcagattcagacagtgattcggac  
S D A D S D S D A D S D S D S D S D S D S D  
gcagacagtgactcggactcagatagtgattcagatgcagacagcgcgattcagactcagat  
A D S D S D S D S D S D A D S D S D S D  
aggactcggattcagacagcgcgactccgacgcagacagcgcgactcggattcagatagtgat  
S D S D S D S D S D A D S D S D S D S D  
tctgactcagacagtgactcagattccgatatgattcggattcagatagtgattcggac  
S D S D S D S D S D S D S D S D S D S D  
gcagacagcgcgattcggattccgatatgactcagactcagacagcgcgattcagattcagac  
A D S D S D S D S D S D S D S D S D S D  
aggactcagatagtgattcggacgcgactccgacgcgacagcgcgactcagacagcgcgactcagac  
S D S D S D S D S D A D S D A D S D S D  
gcagacagtgattcagatgcagacagcgcgattctgactcagatagtgactcagacgcgacat  
A D S D S D A D S D S D S D S D S D A D

FIG. 2(cont'd)

agtattccgattccgattagcgatttcagatttctgatttagtgactcagactcagacagtgac  
S D S D S D S D S D S D S D S D S D S D S D  
tcagattccgattagcgactcggatttcagatttagtgatttccgacgcagacagtgactcagac  
S D S D S D S D S D S D S D A D S D S D  
tcagattagtgactcggattccgatttagtgattccgacgcagacagcgatttctgactcagat  
S D S D S D S D S D A D S D S D S D  
agtactcagacgcagattagtgattccgatttccgatttagcgatttccgattcggattgcagacagcgac  
S D S D A D S D S D S D S D S D A D S D  
tcggattcagattagtgattccgacgcagacagtgactcagactcagatagtgactcggat  
S D S D S D S D A D S D S D S D S D S D  
tccgattagtgattccgacgcagacagcgatttccgatttccgattagcgatttccgactcagac  
S D S D S D A D S D S D S D S D S D S D

FIG. 2(cont'd)

agcattcagattcagacagcgactcagattccgatatgtgattccgattcagacagtgac  
 S D S D S D S D S D S D S D S D S D S D S D  
 tcggattccgatatgtactcagactcagacagtgactcagattcagatagcgactcagat  
 S D S D S D S D S D S D S D S D S D S D S D  
 tcagacagtgattcggactcagatagtgactccgattcagacagtgattcggattccgat  
 S D S D S D S D S D S D S D S D S D S D S D  
 agcattcggattccgatatgtactcggattcagacagtgattcggactcagacagcgac  
 S D S D S D S D S D S D S D S D S D S D S D  
 tcgattcagatagtgattccgactcagacagcgattcggattccgatatgtgactcggat  
 S D S D S D S D S D S D S D S D S D S D S D  
 tcagacagtgattcggactcagacagcgactccgattcagatagtgattccgacgcagac  
 S D S D S D S D S D S D S D S D S D S D A D  
 agcactccgattcagatagtgattcggacgcagacagcgattccgatatgtgactcggat  
 S D S D S D S D S D A D S D S D S D S D  
 tcagacagtgattcggactcagacagcgattccgattcagacagtgactcggactcagat  
 S D S D S D S D S D S D S D S D S D S D S D  
 agcactcggattcagacagtgactcggactcagatagtgactccgattcagacagcgac  
 S D S D S D S D S D S D S D S D S D S D S D  
 tcggattctgataaaaatgcaaaagataaattacctgatcacaggagcaaatgaagatcat  
 S D S D K N A K D K L P D T G A N E D H

FIG. 2(cont'd)

gattctaaaggcacattacttgggaactttatttgcaggtttaggagcattattattagga  
D S K G T L L G T L F A G L G A L L L G  
agacgtcgtaaaagataaagaataaagcactatttgattcattcataagttattt  
R R R K K D N K E K \* H Y - F I H K L F  
caagccagggtctatatatggccctgggtttgaaatcatattaaattgaaaggagaaaaagatga  
Q A R S I W P G L K S Y - I E R R K R -  
gtatgg  
V W

*FIG. 2(cont'd)*

SdrG coding and flanking sequences.  
atattgcaaaaaagacttataataactataattgtatttttactctagaaaacgatttttactttgaa  
I A K K T Y I L Y C I L L - K R F L L E  
aattacattgaaatagtcaagataaggagtttttatgatataaaaaaaataatttacta  
N Y I E I V K D K E F L - L K K N N L L  
actaaaaaagaaacctatagcaataaataccaataaataatgcaattagaaaaattcacagta  
T K K P I A N K S N K Y A I R K F T V  
ggtacagcgtctattgtaataggtcagcattattgtttggttaggtcataatgagggcc  
G T A S I V I G A A L L F G L G H N E A  
aaagctgaggagaatacagtaagcgttaagattcgaatatggatgatgaattatca  
K A E E N T V Q D V K D S N M D D E L S  
gatagcaatgatcagtcagtaataagaagaagaatgatgtaataatcaataatagtcagtca  
D S N D Q S S N E E K N D V I N N S Q S  
ataaacaccgatgatgataaccaataaaaaagaagaacgaatagcaacgatgccata  
I N T D D N Q I K K E E T N S N D A I  
gaaaatcgctctaaagataatacacagtcacaacaatgtagatgaaaacgaagcaaca  
E N R S K D I T Q S T F N V D E N E A T  
ttttacaagaagaccctcaagataataactcagcttaagaagaagtggtaaaagaaccc  
F L Q K T P Q D N T Q L K E E V V K E P  
tcatcagtcgaatcctcaaatcattcagtgatgactgcccaacaaccatctcacaaca  
S S V E S S N S S M D T A Q Q P S H T T

FIG. 3

ataaatgtagcatctattcaacaagtgataatgaagaaaattcccgcgtatcagat  
I N S E A S I Q T S D N E E N S R V S D  
tttgtaacttaaaaatagagagtaaacactgaatccaataaagaagagaatactata  
F A N S K I I E S N T E S N K E E N T I  
gagcaacctaaagaagagaagattcaataacaagtcacaaccgtctagctataaaaat  
E Q P N K V R E D S I T S Q P S S Y K N  
atagatgaaaaaattcaaatcaagatgagttattaaatttaccataaatgaatatgaa  
I D E K I S N Q D E L L N L P I N E Y E  
aataaggtagaccgttatctacaacatctgcccaaccatcgagtaagcgtgtaaccgta  
N K V R P L S T S A Q P S S K R V T V  
aatcaattagggcagaacaaggttcgaatgttaattcaattaaagttactgatcaa  
N Q L A A E Q G S N V N H L I K V T D Q  
agtattactgaaggatatgatgatgtagtgattatataagcacatgatgctgaaac  
S I T E G Y D D S D G I I K A H D A E N  
ttaatctatgtagtaacttttgaagtagatgataagggtgaaatctggtgatacgtgaca  
L I Y D V T F E V D D K V K S G D T M T  
gtgaatataagataacagttccatcagatttaaccgatagttttgcaataccaaaa  
V N I D K N T V P S D L T D S F A I P K  
ataaaagataattctggagaaatcatogctacaggtacttatgacaacacaataaaaa  
I K D N S G E I I A T G T Y D N T N K Q

FIG. 3(cont'd)

attacctaacacttttacagattatgtagataaataatgaaaataatgaaagcgcaccttaaa  
I T Y T F T D Y V D K Y E N I K A H L K  
ttaaocatcatacatgataaatacaagggttccaataataaacaactaagttagatgtagaa  
L T S Y I D K S K V P N N T K L D V E  
tataagacggcccttcatcagtaataaacaattacgggtgaataatcaaaaaccctaac  
Y K T A L S S V N K T I T V E Y Q K P N  
gaaaatcggactgctaaccctcaaaagtatggttcacaacaatagatacgaaaaaaccataca  
E N R T A N L Q S M F T N I D T K N H T  
gtagcaaacgattatataaccctcttcggttattcagccaagaacaatgtaaat  
V E Q T I Y I N P L R Y S A K E T N V N  
atctcagggaatggcgatgaagggtccaacaattatcgacgatagtagtaaatcattaaagtt

*FIG. 3(cont'd)*



I S G N G D E G S T I I D S T I I K V  
tataagggtggagataatcaaaattaccagatagtaacagaatttatgattacagtgaa  
Y K V G D N Q N L P D S N R I Y D Y S E  
tatgaagatgtcacaatgatgattatgcccaattaggaataataatgacgtgaatatt  
Y E D V T N D D Y A Q L G N N D V N I  
aattttggtaataatagattccaccataataattaaagttatagtaaatatgacccta  
N F G N I D S P Y I I K V I S K Y D P N  
aaggacgattacacgacgatacagcaactgtgacaatgcaaacgactataaatgagtat  
K D D Y T I Q Q T V T M Q T I N E Y  
actggtgagtttagaacagcctcctatgataatacaattgcttctctacaagttcaggt  
T G E F R T A S Y D N T I A F S T S S G  
caaggacaagggtgacttgcctcctgaaaaactataaaatcggagattacgtatgggaa  
Q G Q G D L P P E K T Y K I G D Y V W E  
gatgataaaagatgggtattcaaaatacaaatgataatgaaaaaccgcttagtaatgta  
D V D K D G I Q N T N D N E K P L S N V  
ttggtaactttgacgtatcctgatggacttcaaaatcagtcagaacagatgaagagggg  
L V T L T Y P D G T S K S V R T D E E G  
aaatatcaatttgatgggttaaaaacggattgacttataaaattacattcgaacaccg  
K Y Q F D G L K N G L T Y K I T F E T P  
gaaggatatacggcagcgttaaacattcaggaaacaatcctgactagactcagaaggg  
E G Y T P T L K H S G T N P A L D S E G

**FIG. 3(cont'd)**

aattctgtatgggtaactattaacggacaagacgatatgactattgatatagggattttat  
N S V W V T I N G Q D D M T I D S G F Y  
caaacacctaataatagcttagggaactatgtatggtatgacactaataaagatgggtatt  
Q T P K Y S L G N Y V W Y D T N K D G I  
caaggtgatgaaaaaggaatctctggagtaaaagtacggttaaaagatgaaaacgga  
Q G D D E K G I S G V K V T L K D E N G  
aatatcattagtacaacaactgatgaaaatggaaagtatcaatttgataatttaaat  
N I I S T T T D E N G K Y Q F D N L N  
agtgtaattatattgttcattttgataaaccttcagggtatgactcaaacacaacagat  
S G N Y I V H F D K P S G M T Q T T D  
tctggtgatgacgaaacaggatgctgatggggaagaagtccttaacaattactgat  
S G D D E Q D A D G E E V H V T I T D  
catgactttagtataagataacggatactatgatgacgactcagattcagatagtgat  
H D D F S I D N G Y Y D D S D S D S D  
tcagactcagatagcgactcagactccgatatgctagcattccgactcagacagcgactca  
S D S D S D S D S D S D S D S D S D S  
gattccgatagtgattcagattcagacagtgactcagactcagatagtgattcagattca  
D S D S D S D S D S D S D S D S D S  
gacagcattccgactcagacagtgactcaggattagacaatagctcagataagaataca  
D S D S D S D S D S G L D N S S D K N T

*FIG. 3(cont'd)*

aaagataaattaccggatacacaggagctaatgaagatcatgattctaaaggcacattactt  
K D K L P D T G A N E D H D S K G T L L  
ggagcttatttgcagggttaggagcgttattattaggaagcgtcgcaaaaatagaaaa  
G A L F A G L G A L L L G K R R K N R K  
aataaaaattaaattattcaaatgaaatttagtgaagaagcagatacgcacatttgaatag  
N K N \* I I Q M K L V K E A D T T F E -  
aaagtataatttagtccaacaataataagggttg  
K V Y L V Q Q I - G V

*FIG. 3(cont'd)*

SdrH coding region  
atgaaaagtttaacattaacatttaacatttatgcttacgggctttgctttcatggtaact  
M K K F N I K H S F M L T G F A F M V T  
acatcattattcagtcaccaagcacatgctgaaggtaatcctcattgacattaatttt  
T S L F S H Q A H A E G N H P I D I N F  
tctaagatcaaattgatagaataacagctaagagcaatattatcaatcgagtgaatgac  
S K D Q I D R N T A K S N I I N R V N D  
actagtcgcacaggaattagtatgaattcggataatgatttagatcacagatatcgtttca  
T S R T G I S M N S D N D L D T D I V S  
aatagtgactcagaaaatgacacataatttagatagtgattcagattcagacagtgactca  
N S D S E N D T Y L D S D S D S D S  
gattcagatagtgactcagattcagatagtgactcagattcagatagtgactcagattca  
D S D S D S D S D S D S D S D S D S D S  
gacagtgattcagactcagatagtgactcagattcagacagtgattcagactcagatagt  
D S D S D S D S D S D S D S D S D S  
gattcagattcagacagtgattcagattcagacagtgactcagactcagacagtgattca  
D S D S D S D S D S D S D S D S D S  
gattcagatagtgattcagattcagatagtgattcagattcagatagtgattcagattca  
D S D S D S D S D S D S D S D S D S  
gacagtgactcagactcagacagtgattcagattcagatagtgattcagactcagatagt  
D S D S D S D S D S D S D S D S D S


FIG. 4

gactcagattcagatagtgattcagactctggtaacaagttcaggtaagggttcacatacc  
D S D S D S D S D S G T S S G K G S H T  
ggaaaaaacctggtaaccctaaaggaaatacaaatagacaccttccaagacatacgaat  
G K P G N P K G N T N R P S Q R H T N  
caacccaaaggcctaatacaaatcaaaacaatacaataataaacaataataaaccat  
Q P Q R P K Y N Q T N Q N N I N N I N H  
aataataatcacgtactagtgagatgggtgcgcctttaaocgtcaacaaaatatt  
N I N H T R T S G D G A P F K R Q Q N I  
attaattctaattcaggctatagaaatacaaaataataataatcaatttatatggaaacaaa  
I N S N S G H R N Q N N I N Q F I W N K  
aatggctttttaaattcaaaataataaccgaaacatagaatgaaatagtagcgataataacc  
N G F F K S Q N N T E H R M N S S D N T  
aattcattaattagcagattcagacaattagcccagggtgcttataagtaacaatccgttt  
N S L I S R F R Q L A T G A Y K Y N P F  
ttgattaatcaagtaaaaaattgaaatcaattagatggaaaggtagacagatagtgacatt  
L I N Q V K N L N Q L D G K V T D S D I  
tatagcttgttagaagcaatcatttagaggaaatgaataatttaaatcattacaacaaa  
Y S L F R K Q S F R G N E Y L N S L Q K  
ggacaagctattcagatttcaatatatttaattcaacttaattctagtaaaatactatgaa  
G T S Y F R F Q Y F N P L N S S K Y Y E


FIG. 4(cont'd)

aatttagatgatcagggttttagctttaaattacaggagaaatcggctcaatgccagaactt  
N L D D Q V L A L I T G E I G S M P E L  
aaaaaacctacggataaagaagataaaaaatcatagcgccttcaaaaaaccatagtcagat  
K K P T D K E D K N H S A F K N H S A D  
gagataacaacaataatgatggacactccaagaattatgataagaaaaagaaaatacat  
E I T T N N D G H S K D Y D K K K I H  
cgaagtcttttatcgtaaagtattgcaataattggaatttttctaggagtcactggacta  
R S L L S L S I A I I G I F L G V T G L  
tatatctttagaagaaaaagtaa  
Y I F R R K K \*


*FIG. 4(cont'd)*




**FIG. 5**




**FIG. 6A**



**FIG. 6B**



**FIG. 6C**



**FIG. 6D**






FIG. 7A




FIG. 7B







FIG. 7C




**FIG. 8C**




**FIG. 8B**






**FIG. 8A**



**FIG. 9A**



**FIG. 9B**



**FIG. 10C**

**FIG. 10B**

**FIG. 10A**




FIG. 11

1

**PROTEINS AND POLYPEPTIDES FROM  
COAGULASE-NEGATIVE  
STAPHYLOCOCCI**

CROSS-REFERENCE TO RELATED  
APPLICATIONS

The present application is a divisional application of U.S. application Ser. No. 09/386,962, filed Aug. 31, 1999, now U.S. Pat. No. 6,635,473, and claims the benefit of U.S. Provisional Applications Ser. No. 60/117,119, filed Jan. 25, 1999, and Ser. No. 60/098,443, filed Aug. 31, 1998.

FIELD OF THE INVENTION

The present invention is in the fields of microbiology and molecular biology and more particularly is in the field of biological products for the prevention, treatment or diagnosis of coagulase negative staphylococcal infections in man and animals.

BACKGROUND OF THE INVENTION

Staphylococci are Gram-positive spherical cells, usually arranged in grape-like irregular clusters. Some are members of the normal flora of the skin and mucous membranes of humans, others cause suppuration, abscess formation, a variety of pyogenic infections, and even fatal septicemia. Pathogenic staphylococci often hemolyze blood, coagulate plasma, and produce a variety of extracellular enzymes and toxins. The most common type of food poisoning is caused by a heat-stable staphylococcal enterotoxin. The genus *Staphylococcus* has at least 30 species. The three main species of clinical importance are *Staphylococcus aureus*, *Staphylococcus epidermidis*, and *Staphylococcus saprophyticus*. *Staphylococcus aureus* is coagulase-positive, which differentiates it from the other species. *S. aureus* is a major pathogen for humans. Almost every person has some type of *S. aureus* infection during a lifetime, ranging in severity from food poisoning or minor skin infections to severe life-threatening infections.

The coagulase-negative staphylococci are normal human flora which sometimes cause infection, often associated with implanted devices, especially in very young, old and immunocompromised patients. Approximately 75% of the infections caused by coagulase-negative staphylococci are due to *S. epidermidis*. Infections due to *Staphylococcus warneri*, *Staphylococcus hominis*, and other species are less common. *S. saprophyticus* is a relatively common cause of urinary tract infections in young women. The staphylococci produce catalase, which differentiates them from the streptococci.

Both *Staphylococcus aureus* and *Staphylococcus epidermidis* have a characteristic propensity for invading skin and adjacent tissues at the site of prosthetic medical devices, including intravascular catheters, cerebrospinal fluid shunts, hemodialysis shunts, vascular grafts, and extended wear contact lenses. Within 48 to 72 hours, relatively large numbers of staphylococci are demonstrable at the site of insertion of these foreign bodies. (Archer, G. L., in Remington, J. S., et al., *Current Clinical Topics in Infectious Diseases*, McGraw-Hill, NY, 25-46, 1986.)

*Staphylococcus epidermidis* is a generally avirulent commensal organism of the human skin, and is the principal etiologic agent of infections of peripheral and central venous catheters, prosthetic heart valves, artificial joints, and other prosthetic devices. It has been demonstrated that *S. epidermidis* cells attach and proliferate on the inner or outer surfaces

2

of catheters, irrespective of their composition—whether polyethylene, polyvinylchloride, polyvinylfluoride or polyester based.

Initial localized infections of indwelling medical devices can lead to more serious invasive infections such as septicemia, osteomyelitis, and endocarditis. Vascular catheters are thought to become infected when microorganisms gain access to the device, and hence the bloodstream, by migration from the skin surface down the transcutaneous portion of the catheter. In infections associated with medical devices, plastic and metal surfaces become coated with host plasma and matrix proteins such as fibrinogen, vitronectin and fibronectin shortly after implantation. *S. epidermidis* bacteremia can result in an excess hospital stay of 8 days, which is quite expensive.

Although the virulence of coagulase-negative staphylococci is enhanced in the presence of a foreign body, the microbial factors that permit these normal skin commensals to become nosocomial pathogens have not been well characterized. The ability of coagulase-negative *S. epidermidis* to adhere to these proteins is of crucial importance for initiating infection. As adherence is believed to be the critical first step in the pathogenesis of coagulase-negative staphylococcal foreign-body infections, attention has focused on surface properties of these organisms that might mediate adherence to, and then colonization of, polymeric prosthetic materials.

A number of factors influence an organism's ability to adhere to prosthetic material. These include characteristics of the microorganism and the biomaterial, and the nature of the surrounding environment. The initial attraction between the organism and the host is influenced by nonspecific forces such as surface charge, polarity, Van der Waal forces and hydrophobic interactions. The critical stage of adherence involves specific interactions between cell surface adhesins and immobilized host proteins. To date, investigation concerning the adherence of *S. epidermidis* to biomaterials has concerned itself primarily with the role of the extracellular polysaccharide or glycocalyx, also known as slime. Despite intensive study, however, the proposed role of slime in the pathogenesis of disease or even its composition remain debated. (Drewry et al., *Clin. Microbiol* 28:1292-1296, 1990) Currently, extracellular slime is thought to play a role in the later stages of adherence and persistence of infection. It may serve as an ion exchange resin to optimize a local nutritional environment, prevent penetration of antibiotics into the macro-colony or protect bacteria from phagocytic host defense cells. Peters et al. have shown by electron microscopy studies that extracellular polysaccharide appears in the later stages of attachment and is not present during the initial phase of adherence. (*J. Infect. Dis.*, 65146:479-482, 1982) Hogt et al. demonstrated that removal of the extracellular slime layer by repeated washing does not diminish the ability of *S. epidermidis* to adhere to biomaterials. (*J. Gen. Microbiol.* 129: 2959-2968, 1983)

Thus far, study of exopolysaccharide has lent little to prevention of initial adherence by the bacteria. Several other studies have identified other potential adhesins of *S. epidermidis* including the polysaccharide adhesin (PS/A) observed by Tojo et al. (*J. Infect. Dis.* 157:713-722, 1988) and the slime associated antigen (SAA) of Christensen et al. (*Infect Immun*, 58:2906-2911, 1990).

It has been demonstrated that PS/A is a complex mixture of monosaccharide adhesins which blocks adherence of PS/A producing strains of *S. epidermidis*. In an animal model of endocarditis antibodies directed against PS/A were protective. However, it is not clear whether this protective effect was specific, related to anti-adhesive effects of the antibody or due

to a more generalized increase in the efficiency of opsonophagocytosis of blood borne bacteria. It has been hypothesized that each adhesin functions in different stages of the adherence process with one or more of these adhesins responsible for initial attraction while others are needed for aggregation in the macro-colonies.

Despite many studies, factors involved in the initial adherence of *S. epidermidis* to biomaterials remain largely unknown. Further unknown is a practical method for preventing the first stage of infection, adherence or adhesion. Therefore, a great need remains for the discovery and characterization of bacterial adhesin proteins and the genes that encode them.

Accordingly, it is an object of the present invention to provide cell-wall associated extracellular matrix binding proteins of coagulase-negative staphylococci.

It is a further object of the present invention to provide coagulase-negative staphylococcal surface proteins that are able to inhibit staphylococcal adhesion to the immobilized extracellular matrix or host cells present on the surface of implanted biomaterials.

It is a further object of the present invention to provide a coagulase-negative staphylococci vaccine, to generate antisera and antibodies to coagulase-negative staphylococcal proteins, and to isolate antibodies to coagulase-negative staphylococci.

It is a further object of the present invention to provide improved materials and methods for detecting and differentiating coagulase-negative staphylococcal organisms in clinical and laboratory settings.

It is a further object of the invention to provide nucleic acid probes and primers specific for coagulase-negative staphylococci.

It is a further object of the invention to provide methods for detecting, diagnosing, treating or monitoring the progress of therapy for bacterial infections that are sensitive and specific for coagulase-negative staphylococci.

These and other objects, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiments and the appended claims.

### SUMMARY OF THE INVENTION

Isolated proteins from coagulase-negative staphylococci and their corresponding amino acid and nucleic acid sequences are provided. The proteins are designated SdrF, SdrG and SdrH. The DNA sequence of sdrF and the amino acid sequence of the protein SdrF (in bold) are shown in FIG. 2 along with their flanking sequences. The DNA sequence of sdrG and the amino acid sequence of the protein SdrG (in bold) are shown in FIG. 3 along with their flanking sequences. Finally, the SdrH coding region including DNA and amino acid sequence is shown in FIG. 4.

It has also been discovered that in the A region of SdrF and SdrG there is highly conserved amino acid sequence that can be used to derive a consensus TYTFTDYVD (SEQ ID NO:16) motif. The motif can be used in multicomponent vaccines to impart broad spectrum immunity to bacterial infections, and also can be used to produce monoclonal or polyclonal antibodies that impart broad spectrum passive immunity. In an alternative embodiment, any combination of the variable sequence motif derived from the Sdr protein family, (T) (Y) (T) (F) (T) (DIN) (Y) (V) (D) (SEQ ID NO: 40), can be used to impart immunity or to induce protective antibodies. The proteins, or antigenic portions thereof, are used to produce antibodies for the diagnosis of coagulase-

negative staphylococcal bacterial infections or for the development of anti-coagulase-negative staphylococcal vaccines for active or passive immunization. When administered to a wound or used to coat polymeric biomaterials in vitro and in vivo, both the protein and antibodies thereof are also useful as blocking agents to prevent or inhibit the binding of coagulase-negative staphylococci to the wound site or to any biomaterials. The SdrF, SdrG and SdrH proteins are further useful as scientific research tools to understand of the mechanisms of bacterial pathology and the development of antibacterial therapies.

The sdrF, sdrG and sdrH gene sequences are useful as nucleic acid probes for the detection and identification of coagulase-negative staphylococcal cell surface proteins. The nucleic acid sequences may also be inserted into a vector and placed in a microorganism for the production of recombinant SdrF, SdrG and SdrH proteins. The amino acid sequences of these Sdr proteins are useful as well, for example, in the production of synthetic SdrF, SdrG and SdrH proteins or portions thereof, such as consensus or variable sequence amino acid motifs.

Antisera and antibodies raised against the SdrF, SdrG and SdrH proteins or portions thereof, such as consensus or variable sequence amino acid motifs, and vaccines or other pharmaceutical compositions containing the proteins are also provided herein.

In addition, diagnostic kits containing nucleic acid molecules, the proteins, antibodies or antisera raised against SdrF, SdrG and SdrH or portions thereof, such as consensus or variable sequence amino acid motifs, and the appropriate reagents for reaction with a sample are also provided.

In a first embodiment of this invention the polynucleotide comprises a region encoding SdrF polypeptides comprising the sequence set out in FIG. 2, or a variant thereof.

In accordance with this aspect of the invention there is provided an isolated nucleic acid molecule encoding a mature polypeptide expressible by the *Staphylococcus epidermidis* strain 9491.

In a second embodiment of this invention the polynucleotide comprises a region encoding SdrG polypeptides comprising the sequence set out in FIG. 3, or a variant thereof.

In accordance with this aspect of the invention there is provided an isolated nucleic acid molecule encoding a mature polypeptide expressible by the *Staphylococcus epidermidis* strain K28.

In a third embodiment of this invention the polynucleotide comprises a region encoding SdrH polypeptides comprising the sequence set out in FIG. 4, or a variant thereof.

In accordance with this aspect of the invention there is provided an isolated nucleic acid molecule encoding a mature polypeptide expressible by the *Staphylococcus epidermidis* strain 9491.

In a fourth embodiment of the invention there is a novel protein from *Staphylococcus epidermidis* comprising the SdrF amino acid sequence as shown in FIG. 2, or a variant thereof.

In a fifth embodiment of the invention there is a novel protein from *Staphylococcus epidermidis* comprising the SdrG amino acid sequence as shown in FIG. 3, or a variant thereof.

In a sixth embodiment of the invention there is a novel protein from *Staphylococcus epidermidis* comprising the SdrH amino acid sequence as shown in FIG. 4, or a variant thereof.

In accordance with the fourth, fifth and sixth embodiments of the invention there are provided isolated nucleic acid molecules encoding SdrF, SdrG or SdrH proteins, particularly

*Staphylococcus epidermidis* proteins, including mRNAs, cDNAs, genomic DNAs. Further embodiments of this aspect of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.

In a seventh embodiment of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization.

In an eighth embodiment of the invention are variants of SdrF, SdrG or SdrH polypeptide or portions thereof, such as consensus or variable sequence amino acid motifs, encoded by naturally occurring alleles of the sdrF, sdrG or sdrH gene.

In accordance with this embodiment of the invention there are provided novel polypeptides of *Staphylococcus epidermidis* referred to herein as SdrF, SdrG or SdrH or portions thereof, such as consensus or variable sequence amino acid motifs, as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.

In a ninth embodiment of the invention, there are provided methods for producing the aforementioned SdrF, SdrG or SdrH polypeptides or portions thereof, such as consensus or variable sequence amino acid motifs.

In a tenth embodiment of the invention, there are provided antibodies against SdrF, SdrG or SdrH polypeptides or polynucleotides or portions thereof, such as consensus or variable sequence amino acid motifs or the nucleic acids which encode such motifs.

In an eleventh embodiment of the invention there are provided polynucleotides that hybridize to SdrF, SdrG or SdrH polynucleotide sequences or portions thereof, such as consensus or variable sequence amino acid motifs, particularly under stringent conditions.

In a twelfth embodiment of the invention there are provided compositions comprising an SdrF, SdrG or SdrH polynucleotide or a SdrF, SdrG or SdrH polypeptide or portions thereof, such as consensus or variable sequence amino acid motifs, for administration to a cell or to a multicellular organism.

Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following descriptions and from reading the other parts of the present disclosure.

#### BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a representation of the SdrG protein of *S. epidermidis* strain K28. The regions are labeled along the top of the construct, with the number of amino acids found in each region of the protein disclosed immediately below the corresponding region in the drawing.

FIG. 2 is the DNA sequence of sdrF (SEQ ID No. 1) and the amino acid sequence of the SdrF protein (in bold) along with their flanking sequences (SEQ ID Nos. 2-6).

FIG. 3 is the DNA sequence of sdrG (SEQ ID No. 7) and the amino acid sequence of the SdrG protein (in bold) along with their flanking sequences (SEQ ID No. 8-12).

FIG. 4 is the DNA sequence of the sdrH (SEQ ID No. 13) coding region along with the amino acid sequence of the SdrH protein (SEQ ID No. 14).

FIG. 5 shows the relationships between the Sdr proteins of *S. aureus* and *S. epidermidis* as follows: FIG. 5A is a schematic representation of previously described *S. aureus* Sdr proteins; FIG. 5B is a schematic representation of SdrF, SdrG, and SdrH showing the relative position and/or size of their signal sequences (S), region As (A), region B repeats (B<sub>n</sub>), SD-repeat region (SD), region C (C) (SdrH only), and wall/

membrane spanning regions (WM); and FIG. 5C represents the C-terminal amino acid sequences of SdrF (SEQ ID NO:18), SdrG (SEQ ID NO: 19), and SdrH (SEQ ID NO: 20) showing the positions of the SD repeats, LPXTG motif (underlined), hydrophobic membrane-spanning regions (bold), and charged terminal residues.

FIG. 6 illustrates the prevalence of the sdr genes in *S. epidermidis* strains and shows Southern blots containing *S. epidermidis* genomic DNA hybridizing to DNA probes encoding the: (A) the SD-repeat region; (B) the SdrH region A; (C) the SdrG region A; and (D) the SdrG and SdrF region As. Strains are as follows: lane 1, ATCC14990; lane 2, KH11; lane 3, K28; lane 4, RP62a; lane 5, TU3298; lane 6, 9142; lane 7 1457; lane 8, 8400; lane 9, N910308; lane 10, N910160; lane 11, N910102; lane 12, N910173; lane 13, N910191; lane 14, N910231; lane 15, N950249. Strain 9491 is not shown. Kilobases (kb) size markers are shown at the left of panels A-D.

FIG. 7 shows the recombinant Sdr region A proteins and the specificity of their respective antisera as evidenced by: (A) Coomassie-stained SDS-PAGE of purified proteins used to raise rabbit polyclonal antisera. Lanes 1 and 2, histidine-tagged SdrFA and SdrGA, respectively; lane 3, GST-tagged SdrHA; (B) Left panel: Reactivity of pooled anti-SdrFA, -SdrGA, and -SdrHA antisera to *E. coli* lysates expressing GST-tagged SdrFA (lane 1), SdrGA (lane 2), and SdrHA (lane 3). Middle and right panels: Reactivity of anti-SdrFA and -SdrGA antisera, respectively, to the same proteins; and (C) Left panel: Reactivity of anti-histidine monoclonal antibody to *E. coli* lysates expressing histidine-tagged SdrFA (lane 1), SdrGA (lane 2) and full-length SdrH (lane 3). Right panel: Reactivity of anti-SdrHA antiserum to the same proteins. Kilodalton (kDa) size markers are shown at the left of panels A, B, and C.

FIG. 8 depicts immunoblot analyses of Sdr protein expression in *S. epidermidis*, including: (A) Reactivity of anti-SdrFA antisera to a lysate of *S. epidermidis* 9491. Lane 1, immune antiserum; lane 2, preimmune antiserum; and lane 3, SdrFA-absorbed immune antiserum; (B) Reactivity of anti-SdrGA immune (lane 1), preimmune (lane 2), and SdrGA-absorbed immune (lane 3) antisera to a lysate of *S. epidermidis* strain K28; and (C) Reactivity of anti-SdrHA immune (lane 1) and SdrHA-absorbed immune (lane 2) antisera to a lysate of *S. epidermidis* 9491. kDa size markers are shown to the left of A, B, and C.

FIG. 9 shows the genetic analysis of SdrH protein size variation among *S. epidermidis* strains, including: (A) Reactivity of anti-SdrHA antiserum to different *S. epidermidis* strain lysates which reveal strain variations in the molecular mass of SdrH. Lane 1-3: Strains 9491, 8400, and KH11, respectively; and (B) PCR products representing DNA encoding the SdrH SD-repeat regions (lanes 1-3) or the region Cs (lanes 4-6) of the same strains. kDa and kb size markers are shown at the left of A and B, respectively.

FIG. 10 represents analyses of Sdr proteins in cell-wall extracts and protoplasts, including: (A) Reactivity of anti-SdrFA antiserum to *S. epidermidis* strain 9491 lysates (lane 1), cell-wall extracts (lane 2), and purified protoplasts (lane 3); and (B) and (C) Reactivity of anti-SdrGA and -SdrHA antisera, respectively, to the same samples. kDa size markers are shown at the left of A, B, and C.

FIG. 11 shows the reactivity of IgG from patients convalescing from *S. epidermidis* infections to recombinant SdrFA (open bars), SdrGA (gray bars), and SdrHA (black bars) coated in an ELISA microtiter plate. Pooled IgG from two-year-old children was used as a comparative control. Error bars reflect standard deviations.



## DETAILED DESCRIPTION OF THE INVENTION

Isolated Sdr proteins and their corresponding amino acid and nucleic acid sequences are described herein. The proteins are designated SdrF, SdrG, and SdrH. The DNA sequence of sdrF and the amino acid sequence of the protein SdrF (in bold) are shown in FIG. 2 along with their flanking sequences. The DNA sequence of sdrG and the amino acid sequence of the protein SdrG (in bold) are shown in FIG. 3 along with their flanking sequences. Finally, the SdrH coding region including DNA and amino acid sequence is shown in FIG. 4.

The SdrF, SdrG, and SdrH proteins are related in primary sequence and structural organization to the extracellular matrix-binding Sdr family of proteins from *Staphylococcus aureus* and are localized on the cell surface. The SdrF, SdrG, and SdrH proteins are cell wall-associated proteins, with a signal sequence at the N-terminus and an LPXTG (SEQ ID NO:17) motif, a hydrophobic domain and positively charged residues at the C-terminus. Each also has an SD repeat containing region R of sufficient length to allow efficient expression of the ligand binding domain region A on the cell surface. With the A region of the SdrF, SdrG, and SdrH proteins located on the cell surface, the proteins can interact with proteins in plasma, the extracellular matrix or with molecules on the surface of host cells. SdrG, for example, binds the N-terminal one-half of the beta chain of fibrinogen.

The disclosed extracellular matrix-binding proteins share a unique dipeptide repeat region (region R) including predominantly aspartate and serine residues. This DS repeat is encoded by 18 nucleotide repeats with the consensus GAY TCN GAY TCN GAY AGY (SEQ ID NO: 15), with TCN as the first and second serine codons and AGY as the third serine codon. The R region is near the C-terminus of the proteins and typically contains between 40 and 300 DS residues, or more particularly, greater than 60, 80, 100, 120, 150, 200 or 250 repeating units, of which greater than 90, 95 or even 98% are the amino acids D or S. The R region DS repeat varies in length between proteins, and while the region R itself does not bind extracellular matrix proteins, the R region enables the presentation of the binding regions of the protein on the cell surface of *S. aureus*. Thus, probes to the consensus DNA encoding the DS repeat (see above) can be used to identify other genes encoding different binding proteins essential to the attachment of *S. aureus* to host tissues. Antibodies to an R region can also be used to identify such additional binding proteins.

It has been discovered that in the A region of SdrF and SdrG there is highly conserved amino acid sequence that can be used to derive a consensus TYTFTDYVD (SEQ ID NO:16) motif. The motif can be used in multicomponent vaccines to impart broad spectrum immunity to bacterial infections, and also can be used to produce monoclonal or polyclonal antibodies that impart broad spectrum passive immunity. In an alternative embodiment, any combination of the variable sequence motif derived from the Sdr protein family, (T) (Y) (T) (F) (T) (D/N) (Y) (V) (D) (SEQ ID NO: 40), can be used to impart immunity or to induce protective antibodies.

It has further been discovered that SdrG has an open reading frame of 2736 nucleotides that encode a protein of 913 amino acid residues. The protein has a signal sequence of 30 amino acids, a ligand binding A region of 542 amino acids, and two repeated motifs termed B regions. B1 is 113 amino acids and B2 is 110 amino acids, and the R region is 77 amino acids. B regions contain EF hand motifs that signify Ca<sup>++</sup> binding, and are similar to those found in other Ca<sup>++</sup> binding proteins such as calmodulin and troponin. An additional more degenerate form of the EF hand motif was found in the A

region of SdrG between the residues 459-471. A significant decrease in the binding of SdrG A to Fibrinogen was noted in the presence of EDTA, demonstrating a metal-ion dependence for binding.

## I. Definitions

The terms "SdrF protein", "SdrG protein" and "SdrH protein" are defined herein to include SdrF, SdrG, and SdrH subdomains, and active or antigenic fragments of SdrF, SdrG, and SdrH proteins, such as consensus or variable sequence amino acid motifs.

As used herein, "pg" means picogram, "ng" means nanogram, "ug" or "μg" mean microgram, "mg" means milligram, "ul" or "μl" mean microliter, "ml" means milliliter, "l" means liter.

"Active fragments" of SdrF, SdrG, and SdrH proteins are defined herein as peptides or polypeptides capable of blocking the binding of coagulase-negative staphylococci to immobilized or soluble host proteins.

The term "adhesin" as used herein includes naturally occurring and synthetic or recombinant proteins and peptides which can bind to extracellular matrix proteins and/or mediate adherence to host cells.

The term "amino acid" as used herein includes naturally occurring and synthetic amino acids and includes, but is not limited to, alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, methionine, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamate, aspartic acid, glutamic acid, lysine, arginine, and histidine.

An "antibody" is any immunoglobulin, including antibodies and fragments thereof, that binds a specific epitope. The term as used herein includes monoclonal antibodies, polyclonal, chimeric, single chain, bispecific, simianized, and humanized antibodies as well as Fab fragments, including the products of an Fab immunoglobulin expression library.

The phrase "antibody molecule" in its various grammatical forms as used herein contemplates both an intact immunoglobulin molecule and an immunologically active portion of an immunoglobulin molecule.

"Antigenic fragments" of SdrF, SdrG, and SdrH proteins are defined herein as peptides or polypeptides capable of producing an immunological response.

As used herein, an "antigenically functional equivalent" protein or peptide is one that incorporates an epitope that is immunologically cross-reactive with one or more epitopes of the particular proteins disclosed. Antigenically functional equivalents, or epitopic sequences, may be first designed or predicted and then tested, or may simply be directly tested for cross-reactivity.

A "cell line" is a clone of a primary cell that is capable of stable growth in vitro for many generations.

A "clone" is a population of cells derived from a single cell or common ancestor by mitosis.

A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genetic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

"DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in either its single stranded form, or a double stranded helix.

This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g. restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA).

Transcriptional and translational control sequences are "DNA regulatory sequences", such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell.

An "expression control sequence" is a DNA sequence that controls and regulates the transcription and translation of another DNA sequence. A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence.

As used herein, the term "extracellular matrix proteins," or ECM, refers to four general families of macromolecules, collagens, structural glycoproteins, proteoglycans and elastins, including fibronectin, and fibrinogen, that provide support and modulate cellular behavior.

As used herein, a "host cell" is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence.

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences.

"Identity" and "similarity" can be readily calculated by known methods (*Computational Molecular Biology*, Lesk, A. M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D. W., ed., Academic Press, New York, 1993). While there exist a number of methods to measure identity and similarity between two sequences, both terms are well known to skilled artisans. Methods commonly employed to determine identity or similarity between sequences include, but are not limited to those disclosed in Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48:1073 (1988). Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux et al., *Nucleic Acids Research* 12(1): 387, 1984), BLASTP, BLASTN, and FASTA (Atschul et al., *J. Molec. Biol.* 215: 403-410, 1990). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul et al., NCBI NLM NIH Bethesda, Md. 20894; Altschul et al., *J. Mol. Biol.* 215: 403-410, 1990).

By "immunologically effective amount" is meant an amount of a peptide composition that is capable of generating an immune response in the recipient animal. This includes both the generation of an antibody response (B cell response), and/or the stimulation of a cytotoxic immune response (T cell response). The generation of such an immune response will have utility in both the production of useful bioreagents, e.g., CTLs and, more particularly, reactive antibodies, for use in

diagnostic embodiments, and will also have utility in various prophylactic or therapeutic embodiments.

As used herein, the term "in vivo vaccine" refers to immunization of animals with proteins so as to elicit a humoral and cellular response that protects against later exposure to the pathogen.

The term "isolated" is defined herein as free from at least some of the components with which it naturally occurs. "Isolated" as used herein also means altered "by the hand of man" from its natural state, i.e., if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

The term "ligand" is used to include molecules, including those within host tissues, to which pathogenic bacteria attach.

The phrase "monoclonal antibody" in its various grammatical forms refers to an antibody having only one species of antibody combining site capable of immunoreacting with a particular antigen.

The term "oligonucleotide," as used herein is defined as a molecule comprised of two or more nucleotides, preferably more than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide.

As used herein, the phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an unacceptable allergic or similar untoward reaction when administered to a human.

"Polynucleotide(s)" generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotide(s)" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions or single-, double- and triple-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded, or triple-stranded, or a mixture of single- and double-stranded regions. In addition, "polynucleotide" as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. As used herein, the term "polynucleotide(s)" includes DNAs or RNAs as described above that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotide(s)" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term "polynucleotide(s)" as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including, for example, simple and complex cells. "Polynucleotide(s)" embraces short polynucleotides often referred to as oligonucleotide(s).

“Polypeptide(s)” refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds. “Polypeptide(s)” refers to both short chains, commonly referred to as peptides, oligopeptides and oligomers and to longer chains generally referred to as proteins. Polypeptides may contain amino acids other than the 20 genetically encoded amino acids. “Polypeptide(s)” include those modified either by natural processes, such as processing and other post-translational modifications, but also by chemical modification techniques which are well known to the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature, and they are well known to those of skill in the art. It will be appreciated that the same type of modification may be present in the same or varying degree at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formulation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. See, for instance Seifter et al., *Meth. Enzymol.* 182:626-646, 1990 and Rattan et al., *Ann. N.Y. Acad. Sci.* 663: 48-62, 1992. Polypeptides may be branched or cyclic, with or without branching. Cyclic, branched and branched circular polypeptides may result from post-translational natural processes and may be made by entirely synthetic methods, as well.

The term “primer” as used herein refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and pH. The primer may be either single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, source of primer and use of the method. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides.

The primers herein are selected to be substantially complementary to different strands of a particular target DNA sequence. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. For example, a noncomplementary nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being complementary to the strand. Alternatively, noncomplemen-

tary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence of the strand to hybridize therewith and thereby form the template for the synthesis of the extension product.

A “promoter sequence” is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined by mapping with nuclease SI), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain “TATA” boxes and “CAT” boxes. Prokaryotic promoters contain Shine-Dalgarno sequences in addition to the -10 and -35 consensus sequences.

A “replicon” is a genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication in vivo; i.e., capable of replication under its own control.

As used herein, the terms “restriction endonucleases” and “restriction enzymes” refer to bacterial enzymes, each of which cuts double-stranded DNA at or near a specific palindromic nucleotide sequence.

A “signal sequence” can be included before the coding sequence. This sequence encodes a signal peptide, N-terminal to the polypeptide, that communicates to the host cell to direct the polypeptide to the cell surface or secrete the polypeptide into the media, and this signal peptide is clipped off by the host cell before the protein leaves the cell. Signal sequences can be found associated with a variety of proteins native to prokaryotes and eukaryotes.

A cell has been “transformed” by exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA.

“Variant(s)” as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions or truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or

more substitutions, additions or deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans.

A "vector" is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment.

#### II. Nucleic Acid and Amino Acid Sequences

The nucleic acid sequences encoding SdrF, SdrG, and SdrH (as shown in FIGS. 2-4, respectively) or portions thereof, such as consensus or variable sequence amino acid motifs, are useful for the production of recombinant proteins or as nucleic acid probes for the detection of coagulase-negative staphylococci proteins in a sample or specimen with high sensitivity and specificity. The probes can be used to detect the presence of coagulase-negative staphylococci in the sample, diagnose infection with the disease, quantify the amount of coagulase-negative staphylococci in the sample, or monitor the progress of therapies used to treat the infection. The nucleic acid and amino acid sequences can also be useful as laboratory research tools to study the organism and the disease or to develop therapies and treatments for the disease.

It will be understood by those skilled in the art that the SdrF, SdrG, or SdrH proteins are also encoded by sequences substantially similar to the nucleic acid sequences provided in the Sequence Listing. Two DNA sequences are "substantially similar" when approximately 70% or more (preferably at least about 80%, and most preferably at least about 90 or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, 1982; *DNA Cloning*, Vols. I & II, supra; *Nucleic Acid Hybridization*, [B. D. Hames & S. J. Higgins eds. (1985)]. By "substantially similar" is further meant a DNA sequence which, by virtue of the degeneracy of the genetic code, is not identical with that shown in any of the sequences shown in FIGS. 2-4, but which still encodes the same amino acid sequence; or a DNA sequence which encodes a different amino acid sequence that retains the activities of the proteins, either because one amino acid is replaced with a similar amino acid, or because the change (whether it be substitution, deletion or insertion) does not affect the active site of the protein. Two amino acid sequences or two nucleic acid sequences are "substantially similar" when approximately 70% or more (preferably at least about 80%, and more preferably at least about 90% or 95%) of the amino acids match over the defined length of the sequences.

Modification and changes may be made in the structure of the peptides of the present invention and DNA segments which encode them and still obtain a functional molecule that encodes a protein or peptide with desirable characteristics. The following is a discussion based upon changing the amino acids of a protein to create an equivalent, or even an improved, second generation molecule. The amino acid changes may be achieved by changing the codons of the DNA sequence, according to Table 1. It should be understood by one skilled in the art that the codons specified in Table 1 are for RNA

sequences. The corresponding codons for DNA have a T substituted for U. In keeping with standard nomenclature (*J. Biol. Chem.*, 243:3552-3559, 1969), abbreviations for amino acid residues are further shown in Table 1.

TABLE 1

Amino Acids		Codons					
Alanine	Ala	A	GCA	GCC	GCG	GCU	
Cysteine	Cys	C	UGC	UGU			
Aspartic acid	Asp	D	GAC	GAU	GAC	GAU	
Glutamic acid	Glu	E	GAA	GAG			
Phenylalanine	Phe	F	UUC	UUU			
Glycine	Gly	G	GGA	GCG	GGG	GGU	
Histidine	His	H	CAC	CAU			
Isoleucine	Ile	I	AUA	AUC	AUU		
Lysine	Lys	K	AAA	AAG			
Leucine	Leu	L	UUA	UUG	CUA	CUC	CUG
Methionine	Met	M	AUG				
Asparagine	Asn	N	AAC	AAU			
Proline	Pro	P	CCA	CCC	CCG	CCU	
Glutamine	Gln	Q	CAA	CAG			
Arginine	Arg	R	AGA	AGG	CGA	CGC	CGG
Serine	Ser	S	AGC	AGU	UCA	UCC	UCG
Threonine	Thr	T	ACA	ACC	ACG	ACU	
Valine	Val	V	GUA	GUC	GUG	GUU	
Tryptophan	Trp	W	UGG				
Tyrosine	Tyr	Y	UAC	UAU			

For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence substitutions can be made in a protein sequence, and, of course, its underlying DNA coding sequence, and nevertheless obtain a protein with like properties. It is thus contemplated by the inventors that various changes may be made in the peptide sequences of the disclosed compositions, or corresponding DNA sequences which encode said peptides without appreciable loss of their biological utility or activity.

In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and Doolittle, *J. Mol Biol*, 157(1):105-132, 1982, incorporate herein by reference). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like. Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics (Kyte and Doolittle, supra, 1982), these are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

It is known in the art that certain amino acids may be substituted by other amino acids having a similar hydropathic index or score and still result in a protein with similar biological activity, i.e., still obtain a biological functionally equivalent protein. In making such changes, the substitution of amino acids whose hydropathic indices are within  $\pm 2$  is preferred, those which are within  $\pm 1$  are particularly preferred, and those within  $\pm 0.5$  are even more particularly preferred.

ferred. It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Pat. No. 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein.

As detailed in U.S. Pat. No. 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+1.0); aspartate (+3.0±1); glutamate (+3.0±1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5±1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4). It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent protein. In such changes, the substitution of amino acids whose hydrophilicity values are within ±2 is preferred, those which are within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred.

As outlined above, amino acid substitutions are generally therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions which take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

The polypeptides of the present invention can be chemically synthesized. The synthetic polypeptides are prepared using the well known techniques of solid phase, liquid phase, or peptide condensation techniques, or any combination thereof, and can include natural and unnatural amino acids. Amino acids used for peptide synthesis may be standard Boc (N<sup>α</sup>-amino protected N<sup>α</sup>-t-butyloxycarbonyl) amino acid resin with the standard deprotecting, neutralization, coupling and wash protocols of the original solid phase procedure of Merrifield (*J. Am. Chem. Soc.*, 85:2149-2154, 1963), or the base-labile N<sup>α</sup>-amino protected 9-fluorenylmethoxycarbonyl (Fmoc) amino acids first described by Carpino and Han (*J. Org. Chem.*, 37:3403-3409, 1972). Both Fmoc and Boc N<sup>α</sup>-amino protected amino acids can be obtained from Fluka, Bachem, Advanced Chemtech, Sigma, Cambridge Research Biochemical, Bachem, or Peninsula Labs or other chemical companies familiar to those who practice this art. In addition, the method of the invention can be used with other N<sup>α</sup>-protecting groups that are familiar to those skilled in this art. Solid phase peptide synthesis may be accomplished by techniques familiar to those in the art and provided, for example, in Stewart and Young, 1984, *Solid Phase Synthesis*, Second Edition, Pierce Chemical Co., Rockford, Ill.; Fields and Noble, 1990, *Int. J. Pept Protein Res.* 35:161-214, or using automated synthesizers, such as sold by ABS. Thus, polypeptides of the invention may comprise D-amino acids, a combination of D- and L-amino acids, and various "designer" amino acids (e.g., β-methyl amino acids, Cα-methyl amino acids, and Nα-methyl amino acids, etc.) to convey special properties. Synthetic amino acids include ornithine for lysine, fluorophenylalanine for phenylalanine, and norleucine for leucine or isoleucine. Additionally, by assigning specific amino acids at specific coupling steps, α-helices, β turns, β sheets, γ-turns, and cyclic peptides can be generated.

In a further embodiment, subunits of peptides that confer useful chemical and structural properties will be chosen. For example, peptides comprising D-amino acids will be resistant to L-amino acid-specific proteases in vivo. In addition, the present invention envisions preparing peptides that have more well defined structural properties, and the use of peptidomimetics and peptidomimetic bonds, such as ester bonds, to prepare peptides with novel properties. In another embodiment, a peptide may be generated that incorporates a reduced peptide bond, i.e., R<sub>1</sub>-CH<sub>2</sub>-NH-R<sub>2</sub>, where R<sub>1</sub> and R<sub>2</sub> are amino acid residues or sequences. A reduced peptide bond may be introduced as a dipeptide subunit. Such a molecule would be resistant to peptide bond hydrolysis, e.g., protease activity. Such peptides would provide ligands with unique function and activity, such as extended half-lives in vivo due to resistance to metabolic breakdown or protease activity. Furthermore, it is well known that in certain systems constrained peptides show enhanced functional activity (Hruby, *Life Sciences*, 31:189-199, 1982); (Hruby et al., *Biochem J.*, 268:249-262, 1990).

The following non-classical amino acids may be incorporated in the peptide in order to introduce particular conformational motifs: 1,2,3,4-tetrahydroisoquinoline-3-carboxylate (Kazmierski et al., *J. Am. Chem. Soc.*, 113:2275-2283, 1991); (2S,3S)-methyl-phenylalanine, (2S,3R)-methyl-phenylalanine, (2R,3S)-methyl-phenylalanine and (2R,3R)-methyl-phenylalanine (Kazmierski and Hruby, *Tetrahedron Lett.*, 1991); 2-aminotetrahydronaphthalene-2-carboxylic acid (Landis, *Ph.D. Thesis, University of Arizona*, 1989); hydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylate (Miyake et al., *J. Takeda Res. Labs.*, 43:53-76, 1989); β-carboline (D and L) (Kazmierski, *Ph.D. Thesis, University of Arizona*, 1988); HIC (histidine isoquinoline carboxylic acid) (Zechel et al., *Int. J. Pept. Protein Res.*, 43, 1991); and HIC (histidine cyclic urea) (Dharanipragada).

The following amino acid analogs and peptidomimetics may be incorporated into a peptide to induce or favor specific secondary structures: LL-Acp (LL-3-amino-2-propenidone-6-carboxylic acid), a β-turn inducing dipeptide analog (Kemp et al., *J. Org. Chem.*, 50:5834-5838 (1985); β-sheet inducing analogs (Kemp et al., *Tetrahedron Lett.*, 29:5081-5082, 1988); β-turn inducing analogs (Kemp et al., *Tetrahedron Lett.*, 29:5057-5060, 1988); α-helix inducing analogs (Kemp et al., *Tetrahedron Lett.*, 29:4935-4938, 1988); γ-turn inducing analogs (Kemp et al., *J. Org. Chem.*, 54:109:115, 1989); and analogs provided by the following references: Nagai and Sato, *Tetrahedron Lett.*, 26:647-650 (1985); DiMaio et al., *J. Chem. Soc. Perkin Trans.*, p. 1687 (1989); also a Gly-Ala turn analog (Kahn et al., *Tetrahedron Lett.*, 30:2317, 1989); amide bond isostere (Jones et al., *Tetrahedron Lett.*, 29:3853-3856, 1989); tetrazole (Zabrocki et al., *J. Am. Chem. Soc.*, 110:5875-5880, 1988); DTC (Samanen et al., *Int. J. Protein Pep. Res.*, 35:501:509, 1990); and analogs taught in Olson et al., (*J. Am. Chem. Sci.*, 112:323-333, 1990) and Garvey et al., (*J. Org. Chem.*, 56:436, 1990). Conformationally restricted mimetics of beta turns and beta bulges, and peptides containing them, are described in U.S. Pat. No. 5,440,013, issued Aug. 8, 1995 to Kahn.

Also provided herein are sequences of nucleic acid molecules that selectively hybridize with nucleic acid molecules encoding the fibrinogen-binding proteins or portions thereof, such as consensus or variable sequence amino acid motifs, from coagulase-negative staphylococcal bacteria such as *S. epidermidis* described herein or complementary sequences thereof. By "selective" or "selectively" is meant a sequence which does not hybridize with other nucleic acids. This is to promote specific detection of sdrF, sdrG, or sdrH. Therefore,

in the design of hybridizing nucleic acids, selectivity will depend upon the other components present in a sample. The hybridizing nucleic acid should have at least 70% complementarity with the segment of the nucleic acid to which it hybridizes. As used herein to describe nucleic acids, the term "selectively hybridizes" excludes the occasional randomly hybridizing nucleic acids, and thus, has the same meaning as "specifically hybridizing". The selectively hybridizing nucleic acids of the invention can have at least 70%, 80%, 85%, 90%, 95%, 97%, 98%, and 99% complementarity with the segment of the sequence to which they hybridize.

The invention contemplates sequences, probes and primers which selectively hybridize to the encoding DNA or the complementary, or opposite, strand of DNA as those specifically provided herein. Specific hybridization with nucleic acid can occur with minor modifications or substitutions in the nucleic acid, so long as functional species-specific hybridization capability is maintained. By "probe" is meant nucleic acid sequences that can be used as probes or primers for selective hybridization with complementary nucleic acid sequences for their detection or amplification, which probes can vary in length from about 5 to 100 nucleotides, or preferably from about 10 to 50 nucleotides, or most preferably about 18-24 nucleotides. Therefore, the terms "probe" or "probes" as used herein are defined to include "primers". Isolated nucleic acids are provided herein that selectively hybridize with the species-specific nucleic acids under stringent conditions and should have at least 5 nucleotides complementary to the sequence of interest as described by Sambrook et al., 1989. MOLECULAR CLONING: A LABORATORY MANUAL, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.

If used as primers, the composition preferably includes at least two nucleic acid molecules which hybridize to different regions of the target molecule so as to amplify a desired region. Depending on the length of the probe or primer, the target region can range between 70% complementary bases and full complementarity and still hybridize under stringent conditions. For example, for the purpose of diagnosing the presence of the *S. epidermidis*, the degree of complementarity between the hybridizing nucleic acid (probe or primer) and the sequence to which it hybridizes (e.g., coagulase-negative staphylococcal DNA from a sample) is at least enough to distinguish hybridization with a nucleic acid from other bacteria.

The nucleic acid sequences encoding SdrF, SdrG, or SdrH proteins or portions thereof, such as consensus or variable sequence amino acid motifs, can be inserted into a vector, such as a plasmid, and recombinantly expressed in a living organism to produce recombinant SdrF, SdrG, or SdrH proteins or fragments thereof. For example, DNA molecules producing recombinant SdrF, SdrG, and SdrH have been produced in plasmids in accordance with the present invention.

Recombinant proteins are produced by methods well known to those skilled in the art. A cloning vector, such as a plasmid or phage DNA is cleaved with a restriction enzyme, and the DNA sequence encoding the SdrF, SdrG, or SdrH protein or fragments thereof, such as consensus or variable sequence amino acid motifs, is inserted into the cleavage site and ligated. The cloning vector is then inserted into a host to produce the protein or fragment encoded by the SdrF, SdrG, or SdrH encoding DNA. Suitable hosts include bacterial hosts such as *Escherichia coli*, *Bacillus subtilis*, yeasts and other cell cultures. Production and purification of the gene product may be achieved and enhanced using known molecular biology techniques.

### III. Uses of Sdr Nucleic Acids

Methods of using the nucleic acids described herein to detect and identify the presence of coagulase-negative staphylococci are provided. The methods are useful for diagnosing coagulase-negative staphylococcal infections and other associated diseases such as catheter related infections, bio-material related infections, upper respiratory tract infections (such as otitis media, bacterial tracheitis, acute epiglottitis, thyroiditis), lower respiratory infections (such as emphysema, lung abscess), cardiac (such as infective endocarditis), gastrointestinal (such as secretory diarrhea, splenic abscess, retroperitoneal abscess), central nervous system (such as cerebral abscess), ocular (such as blepharitis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital cellulitis, dacryocystitis), kidney and urinary tract (such as epididymitis, intrarenal and perinephric abscess, toxic shock syndrome), skin (such as impetigo, folliculitis, cutaneous abscesses, cellulitis, wound infection, bacterial myositis, bone and joint (such as septic arthritis, osteomyelitis), bovine mastitis, and canine pyoderma.

The method involves the steps of obtaining a sample suspected of containing coagulase-negative staphylococci. The sample may be taken from an individual, for example, from one's blood, saliva, tissues, bone, muscle, cartilage, or skin. The cells can then be lysed, and the DNA extracted, precipitated and amplified. Detection of DNA from coagulase-negative staphylococci is achieved by hybridizing the amplified DNA with a probe for coagulase-negative staphylococci that selectively hybridizes with the DNA as described above in the Detailed Description of the Invention. Detection of hybridization is indicative of the presence of coagulase-negative staphylococci.

Preferably, detection of nucleic acid (e.g. probes or primers) hybridization can be facilitated by the use of detectable moieties. For example, the probes can be labeled with biotin and used in a streptavidin-coated microtiter plate assay. Other detectable moieties include radioactive labeling, enzyme labeling, and fluorescent labeling, for example.

DNA may be detected directly or may be amplified enzymatically using polymerase chain reaction (PCR) or other amplification techniques prior to analysis. RNA or cDNA can be similarly detected. Increased or decrease expression of sdrF, sdrG, or sdrH can be measured using any of the methods well known in the art for the quantification of nucleic acid molecules, such as, for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting, and other hybridization methods.

Diagnostic assays for SdrF, SdrG, or SdrH proteins or portions thereof, such as consensus or variable sequence amino acid motifs, or anti-SdrF, SdrG, or SdrH antibodies may also be used to detect the presence of a *Staphylococcus epidermidis* infection. Assay techniques for determining protein or antibody levels in a sample are well known to those skilled in the art and include methods such as radioimmunoassay, Western blot analysis and ELISA assays.

### IV. Uses of Sdr Protein or Antibody

The isolated, recombinant or synthetic proteins, or antigenic portions thereof (including epitope-bearing fragments), or fusion proteins thereof can be administered to animals as immunogens or antigens, alone or in combination with an adjuvant, for the production of antibodies reactive with SdrF, SdrG, or SdrH proteins or portions thereof, such as consensus or variable sequence amino acid motifs. In addition, the proteins can be used to screen antibodies or antisera for hyper-immune patients from whom can be derived specific antibodies having a very high affinity for the proteins.

Antibodies to SdrF, SdrG, or SdrH or to fragments thereof, such as consensus or variable sequence amino acid motifs, can be used to impart passive immunity are useful for the specific detection of coagulase-negative staphylococci proteins, for the prevention of a coagulase-negative staphylococcal infection, for the treatment of an ongoing infection or for use as research tools. The term "antibodies" as used herein includes monoclonal, polyclonal, chimeric, single chain, bispecific, simianized, and humanized or primatized antibodies as well as Fab fragments, including the products of an Fab immunoglobulin expression library. Generation of any of these types of antibodies or antibody fragments is well known to those skilled in the art.

Monoclonal antibodies are generated by methods well known to those skilled in the art. The preferred method is a modified version of the method of Kearney et al., *J. Immunol.* 123:1548-1558 (1979), which is incorporated by reference herein. Briefly, animals such as mice or rabbits are inoculated with the immunogen in adjuvant, and spleen cells are harvested and mixed with a myeloma cell line, such as P3X63Ag8,653. The cells are induced to fuse by the addition of polyethylene glycol. Hybridomas are chemically selected by plating the cells in a selection medium containing hypoxanthine, aminopterin and thymidine (HAT). Hybridomas are subsequently screened for the ability to produce anti-SdrF, SdrG, or SdrH monoclonal antibodies. Hybridomas producing antibodies are cloned, expanded and stored frozen for future production.

Techniques for the production of single chain antibodies are known to those skilled in the art and described in U.S. Pat. No. 4,946,778 and can be used to produce single chain antibodies to the proteins described herein. Phage display technology may be used to select antibody genes having binding activities for SdrF, SdrG, or SdrH, or antigenic portions thereof, such as consensus or variable sequence amino acid motifs, from PCR-amplified genes of lymphocytes from humans screened for having antibodies to SdrF, SdrG, or SdrH or naive libraries. Bispecific antibodies have two antigen binding domains wherein each domain is directed against a different epitope.

Any of the above described antibodies may be labeled directly with a detectable label for identification and quantification of coagulase-negative staphylococci. Labels for use in immunoassays are generally known to those skilled in the art and include enzymes, radioisotopes, and fluorescent, luminescent and chromogenic substances, including colored particles such as colloidal gold or latex beads. Suitable immunoassays include enzyme-linked immunosorbent assays (ELISA).

Alternatively, the antibody may be labeled indirectly by reaction with labeled substances that have an affinity for immunoglobulin. The antibody may be conjugated with a second substance and detected with a labeled third substance having an affinity for the second substance conjugated to the antibody. For example, the antibody may be conjugated to biotin and the antibody-biotin conjugate detected using labeled avidin or streptavidin. Similarly, the antibody may be conjugated to a hapten and the antibody-hapten conjugate detected using labeled anti-hapten antibody. These and other methods of labeling antibodies and assay conjugates are well known to those skilled in the art.

Antibodies to the extracellular matrix-binding proteins SdrF, SdrG, SdrH or portions thereof, such as consensus or variable sequence amino acid motifs, may also be used in production facilities or laboratories to isolate additional quantities of the proteins, such as by affinity chromatography.

For example, antibodies to the fibrinogen-binding protein SdrG may be used to isolate additional amounts of fibrinogen.

The proteins, or active fragments thereof, and antibodies to the proteins are useful for the treatment and diagnosis of coagulase-negative staphylococci bacterial infections as described above with regard to diagnosis method, or for the development of anti-coagulase-negative staphylococci vaccines for active or passive immunization. Further, when administered as pharmaceutical composition to a wound or used to coat medical devices or polymeric biomaterials in vitro and in vivo, both the proteins and the antibodies are useful as blocking agents to prevent or inhibit the binding of coagulase-negative staphylococci to the wound site or the biomaterials themselves. Preferably, the antibody is modified so that it is less immunogenic in the patient to whom it is administered. For example, if the patient is a human, the antibody may be "humanized" by transplanting the complementarity determining regions of the hybridoma-derived antibody into a human monoclonal antibody as described by Jones et al., *Nature* 321:522-525 (1986) or Tempest et al. *Biotechnology* 9:266-273 (1991) and as mentioned above.

Medical devices or polymeric biomaterials to be coated with the antibodies, proteins and active fragments described herein include, but are not limited to, staples, sutures, replacement heart valves, cardiac assist devices, hard and soft contact lenses, intraocular lens implants (anterior chamber or posterior chamber), other implants such as corneal inlays, keratoprotheses, vascular stents, epikeratophalia devices, glaucoma shunts, retinal staples, scleral buckles, dental prostheses, thyroplastic devices, laryngoplastic devices, vascular grafts, soft and hard tissue prostheses including, but not limited to, pumps, electrical devices including stimulators and recorders, auditory prostheses, pacemakers, artificial larynx, dental implants, mammary implants, penile implants, cranio/facial tendons, artificial joints, tendons, ligaments, menisci, and disks, artificial bones, artificial organs including artificial pancreas, artificial hearts, artificial limbs, and heart valves; stents, wires, guide wires, intravenous and central venous catheters, laser and balloon angioplasty devices, vascular and heart devices (tubes, catheters, balloons), ventricular assists, blood dialysis components, blood oxygenators, urethral/ureteral/urinary devices (Foley catheters, stents, tubes and balloons), airway catheters (endotracheal and tracheostomy tubes and cuffs), enteral feeding tubes (including nasogastric, intragastric and jejunal tubes), wound drainage tubes, tubes used to drain the body cavities such as the pleural, peritoneal, cranial, and pericardial cavities, blood bags, test tubes, blood collection tubes, vacutainers, syringes, needles, pipettes, pipette tips, and blood tubing.

It will be understood by those skilled in the art that the term "coated" or "coating", as used herein, means to apply the protein, antibody, or active fragment to a surface of the device, preferably an outer surface that would be exposed to coagulase-negative staphylococcal infection. The surface of the device need not be entirely covered by the protein, antibody or active fragment.

#### V. Pharmaceutical Compositions

Immunological compositions, including vaccines, and other pharmaceutical compositions containing the SdrF, SdrG, or SdrH proteins or portions thereof, such as consensus or variable sequence amino acid motifs, are included within the scope of the present invention. One or more of the SdrF, SdrG, or SdrH proteins, or active or antigenic fragments thereof, or fusion proteins thereof can be formulated and packaged, alone or in combination with other antigens, using methods and materials known to those skilled in the art for

vaccines. The immunological response may be used therapeutically or prophylactically and may provide antibody immunity or cellular immunity, such as that produced by T lymphocytes.

The immunological compositions, such as vaccines, and other pharmaceutical compositions can be used alone or in combination with other blocking agents to protect against human and animal infections caused by or exacerbated by coagulase-negative staphylococci. In particular, the compositions can be used to protect humans against endocarditis, toxic shock syndrome, osteomyelitis, epididymitis, cellulitis or many other infections. The compositions may also protect humans or ruminants against mastitis caused by coagulase-negative staphylococci infections. The vaccine can further be used to protect other species of animals, for example canine and equine animals, against similar coagulase-negative staphylococcal infections.

To enhance immunogenicity, the proteins may be conjugated to a carrier molecule. Suitable immunogenic carriers include proteins, polypeptides or peptides such as albumin, hemocyanin, thyroglobulin and derivatives thereof, particularly bovine serum albumin (BSA) and keyhole limpet hemocyanin (KLH), polysaccharides, carbohydrates, polymers, and solid phases. Other protein derived or non-protein derived substances are known to those skilled in the art. An immunogenic carrier typically has a molecular mass of at least 1,000 Daltons, preferably greater than 10,000 Daltons. Carrier molecules often contain a reactive group to facilitate covalent conjugation to the hapten. The carboxylic acid group or amine group of amino acids or the sugar groups of glycoproteins are often used in this manner. Carriers lacking such groups can often be reacted with an appropriate chemical to produce them. Preferably, an immune response is produced when the immunogen is injected into animals such as mice, rabbits, rats, goats, sheep, guinea pigs, chickens, and other animals, most preferably mice and rabbits. Alternatively, a multiple antigenic peptide comprising multiple copies of the protein or polypeptide, or an antigenically or immunologically equivalent polypeptide may be sufficiently antigenic to improve immunogenicity without the use of a carrier.

The SdrF, SdrG, or SdrH protein or portions thereof, such as consensus or variable sequence amino acid motifs, or combination of proteins may be administered with an adjuvant in an amount effective to enhance the immunogenic response against the conjugate. At this time, the only adjuvant widely used in humans has been alum (aluminum phosphate or aluminum hydroxide). Saponin and its purified component Quil A, Freund's complete adjuvant and other adjuvants used in research and veterinary applications have toxicities which limit their potential use in human vaccines. However, chemically defined preparations such as muramyl dipeptide, monophosphoryl lipid A, phospholipid conjugates such as those described by Goodman-Snitkoff et al. *J. Immunol.* 147:410-415 (1991) and incorporated by reference herein, encapsulation of the conjugate within a proteoliposome as described by Miller et al., *J. Exp. Med.* 176:1739-1744 (1992) and incorporated by reference herein, and encapsulation of the protein in lipid vesicles such as Novasome™ lipid vesicles (Micro Vesicular Systems, Inc., Nashua, NH) may also be useful.

The term "vaccine" as used herein includes DNA vaccines in which the nucleic acid molecule encoding SdrF, SdrG, or SdrH, or antigenic portions thereof, such as any consensus or variable sequence amino acid motif, in a pharmaceutical composition is administered to a patient. For genetic immunization, suitable delivery methods known to those skilled in the art include direct injection of plasmid DNA into muscles (Wolff et al., *Hum. Mol. Genet.* 1:363, 1992), delivery of

DNA complexed with specific protein carriers (Wu et al., *J. Biol. Chem.* 264:16985, 1989), coprecipitation of DNA with calcium phosphate (Benvenisty and Reshef, *Proc. Natl. Acad. Sci.* 83:9551, 1986), encapsulation of DNA in liposomes (Kaneda et al., *Science* 243:375, 1989), particle bombardment (Tang et al., *Nature* 356:152, 1992 and Eisenbraun et al., *DNA Cell Biol.* 12:791, 1993), and in vivo infection using cloned retroviral vectors (Seeger et al., *Proc. Natl. Acad. Sci.* 81:5849, 1984).

In another embodiment, the invention is a polynucleotide which comprises contiguous nucleic acid sequences capable of being expressed to produce a gene product upon introduction of said polynucleotide into eukaryotic tissues in vivo. The encoded gene product preferably either acts as an immunostimulant or as an antigen capable of generating an immune response. Thus, the nucleic acid sequences in this embodiment encode an immunogenic epitope, and optionally a cytokine or a T-cell costimulatory element, such as a member of the B7 family of proteins.

There are several advantages to immunization with a gene rather than its gene product. The first is the relative simplicity with which native or nearly native antigen can be presented to the immune system. Mammalian proteins expressed recombinantly in bacteria, yeast, or even mammalian cells often require extensive treatment to ensure appropriate antigenicity. A second advantage of DNA immunization is the potential for the immunogen to enter the MHC class I pathway and evoke a cytotoxic T cell response. Immunization of mice with DNA encoding the influenza A nucleoprotein (NP) elicited a CD8<sup>+</sup> response to NP that protected mice against challenge with heterologous strains of flu. (Montgomery, D. L. et al., *Cell Mol Biol.* 43(3):285-92, 1997 and Ulmer, J. et al., *Vaccine*, 15(8):792-794, 1997.)

Cell-mediated immunity is important in controlling infection. Since DNA immunization can evoke both humoral and cell-mediated immune responses, its greatest advantage may be that it provides a relatively simple method to survey a large number of *S. epidermidis* genes for their vaccine potential.

#### VI. Methods of Administration and Dosage of Pharmaceutical Compositions

Pharmaceutical compositions containing the SdrF, SdrG, or SdrH proteins or portions thereof, such as consensus or variable sequence amino acid motifs, nucleic acid molecules, antibodies, or fragments thereof may be formulated in combination with a pharmaceutical carrier such as saline, dextrose, water, glycerol, ethanol, other therapeutic compounds, and combinations thereof. The formulation should be appropriate for the mode of administration. The compositions are useful for interfering with, modulating, or inhibiting binding interactions between coagulase-negative staphylococci and fibrinogen on host cells.

The amount of expressible DNA or transcribed RNA to be introduced into a vaccine recipient will have a very broad dosage range and may depend on the strength of the transcriptional and translational promoters used. In addition, the magnitude of the immune response may depend on the level of protein expression and on the immunogenicity of the expressed gene product. In general, effective dose ranges of about 1 ng to 5 mg, 100 ng to 2.5 mg, 1 µg to 750 µg, and preferably about 10 µg to 300 µg of DNA is administered directly into muscle tissue. Subcutaneous injection, intradermal introduction, impression through the skin, and other modes of administration such as intraperitoneal, intravenous, or inhalation delivery are also suitable. It is also contemplated that booster vaccinations may be provided. Following vacci-



nation with a polynucleotide immunogen, boosting with protein immunogens such as the SdrH gene product is also contemplated.

The polynucleotide may be "naked", that is, unassociated with any proteins, adjuvants or other agents which affect the recipient's immune system. In this case, it is desirable for the polynucleotide to be in a physiologically acceptable solution, such as, but not limited to, sterile saline or sterile buffered saline. Alternatively, the DNA may be associated with liposomes, such as lecithin liposomes or other liposomes known in the art, as a DNA-liposome mixture, or the DNA may be associated with an adjuvant known in the art to boost immune responses, such as a protein or other carrier. Agents which assist in the cellular uptake of DNA, such as, but not limited to, calcium ions, may also be used. These agents are generally referred to herein as transfection facilitating reagents and pharmaceutically acceptable carriers. Techniques for coating microprojectiles coated with polynucleotide are known in the art and are also useful in connection with this invention. For DNA intended for human use it may be useful to have the final DNA product in a pharmaceutically acceptable carrier or buffer solution. Pharmaceutically acceptable carriers or buffer solutions are known in the art and include those described in a variety of texts such as Remington's Pharmaceutical Sciences.

It is recognized by those skilled in the art that an optimal dosing schedule for a DNA vaccination regimen may include as many as five to six, but preferably three to five, or even more preferably one to three administrations of the immunizing entity given at intervals of as few as two to four weeks, to as long as five to ten years, or occasionally at even longer intervals.

Suitable methods of administration of any pharmaceutical composition disclosed in this application include, but are not limited to, topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal and intradermal administration.

For topical administration, the composition is formulated in the form of an ointment, cream, gel, lotion, drops (such as eye drops and ear drops), or solution (such as mouthwash). Wound or surgical dressings, sutures and aerosols may be impregnated with the composition. The composition may contain conventional additives, such as preservatives, solvents to promote penetration, and emollients. Topical formulations may also contain conventional carriers such as cream or ointment bases, ethanol, or oleyl alcohol.

In a preferred embodiment, a vaccine is packaged in a single dosage for immunization by parenteral (i.e., intramuscular, intradermal or subcutaneous) administration or nasopharyngeal (i.e., intranasal) administration. The vaccine is most preferably injected intramuscularly into the deltoid muscle. The vaccine is preferably combined with a pharmaceutically acceptable carrier to facilitate administration. The carrier is usually water or a buffered saline, with or without a preservative. The vaccine may be lyophilized for resuspension at the time of administration or in solution.

Microencapsulation of the protein will give a controlled release. A number of factors contribute to the selection of a particular polymer for microencapsulation. The reproducibility of polymer synthesis and the microencapsulation process, the cost of the microencapsulation materials and process, the toxicological profile, the requirements for variable release kinetics and the physicochemical compatibility of the polymer and the antigens are all factors that must be considered. Examples of useful polymers are polycarbonates, polyesters, polyurethanes, polyorthoesters, polyamides, poly (D,L-lactide-co-glycolide) (PLGA) and other biodegradable poly-

mers. The use of PLGA for the controlled release of antigen is reviewed by Eldridge et al., *CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY*, 146:59-66 (1989).

The preferred dose for human administration is from 0.01 mg/kg to 10 mg/kg, preferably approximately 1 mg/kg. Based on this range, equivalent dosages for heavier body weights can be determined. The dose should be adjusted to suit the individual to whom the composition is administered and will vary with age, weight and metabolism of the individual. The vaccine may additionally contain stabilizers or pharmaceutically acceptable preservatives, such as thimerosal (ethyl(2-mercaptobenzoate-S)mercury sodium salt) (Sigma Chemical Company, St. Louis, Mo.).

#### VII. Protein-Label Conjugates

When labeled with a detectable biomolecule or chemical, the fibrinogen-binding proteins described herein are useful for purposes such as in vivo and in vitro diagnosis of staphylococcal infections or detection of coagulase-negative staphylococci. Laboratory research may also be facilitated through use of such Sdr protein-label conjugates. Various types of labels and methods of conjugating the labels to the proteins are well known to those skilled in the art. Several specific labels are set forth below. The labels are particularly useful when conjugated to a protein such as an antibody or receptor.

For example, the protein can be conjugated to a radiolabel such as, but not restricted to,  $^{32}\text{P}$ ,  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{35}\text{S}$ ,  $^{125}\text{I}$ , or  $^{131}\text{I}$ . Detection of a label can be by methods such as scintillation counting, gamma ray spectrometry or autoradiography.

Bioluminescent labels, such as derivatives of firefly luciferin, are also useful. The bioluminescent substance is covalently bound to the protein by conventional methods, and the labeled protein is detected when an enzyme, such as luciferase, catalyzes a reaction with ATP causing the bioluminescent molecule to emit photons of light.

Fluorogens may also be used to label proteins. Examples of fluorogens include fluorescein and derivatives, phycoerythrin, allo-phycoyanin, phycocyanin, rhodamine, and Texas Red. The fluorogens are generally detected by a fluorescence detector.

The protein can alternatively be labeled with a chromogen to provide an enzyme or affinity label. For example, the protein can be biotinylated so that it can be utilized in a biotin-avidin reaction, which may also be coupled to a label such as an enzyme or fluorogen. For example, the protein can be labeled with peroxidase, alkaline phosphatase or other enzymes giving a chromogenic or fluorogenic reaction upon addition of substrate. Additives such as 5-amino-2,3-dihydro-1,4-phthalazinedione (also known as Luminol<sup>®</sup>) (Sigma Chemical Company, St. Louis, Mo.) and rate enhancers such as p-hydroxybiphenyl (also known as p-phenylphenol) (Sigma Chemical Company, St. Louis, Mo.) can be used to amplify enzymes such as horseradish peroxidase through a luminescent reaction; and luminogenic or fluorogenic dioxetane derivatives of enzyme substrates can also be used. Such labels can be detected using enzyme-linked immunoassays (ELISA) or by detecting a color change with the aid of a spectrophotometer. In addition, proteins may be labeled with colloidal gold for use in immunoelectron microscopy in accordance with methods well known to those skilled in the art.

The location of a ligand in cells can be determined by labeling an antibody as described above and detecting the label in accordance with methods well known to those skilled in the art, such as immunofluorescence microscopy using

procedures such as those described by Warren and Nelson (*Mol. Cell. Biol.*, 7: 1326-1337, 1987).

#### VIII. Therapeutic Applications

In addition to the therapeutic compositions and methods described above, the SdrF, SdrG, or SdrH proteins or portions thereof, such as consensus or variable sequence amino acid motifs, nucleic acid molecules or antibodies are useful for interfering with the initial physical interaction between a pathogen and mammalian host responsible for infection, such as the adhesion of bacteria, particularly Gram-negative bacteria, to mammalian extracellular matrix proteins on in-dwelling devices or to extracellular matrix proteins in wounds; to block SdrF, SdrG, or SdrH protein-mediated mammalian cell invasion; to block bacterial adhesion between mammalian extracellular matrix proteins and bacterial SdrF, SdrG, or SdrH proteins or portions thereof, such as consensus or variable sequence amino acid motifs, that mediate tissue damage; and, to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or surgical techniques.

#### IX. Screening Methods

The SdrF, SdrG, or SdrH proteins, or fragments thereof, such as consensus or variable sequence amino acid motifs, are useful in a method for screening compounds to identify compounds that inhibit coagulase-negative staphylococci binding to host molecules. In accordance with the method, the compound of interest is combined with one or more of the SdrF, SdrG, or SdrH proteins or fragments thereof and the degree of binding of the protein to fibrinogen or other extracellular matrix proteins is measured or observed. If the presence of the compound results in the inhibition of protein-fibrinogen binding, for example, then the compound may be useful for inhibiting coagulase-negative staphylococci in vivo or in vitro. The method could similarly be used to identify compounds that promote interactions of coagulase-negative staphylococci with host molecules.

The method is particularly useful for identifying compounds having bacteriostatic or bacteriocidal properties.

For example, to screen for coagulase-negative staphylococci agonists or antagonists, a synthetic reaction mixture, a cellular compartment (such as a membrane, cell envelope or cell wall) containing one or more of the SdrF, SdrG, or SdrH proteins, or fragments thereof, such as consensus or variable sequence amino acid motifs, and a labeled substrate or ligand of the protein is incubated in the absence or the presence of a compound under investigation. The ability of the compound to agonize or antagonize the protein is shown by a decrease in the binding of the labeled ligand or decreased production of substrate product. Compounds that bind well and increase the rate of product formation from substrate are agonists. Detection of the rate or level of production of product from substrate may be enhanced by use of a reporter system, such as a calorimetric labeled substrate converted to product, a reporter gene that is responsive to changes in SdrF, SdrG, or SdrH nucleic acid or protein activity, and binding assays known to those skilled in the art. Competitive inhibition assays can also be used.

Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a SdrF, SdrG, or SdrH nucleic acid molecules or proteins or portions thereof, such as consensus or variable sequence amino acid motifs, and thereby inhibit their activity or bind to a binding molecule (such as fibrinogen) to prevent the binding of the SdrF, SdrG, or SdrH nucleic acid molecules or proteins to its ligand. For example, a compound that inhibits SdrF, SdrG, or SdrH activity may be a small molecule that binds to and occupies the binding site of the SdrF, SdrG, or SdrH protein, thereby preventing binding to cellular binding molecules, to prevent normal biological activity. Examples of small mol-

ecules include, but are not limited to, small organic molecules, peptides or peptide-like molecules. Other potential antagonists include antisense molecules. Preferred antagonists include compounds related to and variants or derivatives of SdrF, SdrG, or SdrH proteins or portions thereof, such as consensus or variable sequence amino acid motifs.

The nucleic acid molecules described herein may also be used to screen compounds for antibacterial activity.

#### X. Detection Kits for Coagulase-Negative Staphylococci

The invention further contemplates a kit containing one or more sdrF, sdrG, or sdrH-specific nucleic acid probes, which can be used for the detection of coagulase-negative staphylococci or coagulase-negative staphylococcal Sdr proteins or portions thereof, such as consensus or variable sequence amino acid motifs, in a sample or for the diagnosis of coagulase-negative staphylococcal infections. Such a kit can also contain the appropriate reagents for hybridizing the probe to the sample and detecting bound probe.

In an alternative embodiment, the kit contains antibodies specific to one or more SdrF, SdrG, or SdrH protein or peptide portions thereof, such as consensus or variable sequence amino acid motifs, which can be used for the detection of coagulase-negative staphylococci.

In yet another embodiment, the kit contains one or more SdrF, SdrG, or SdrH-proteins, or active fragments thereof, which can be used for the detection of coagulase-negative staphylococci organisms or antibodies to coagulase-negative staphylococcal Sdr proteins in a sample.

The kits described herein may additionally contain equipment for safely obtaining the sample, a vessel for containing the reagents, a timing means, a buffer for diluting the sample, and a colorimeter, reflectometer, or standard against which a color change may be measured.

In a preferred embodiment, the reagents, including the protein or antibody, are lyophilized, most preferably in a single vessel. Addition of aqueous sample to the vessel results in solubilization of the lyophilized reagents, causing them to react. Most preferably, the reagents are sequentially lyophilized in a single container, in accordance with methods well known to those skilled in the art that minimize reaction by the reagents prior to addition of the sample.

#### EXAMPLES

The following examples are included to demonstrate preferred embodiments of the present invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

##### Example 1

#### Identification of Sdr Encoding Genes in Coagulase Negative Staphylococci

Five genes (clfA, clfB, sdrC, sdrD, sdrE) have been identified in *Staphylococcus aureus* that contain the dipeptide aspartic acid and serine (DS), encoded by an 18 bp repeat motif GAY TCN GAY TCN GAY AGY (SEQ ID NO: 15), where Y=pyrimidines and N=any base. This family of proteins has been named the Sdr's for serine-aspartic acid repeat. All of the 5 *S. aureus* sdr genes encode proteins that contain features that characterize them as surface associated proteins in Gram positive bacteria; namely at the N-terminus there is a

secretory signal and at the C-terminus there are (i) several positive charged residues that serve as a stop signal for protein secretion, (ii) a hydrophobic transmembrane region and (iii) a wall-spanning region with an LPXTG motif that is required for accurate sorting and correct protein orientation in the cell wall. To identify novel genes that encode cell surface proteins in coagulase negative staphylococci we used the DS coding region of *clfA* as a gene probe to determine if homologs exist within various coagulase negative staphylococcal species. The coagulase negative staphylococcal species that we characterized were (1) *S. lugdunensis*, (2) *S. haemolyticus*, (3) *S. schleiferi* and (4) *S. epidermidis*. Each strain is listed below.

Ten strains each of *S. epidermidis*, *S. lugdunensis*, *S. schleiferi* and *S. haemolyticus* were obtained from Jerome Etienne (Lyon, France). In addition, Dr. Timothy Foster's strain collection contained *S. epidermidis* strains donated from other researchers. Southern hybridization analysis using genomic DNA isolated from all coagulase-negative staphylococcal strains was performed. Chromosomal DNA was cleaved with HindIII and the DS coding region of *clfA* was DIG-labeled (Boehringer) and used as a probe. Southern hybridization analysis of all ten *S. lugdunensis* strains revealed that a single HindIII fragment, of 9 kb, hybridized to the DS coding region of *clfA*. Analysis of *S. haemolyticus* strains with the DS-coding sequence of *clfA* revealed different sized fragments. Out of the ten strains tested, six strains gave a strongly hybridizing band between 18 kb and 10 kb. The possibility exists that more than one DS coding region is present on the HindIII fragment. After longer exposure of the autoradiogram, the four remaining strains showed weak hybridization to the DS coding region of *clfA*. The *clfA* probe did not detect a DS coding region in the genomic DNA from *S. schleiferi*. All *S. epidermidis* strains characterized revealed at least two HindIII fragments that hybridized to the DS coding region of *clfA*.

#### Strains Tested:

<i>S. lugdunensis</i> strains	
1.	<i>S. lugdunensis</i> N940113
2.	<i>S. lugdunensis</i> N940164
3.	<i>S. lugdunensis</i> N940135
4.	<i>S. lugdunensis</i> N950232
5.	<i>S. lugdunensis</i> N920143
6.	<i>S. lugdunensis</i> N930432
7.	<i>S. lugdunensis</i> N940084
8.	<i>S. lugdunensis</i> N940025
9.	<i>S. lugdunensis</i> N910319
10.	<i>S. lugdunensis</i> N910320

<i>S. epidermidis</i> strains	
1.	<i>S. epidermidis</i> ATCC14990 (Kloos)
2.	<i>S. epidermidis</i> KH1
3.	<i>S. epidermidis</i> K28
4.	<i>S. epidermidis</i> TU3298
5.	<i>S. epidermidis</i> 9142
6.	<i>S. epidermidis</i> 1457
7.	<i>S. epidermidis</i> 8400
8.	<i>S. epidermidis</i> RP62a
9.	<i>S. epidermidis</i> N910102
10.	<i>S. epidermidis</i> N910173
11.	<i>S. epidermidis</i> N910191
12.	<i>S. epidermidis</i> N910231
13.	<i>S. epidermidis</i> N910249
14.	<i>S. epidermidis</i> N910275
15.	<i>S. epidermidis</i> N950190
16.	<i>S. epidermidis</i> N950329

-continued

<i>S. epidermidis</i> strains	
5	17. <i>S. epidermidis</i> N910308
	18. <i>S. epidermidis</i> N910160

<i>S. haemolyticus</i> strains	
10	1. <i>S. haemolyticus</i> N97061
	2. <i>S. haemolyticus</i> N960512
	3. <i>S. haemolyticus</i> N910106
15	4. <i>S. haemolyticus</i> N91024
	5. <i>S. haemolyticus</i> N920160
	6. <i>S. haemolyticus</i> N910287
	7. <i>S. haemolyticus</i> N92018
	8. <i>S. haemolyticus</i> N930100
20	9. <i>S. haemolyticus</i> N950252
	10. <i>S. haemolyticus</i> N93016

<i>S. schleiferi</i> strains	
25	1. <i>S. schleiferi</i> JCM7430
	2. <i>S. schleiferi</i> N920247
	3. <i>S. schleiferi</i> N910245
	4. <i>S. schleiferi</i> N910017
30	5. <i>S. schleiferi</i> N960518
	6. <i>S. schleiferi</i> N950242
	7. <i>S. schleiferi</i> N920162
	8. <i>S. schleiferi</i> N92017
	9. <i>S. schleiferi</i> N930047
35	10. <i>S. schleiferi</i> N920260

#### sdrF Homologues in Other *S. Epidermidis* Strains

17 strains of *S. epidermidis* were examined for the presence of the *sdrF* gene by Southern hybridization. Chromosomal DNA of the individual strains was cleaved with HindIII and probed with a region A coding sequence of *sdrF* as a probe. This DNA probe was DIG-labeled by PCR using pC5 (described further below in Example 2) as a template. The *sdrF* gene was present on a HindIII fragment that varied from 4-10 kb and was present in 12 out of 16 strains tested. Using the region R coding sequence of *clfA* as a probe also identified a band of the same size indicating that *sdrF* homologues in other *S. epidermidis* strains also contain region R coding sequence.

#### sdrG Homologues in Other *S. Epidermidis* Strains

16 strains of *S. epidermidis* were tested for the presence of the *sdrG* gene using a probe designed to the region A coding sequence of *sdrG*. Southern hybridization analysis revealed that *sdrG* was present on a 16 kb HindIII fragment and was present in all *S. epidermidis* strains examined. The primer sequence used for amplification of region A coding sequence of *sdrG* is as follows:

60 F1-sdrG: 5' GATGATGAATTATCAGAC 3' (SEQ ID No. 21)  
 R.-sdrG: 5' CAGGAGGCAAGTCACCTTG 3' (SEQ ID No. 22)

(encompassing coordinates 195 to 1795 of *sdrG*)

#### 65 DS-coding Region Homologues in *S. Epidermidis* Strains

Chromosomal DNA was cleaved with HindIII and the DS-coding region of *clfA* was DIG labeled (Boehringer) and used

a probe. Southern hybridization analysis revealed at least two HindIII fragments that hybridized to the DS-coding region of clfA. Ten strains hybridized to three HindIII fragments.

#### Example 2

Studies of the Sdr Genes in Coagulase Negative Staphylococci, and Identification, Isolation, Sequencing and Expression of SdrF, SdrG and SdrH

##### Overview

*Staphylococcus epidermidis* strains can express three different cell surface-associated proteins that contain serine-aspartate dipeptide repeats. Proteins SdrF and SdrG are similar in sequence and structural organization to the Sdr proteins of *S. aureus*. They comprise 625 and 548 residue unique region As at their N termini, respectively, followed by a variable number of 110-119 residue region B repeats, an SD repeat region, and C-terminal LPXTG motifs and hydrophobic domains characteristic of surface proteins that are covalently anchored to peptidoglycan. In contrast, SdrH has a short 60 residue region A at the N terminus, followed by a SD repeat region, a unique 277 residue region C, and a C-terminal hydrophobic domain. SdrH lacks an LPXTG motif. DNA encoding each region A of SdrF, SdrG and SdrH was cloned into expression vectors in *E. coli*, and recombinant protein was expressed and purified. Specific antisera were raised in rabbits and used to identify the Sdr proteins expressed by *S. epidermidis*. Only SdrF was released from lysostaphin-generated protoplasts of cells grown to late exponential phase. SdrG and SdrH remained associated with the protoplast fraction and were thus not sorted and linked to peptidoglycan. In Southern hybridization analyses, the sdrG and sdrH genes were present in all sixteen strains tested, while sdrF was present in twelve strains. Antisera from fifteen patients that had recovered from *S. epidermidis* infections contained antibodies that reacted with recombinant region As of SdrF, SdrG and SdrH, suggesting that these proteins are expressed during infection.

##### Background

*S. epidermidis* is a common inhabitant of human skin and a frequent cause of foreign-body infections. Pathogenesis is facilitated by the ability of the organism to first adhere to, and subsequently form biofilms on, indwelling medical devices such as artificial valves, orthopedic devices, and intravenous and peritoneal dialysis catheters. Device-related infections jeopardize the success of medical treatment and significantly increase patient morbidity (11).

Adherence of *S. epidermidis* to synthetic surfaces has been correlated with both surface hydrophobicity and cell-surface proteins. (2, 13). Protease treatment of *S. epidermidis* has been shown to reduce hydrophobicity and adherence (24), and a monoclonal antibody reactive to a 220 kDa cell-surface protein of *S. epidermidis* was able to partially block bacterial attachment to polystyrene (30). Polysaccharide expressed by the ica operon is crucial in formation of biofilm. One group suggested that the polysaccharide adhesin (PS/A) is sufficient for both adhesion and cell-cell interaction associated with the accumulation phase of biofilm formation. Another view is that adherence is mediated by a surface-associated protein while the polysaccharide is responsible only for the accumulation phase (5, 12, 19).

Like *S. epidermidis*, *S. aureus* can also adhere to medical-implant devices but this attachment is predominantly mediated by bacterial receptors specific for host fibrinogen and fibronectin that coat biomaterial surfaces shortly after implantation. *S. aureus* adhesins that mediate these interactions include the fibrinogen-binding proteins, ClfA and ClfB, and the fibronectin-binding proteins, FnbpA and FnbpB [reviewed in (3)]. Although *S. epidermidis* has the potential to

interact with fibrinogen, fibronectin, vitronectin, and laminin (6, 25, 29), little is known of the specific adhesins mediating these interactions or of how these interactions influence bacterial adherence to biomaterials coated with host proteins.

The fibrinogen-binding clumping factor protein (or ClfA) of *S. aureus* (FIG. 1A) is distinguished by the presence of a serine-aspartate (SD) dipeptide repeat region (referred to as region R in previous studies) located between a ligand-binding region A and C-terminal sequences and associated with attachment to the cell-wall (16, 17). The SD-repeat region is predicted to span the cell wall and extend the ligand-binding region from the surface of the bacteria (4). ClfA is the predecessor of a SD-repeat (Sdr) protein family found in *S. aureus*. Additional members include ClfB (a second fibrinogen-binding clumping factor), SdrC, SdrD, and SdrE (FIG. 5A) (8, 21). SdrC, SdrD, and SdrE proteins contain additional repeats, termed region B repeats, located between the region A and SD repeats. Each B repeat is 110-113 amino acids in length and contains a putative Ca<sup>2+</sup>-binding, EF-hand motif. Ca binding has been shown to be required for the structural integrity of the region B repeats (9). The functions of SdrC, SdrD, and SdrE are unknown, but the proteins are hypothesized to interact with host matrix molecules via their region As.

This example describes three Sdr proteins expressed by *S. epidermidis*. Two have sequence similarity to, and the same structural organization, as the Sdr proteins of *S. aureus*, while SdrH is distinct. The genes encoding these proteins are prevalent among *S. epidermidis* strains. The presence of antibodies reactive to each Sdr region A in convalescent patient antisera suggest that the proteins are expressed during infection.

##### Materials and Methods

###### Bacterial Strains and Growth Conditions.

*E. coli* XL-1 Blue or JM109 were used as recombinant host strains. Strains XL-1 Blue or TOPP 3 (Stratagene, La Jolla, Calif.) cells were used for protein expression. Bacteria were routinely grown in Luria broth or agar (Gibco BRL, Gaithersburg, Md.) supplemented with 100 µg ml<sup>-1</sup> ampicillin (USB, Cleveland, Ohio). *S. epidermidis* strains (Table 2) were grown in tryptic soy broth (TSB) or agar (TSA) (Difco, Detroit, Mich.).

###### Cloning and Sequencing of the sdr Genes

The sdrF gene was cloned from *S. epidermidis* strain 9491. HindIII-DNA fragments ranging from 6.5 to 7.5 kb in length were isolated from an agarose gel and ligated into a pBlue-script SK+ cloning vector (Stratagene) digested with HindIII and treated with calf-intestine alkaline phosphatase (CIAP) (Promega, Madison, Wis.). One recombinant plasmid, pC5, was identified by PCR screening (27) with primers directed toward DNA encoding the SD-repeat region of ClfA (P3 and P4 primers, Table 3).

The sdrG gene was cloned from a λGem®-11 library of *S. epidermidis* strain K-28 generated with DNA that had been partially digested with Sau3A and ligated into the half-site XhoI arms of λGem®-11 (Promega). After packaging, a positive phage, designated E6-2, was identified by hybridization of a DNA probe representing the ClfA SD-repeat region. A SacI-KpnI DNA fragment from E6-2 was then subcloned into the *E. coli* plasmid vector, pZero (Invitrogen, Carlsbad, Calif.). This clone was then mapped with restriction endonucleases, and a 3.5 kb EcoRI-KpnI fragment containing DNA with homology to that encoding SD-repeat amino acids sequence was subcloned into pUC18 (Amersham Pharmacia Biotech, Piscataway, N.J.) to create pE6-2.

The sdrH gene was cloned as follows. HindIII fragments obtained from *S. epidermidis* strain 9491 genomic DNA were size fractionated on a 5-20% sucrose gradient. DNA from fractions containing 1.5-2.5 kb fragments were ligated into pBluescript digested with HindIII and dephosphorylated with CIAP (Promega). *E. coli* transformants containing the ligated

products were screened by colony-blot hybridization with a DIG-labeled (Boehringer Mannheim, Indianapolis, Ind.) probe made to DNA encoding the ClfA SD-repeat region.

Automated dideoxy-DNA sequencing was performed on both strands of cloned DNA. In most cases, extension of DNA sequence on a given clone was achieved with primer walking. This method, however, could not cover the length of repeat DNA encoding the SD-repeats of SdrF. Therefore, this region of DNA was excised from pC5 with Sau3A, ligated into pBluescript, and used as a template for the construction of exonuclease deletion derivatives (Erase-a-base System, Promega). Appropriate deletions on both strands (not shown) were identified by PCR screening and restriction mapping.

TABLE 2

<i>S. epidermidis</i> strains used in this study		
Strains	Comments and properties	Source or reference
9491	SdrF and SdrH prototype strain	ATCC strain
ATCC14990	Reference strain	W. Kloos
KH11		P. Vaudaux
K28	SdrG prototype strain	P. Vaudaux
RP62a		
TU3298	Transformable strain	F. Gotz
9142	Biofilm former	D. Mack
1457		D. Mack
8400		
N910308	Reference strain, Lyon, France	J. Etienne
N910160	Reference strain, Lyon, France	J. Etienne
N910102	Reference strain, Lyon, France	J. Etienne
N910173	Reference strain, Lyon, France	J. Etienne
N910191	Reference strain, Lyon, France	J. Etienne
N910231	Reference strain, Lyon, France	J. Etienne
N910249	Reference strain, Lyon, France	J. Etienne

were generated with Taq DNA polymerase (Gibco BRL), and probes were digoxigenin (Boehringer Mannheim) or fluorescein (Amersham) labeled.

Protein Expression and Purification for Antisera Production  
 DNA encoding recombinant SdrF, SdrG, or SdrH region A was obtained by PCR amplification of genomic template DNA from *S. epidermidis* strains 9491 or K28 with appropriate primers (Table 3). The SdrF region A construct lacked the terminal residue, proline. PCR utilized Pfu DNA polymerase (Stratagene); specifications have been previously described (7). PCR products were digested with appropriate restriction endonucleases and ligated into the expression vectors pQE30 (Qiagen, Valencia, Calif.) to generate histidine-tagged proteins, or pGEX-2T (Pharmacia) or pGEX-KG to generate GST-tagged proteins. Proteins were expressed in *E. coli* by growing 4 liters of recombinant organisms to an optical density (OD<sub>600</sub>) of 0.5 and inducing with 0.3 mM isopropyl-1-thio-β-D-galactoside (IPTG) (Gibco BRL) for two hours. The cells were harvested in PBS (150 mM NaCl, 4.3 mM Na<sub>2</sub>HPO<sub>4</sub>, 1 mM NaH<sub>2</sub>PO<sub>4</sub>) and frozen at -80° C. *E. coli* were passed through a French press and the supernatants of these lysates were filtered through a 0.45 μm membrane. Soluble histidine-tagged proteins, present in the supernatants, were initially purified by metal-chelating chromatography. The supernatants were applied to a 5 ml Ni<sup>2+</sup>-charged HiTrap chelating column (Pharmacia Biotech Inc.) and bound proteins were eluted with 200 ml linear gradients of 0-200 mM imidazole in 4 mM Tris-HCl, 100 mM NaCl, pH 7.9 at a flow rate of 5 ml/min. Fractions containing recombinant proteins were identified by SDS-PAGE (see below), pooled, and dialyzed against 25 mM Tris-HCl, pH 8.0. Dialyzed proteins were concentrated and further purified by ion-exchange chromatography by applying the samples to a 5 ml

TABLE 3

Primers used in PCR amplification for DNA probes and protein expression constructs				
Regions amplified	Sequence	Vector destination	Template DNA	
cifA SD repeat	F: <u>GCCGGATCC</u> CAATTCAGAGGATTCA	(SEQ ID No. 23)	Na	pCF48
	R: <u>GCCAAGCTT</u> ATTGTTAGAACCTGACTC	(SEQ ID No. 24)		
SD repeats	P3: GATTCAAGATAGCCATTC	(SEQ ID No. 25)	Na	sdr clones strain 9491
	P4: CTGAGTCACTGCTGAG	(SEQ ID No. 26)		
sdrF region A	F: <u>CCCGGATCCG</u> CTGAAGACAATCAATTAG	(SEQ ID No. 27)	pQE30	strain K28
	R: <u>CCCAAGCTT</u> AATTATCCCCCTGTGCTG	(SEQ ID No. 28)		
sdrG region A	F: <u>CCCGGATCCG</u> AGGAGAATACAGTACAAGACG	(SEQ ID No. 29)	pQE30	strain 9491
	R: <u>CCCGGTAC</u> CTAGTTTTTCAGGAGGCAAGTCACC	(SEQ ID No. 30)		
sdrH full length	F: <u>CCCGGATCCG</u> AAGGTAATCATCTATTGAC	(SEQ ID No. 31)	pQE30	strain 9491
	R: <u>CCCAAGCTT</u> ACTTTTTTCTTCTAAGATATATAGTCC	(SEQ ID No. 32)		
sdrF region A	F: same as above		pGEX-2T	strain 9491
	R: <u>CCCGAATTC</u> AATTATCCCCCTGTGCTGTTG	(SEQ ID No. 33)		
sdrG region A	F: same as above		pGEX-2T	strain K28
	R: <u>CCCGAATTC</u> TAGTTTTTCAGGAGGCAAGTCACC	(SEQ ID No. 34)		
sdrH region A	F: <u>GCCGGATCCG</u> AAGGTAATCATCTATTG	(SEQ ID No. 35)	pGEX-KG	strain 9491
	R: <u>GCCAAGCTT</u> CTAATATGTGTCATTTTC	(SEQ ID No. 36)		

na: not applicable

underline: restriction endonuclease site used for cloning

### Southern Hybridizations

Southern blot transfers and hybridizations have been described elsewhere (8). DNA probes were made from PCR products encoding the SD-repeat region of ClfA or each region A of SdrF, SdrG, and SdrH (Table 3). PCR products

HiTrap Q column (Pharmacia Biotech Inc.) and eluting bound proteins with 200 ml linear gradients of 0-0.5 M NaCl in 25 mM Tris-HCl, pH 8.0 at a flow rate of 5 ml/min. Fractions containing purified recombinant proteins were identified by SDS-PAGE. GST-tagged proteins were purified

from *E. coli* lysates obtained as described above. Lysates were passed through 10 ml glutathione-agarose columns under gravity flow and washed with five column volumes of PBS. Proteins were eluted from the columns with freshly prepared 5 mM reduced glutathione (Sigma) in 50 mM Tris-HCl, pH 8.0. Purified proteins were used to raise antisera in New Zealand White rabbits using standard protocols issued by HTI Bioproducts (Romano, Calif.) or by the Biological Core Facility at the National University of Ireland (Dublin, Ireland).

#### SDS-Page and Western Blot Transfer

SDS-PAGE utilized trycine gels containing 10% acrylamide (28). Separated proteins were transferred to PVDF membrane (Immobilon-P, Millipore, Bedford, Mass.) with a semi-dry transfer cell (Bio-Rad Laboratories, Hercules, Calif.). All protein samples were heat denatured under reducing conditions. Purified proteins (1 µg each) were subjected to SDS-PAGE and stained with Coomassie brilliant blue. *E. coli* lysates or lysate fractions were obtained as follows: IPTG induced, recombinant *E. coli* were grown to an OD<sub>600</sub> of 2.0, washed and resuspended to original volume in PBS and prepared for SDS-PAGE. 10 µl of each preparation was loaded into individual wells of acrylamide gels. *S. epidermidis* strains were grown to early stationary phase in TSB containing 1.25 U per 10 ml of the endoproteinase inhibitor α<sub>2</sub>-Macroglobulin (Boehringer Mannheim). The cells were adjusted to an OD<sub>600</sub> of 2, washed, and resuspended in one half the original volume. Protease inhibitors (4 mM phenylmethylsulphonyl fluoride, 1 mM N-ethyl-maleimide, and 25 mM aminohexanoic acid) and DNase (10 µg ml<sup>-1</sup>) were added prior to lysostaphin (100 µg ml<sup>-1</sup>) and lysozyme (100 µg ml<sup>-1</sup>). Enzymatic digestions were performed for 30 min. at 37° C. with shaking. Separation of cell-wall proteins from protoplasts utilized the same conditions in the presence of 30% raffinose. *S. epidermidis* lysates or lysate fractions were treated as those for *E. coli* and 30 µl aliquots of samples were placed into wells of acrylamide gels.

#### Immunoassays

Western immunoassays were performed as follows: Western blots were incubated in PBS containing 1% non-fat dry milk for 1 hr. The blots were then incubated with antisera (diluted in PBS-milk) for 1 hr. Monoclonal, anti-histidine antibody (Clonetech, Palo Alto, Calif.) was diluted to 1:3000. Anti-SdrFA antisera (immune, preimmune, and antigen-absorbed) were diluted to 1:30,000; anti-SdrGA antisera were diluted to 1:2000, and anti-SdrHA antisera were diluted to 1:1000. Antisera absorptions have been previously described (14). Briefly, anti-SdrFA and anti-SdrGA antisera were extensively absorbed, respectively, with GST-tagged SdrGA and SdrFA proteins present in insoluble fractions of induced *E. coli* that had been sonicated and then centrifuged. This procedure was used to remove potential cross-reactive antibodies present in each antiserum. Removal of immunoreactive anti-SdrFA, -SdrGA, and -SdrHA antibodies was accomplished by absorbing each antiserum with *E. coli* lysates containing, respectively, GST-tagged SdrFA, SdrGA, and SdrHA. Following antiserum incubation, Western blots were washed three times with PBS and incubated with a 1:2000 dilution of goat, anti-rabbit or anti-mouse IgG conjugated to alkaline phosphatase (Bio-Rad Laboratories) for 30 min. The blots were then washed and developed in chromogenic substrate (150 µg ml<sup>-1</sup> 5-bromo-4-chloro-3-indolyl phosphate p-toluidine salt and 300 µg ml<sup>-1</sup> p-nitro blue tetrazolium chloride in bicarbonate buffer) (Bio-Rad) for 10-15 min.

Reactivity of convalescent patient IgG to recombinant proteins has been previously described (1). Antisera from fifteen

individuals recovering from *S. epidermidis* infections were collected and IgG was purified using protein-A sepharose chromatography. An enzyme-linked immunosorbent assay (ELISA) was used to demonstrate reactivity of IgG (2 µg per well) to recombinant proteins (1 µg per well of histidine-tagged SdrFA or SdrGA, or GST-tagged SdrHA) coated on microtiter plates.

#### Results

##### 10 Identification of the sdrF, sdrG, and sdrH Genes.

Preliminary Southern hybridization analysis of *S. epidermidis* DNA revealed the presence of several loci hybridizing with DNA encoding the SD repeats of the *S. aureus* Sdr protein family (unpublished observations). To further define these loci, we cloned three DNA fragments from *S. epidermidis* strains 9491 and K28. Two clones, pC5 and pC28, were obtained from strain 9491 by direct ligation of HindIII-DNA fragments into *E. coli* plasmid vectors. A third clone, E6-2, was obtained from a λGem®-11 genomic library made from strain K28. A segment of the E6-2 insert DNA was subcloned into an *E. coli* plasmid vector to form pE6-2. pC5, pE6-2, and pC28 were found to have 6.8, 6.0, and 2.0 kb DNA inserts, respectively (not shown).

DNA sequence analysis revealed the presence of single open reading frames (ORF) in each plasmid. The ORFs, designated sdrF, sdrG, and sdrH, were 5199, 2793, and 1461 base pairs (bp) in length, respectively. A leucine, rather than a methionine, codon is predicted to act as a translational start codon for sdrG. A potential ribosome binding site (GGAG) (SEQ ID No. 37) was identified 7-12 bp 5' of each ORF. DNA sequences of 500-1000 bp flanking the sdrF, sdrG, and sdrH ORFs were not similar, suggesting that they are not tandemly linked like the sdrC, sdrD, and sdrE genes of *S. aureus* (data not shown).

##### 35 The Deduced Amino Acids Sequences of SdrF, SdrG, and SdrH.

The amino acid structural organization of the *S. epidermidis* SdrF and SdrG proteins are similar to the *S. aureus* Sdr proteins and thus have features typical of cell-surface proteins that are covalently anchored to the peptidoglycan of Gram-positive bacteria. These cell-surface features include positively-charged residues at the extreme C terminus preceded by a hydrophobic membrane spanning region, and an LPXTG (SEQ ID No. 17) motif. The SD repeat regions are located N-terminal of the LPXTG (SEQ ID No. 17) motif and are proposed to traverse the cell wall (4, 10). SdrF and SdrG contain predicted signal sequences at their N-termini (52 and 50 residues, respectively) and residues associated with cell wall linkage at their C-termini (FIG. 5B, 5C). The SD-repeat regions of SdrF and SdrG (see below) end seven and thirteen residues, respectively, proximal to the LPXTG motifs. The SD-repeat regions of SdrF and SdrG contain 558 and 56 residues, respectively (FIG. 5B). The dipeptide composition of SdrG does not diverge from serine and aspartate, whereas in SdrF, 26 alanine residues occur within the SD-repeat region. The predicted molecular masses of the mature proteins (with loss of the signal sequences) are 179 kDa for SdrF and 97.6 kDa for SdrG.

60 The Sdr proteins of *S. aureus* each possess a structurally distinct, known or putative ligand-binding domain at their N terminus called region A (8, 16, 21). The N termini of mature SdrF and SdrG possess 625 and 548 amino acid region As, respectively. Pairwise comparisons reveal that the amino acid sequences of SdrF and SdrG region As are 22% identical to each other and 20-35% (mean=23%) identical to the region As of the *S. aureus* Sdr proteins.

Amino acid sequence motifs have been reported in the region As of *S. aureus* Sdr proteins, and these include a putative Ca<sup>2+</sup>-binding EF-hand motif in ClfA, a cation-coordinating MIDAS motif in ClfB, and a common Sdr protein motif, TYTFTDYVD (SEQ ID No. 16), of unknown function (8, 23). The region As of SdrF and SdrG both contain a TYTFTDYVD (SEQ ID No. 16) motif, and an EF-hand motif (DYSEYEDVTNDDY) (SEQ ID No. 38) was found in the region A of SdrG.

Three Sdr proteins of *S. aureus* (SdrC, SdrD, and SdrE) contain variable numbers of 110-113 amino acid segments called region B repeats (FIG. 5A), and each repeat contains a putative Ca<sup>2+</sup>-binding EF-hand motif (8, 9). Likewise, SdrF contains four region B repeats (of 119, 110, 111, and 111 residues), and SdrG contains two region B repeats (of 113 and 111 residues) (FIG. 5B). Each repeat contains a putative EF-hand motif with a consensus sequence of DX(N/D)X(D/N)GXX(D/N/G)XX(E/D). The region B repeats of SdrF and SdrG have 43-85% (mean=55%) identity with each other and 39-73% (mean=54%) identity to the region B repeats found in the *S. aureus* Sdr proteins.

The structural organization of SdrH at the amino acid sequence level is considerably different than that of SdrF and SdrG. Following a potential 30 residue signal sequence at its N terminus, SdrH has a unique 60 residue stretch (region A) followed by a 120-residue SD-repeat region and a 277-residue segment, region C, that contains a hydrophobic sequence at its C terminus but lacks an appropriately placed LPXTG motif. The sequence LGVTG, however, occurs within the hydrophobic region. (FIG. 1B, 1C). SdrH contained no region B repeats. The region A and region C of SdrH have no amino acid sequence similarities with other known Sdr proteins or protein sequences from various databases. Motifs common to other Sdr proteins were not found. The mature molecular mass of SdrH is predicted to be 50.5 kDa.

Together, these results suggest that *S. epidermidis* has the capacity to express two proteins related to the *S. aureus* Sdr protein family, as well as a third Sdr protein with novel structure.

#### Distribution of sdrF, sdrG, and sdrH in *S. Epidermidis* Strains.

In Southern hybridization analysis, a DNA probe representing the encoding region of the ClfA SD-repeats hybridized to several genomic HindIII fragments in sixteen *S. epidermidis* strains (FIG. 6A). Three hybridizing fragments were observed in most strains, presumably representing the sdrF, sdrG, and sdrH genes. To confirm this and determine the frequency of the genes within these strains, additional analyses were performed with probes specific for DNA encoding each region A. The sdrH probe hybridized to fragments between 1.8-6.5 kb in all strains (FIG. 6B). The sdrG probe hybridized to a 16-kb fragment in all strains examined (FIG. 6C). In addition, the probe hybridized to HindIII fragments of 3.4 kb in four of the sixteen strains (KH11, K28, RP62a, and N910102). The same 3.4 kb fragments, however, did not hybridize with a probe specific for DNA encoding SD-repeats (FIG. 6A), suggesting the presence of a gene with similarity to the sdrG region A that lacks a SD-repeat region. FIG. 6D shows a Southern blot probed with both sdrG and sdrF region A DNA. The sdrF probe hybridized to HindIII-DNA fragments between 4.5 kb and 10 kb in twelve out of sixteen strains (strains K28, RP62a, N910173, and N910191 lacked a hybridizing band). These results suggest that the sdrF, sdrG, and sdrH genes are prevalent in *S. epidermidis* strains.

#### Expression of SdrF, SdrG, and SdrH in *S. Epidermidis*.

Immunologic methods were used to determine if SdrF, SdrG, and SdrH are expressed by *S. epidermidis*. Specific

rabbit antisera were raised to recombinant fusion proteins representing different region As (designated SdrFA, SdrGA, and SdrHA). SdrFA and SdrGA were fused to polyhistidine (His<sub>n</sub>), and SdrHA was fused to GST (FIG. 7A). Monospecificity of the antisera was confirmed against a panel of recombinant proteins containing different protein fusions. Specifically, antisera raised to His<sub>n</sub>-SdrFA and -SdrGA did not, respectively, cross react with GST-SdrGA and -SdrFA (FIG. 7B). In addition, these same antisera did not cross react to GST-SdrHA (FIG. 7B). Antiserum raised to GST-SdrHA reacted to a full-length, His<sub>n</sub>-SdrH protein but not to His<sub>n</sub>-SdrFA or -SdrGA proteins (FIG. 7C).

The region A-specific antisera were used to identify native SdrF, SdrG, and SdrH in lysates of their cognate *S. epidermidis* strains by Western immunoblotting. The anti-SdrFA antiserum reacted with a ca 230 kDa band from strain 9491 (FIG. 8A). This band was not present with Western blots reacted with preimmune antiserum or with anti-SdrFA antiserum that had been absorbed with *E. coli* lysates expressing a GST-SdrFA fusion protein (FIG. 8A). The anti-SdrGA antiserum reacted to a 170 kDa band in a lysate of *S. epidermidis* strain K28. This band was not present with preimmune antiserum or with anti-SdrGA antiserum that had been absorbed with an *E. coli* lysate expressing a GST-SdrGA fusion protein (FIG. 8B). Antiserum to SdrHA recognized a 75 kDa band in strain 9491, and this reactivity could be removed by absorbing the antiserum with recombinant SdrH present in an *E. coli* lysate (FIG. 8C). The apparent molecular masses of the anti-SdrFA, -SdrGA, and -SdrHA immunoreactive bands are larger than the masses predicted from the deduced amino acid sequences (179, 97, and 50 kDa, respectively). Decreased migration on SDS-PAGE has been previously noted for two *S. aureus* Sdr proteins, ClfA and ClfB, where up to a 50-100% increase in predicted mass was observed. The acidic nature of the Sdr proteins has been suggested to account for these observations.

#### Differences in Molecular Mass of SdrH in *S. Epidermidis* Strains.

Western immunoblot analysis, different strains of *S. epidermidis* possessed SdrH with apparent molecular masses that varied between 60 and 75 kDa (FIG. 9A). Variations in the molecular mass of ClfA has been previously correlated with the length of the SD-repeat region (15). PCR analysis of the sdrH genes from the *S. epidermidis* strains used above revealed that variations in the size of DNA encoding the SD-repeat regions correlated with the different masses of the SdrH proteins on Western blots. In contrast, PCR products of DNA encoding the region C of each SdrH were similar in size (FIG. 9B).

#### Analyses of SdrF, SdrG, and SdrH in Cell Wall Extracts and Protoplasts.

The presence of a LPXTG motif in both SdrF and SdrG suggests that these proteins are anchored in the cell wall and would therefore be present in cell-wall extracts of lysostaphin-treated *S. epidermidis*. Western blot analyses of early stationary phase, lysostaphin-digested *S. epidermidis* strain 9491 with anti-SdrFA antiserum revealed the presence of the 230 kDa SdrF band in both the whole-cell lysate and the cell-wall extract but not in the protoplast fraction (FIG. 10A). In contrast, analysis of the same samples with anti-SdrGA antiserum revealed the presence of SdrG (170 kDa) in the lysate and protoplast fraction but not in the cell-wall extract (FIG. 10B). Similar results were observed with blots containing lysostaphin-treated strain K28 (not shown). Further analysis of 9491 lysostaphin fractions with anti-SdrHA antiserum revealed an immunoreactive band in both the cell-wall lysate and protoplast fraction (FIG. 10C). These results sug-

gest that, under these in vitro conditions, SdrF is localized and anchored to the cell wall, and that SdrG (despite its LPXTG motif and SdrH are either associated with the cytoplasmic membrane or located inside the cell.

Reactivity of Convalescent Patient Antisera to SdrF, SdrG, and SdrH.

Recently, IgG from patients recovering from *S. aureus* infections has been shown to react with the fibronectin binding protein (FnbpA), suggesting that FnbpA is expressed by *S. aureus* during infection (1). Here, IgG purified from the antisera of fifteen patients recovering from various *S. epidermidis* infections was tested by ELISA for reactivity with the recombinant SdrF, SdrG, and SdrH region A proteins. FIG. 11 shows that IgG from patients' antisera had a higher titer to SdrFA, SdrGA, and SdrHA compared to that of IgG purified from pooled children antisera. The patients' IgG was often more reactive with SdrGA and SdrHA than with SdrFA. These results suggest that the Sdr proteins are expressed during *S. epidermidis* infection in humans.

#### Discussion

*S. epidermidis* infections in humans are associated with foreign-body devices that become rapidly coated with matrix proteins when introduced into the patient (26). Although mechanisms (encoded by the *ica* operon) have been proposed to mediate adherence and biofilm formation on uncoated polymer surfaces, specific factors mediating adherence to surfaces coated with host proteins have been poorly defined. The presence of Sdr proteins in *S. epidermidis* suggest that *S. epidermidis* may bind protein-coated matrix devices in a manner similar to *S. aureus* which utilizes ClfA and ClfB to mediate adherence to prosthetic devices coated with fibrinogen (21, 31). In this regard, a recombinant protein, expressed from cloned *S. epidermidis* DNA and similar to SdrG, has been shown to bind fibrinogen (22).

The *S. epidermidis* Sdr proteins may play a role in pathogenic processes apart from initial adherence. Experiments showing that proteolytic cleavage of the fibronectin-binding protein, Fnbp, from the surface of *S. aureus* produces a soluble, active protein, and this cleavage has been proposed to initiate release and dissemination of *S. aureus* from solid-phase fibronectin (18). Analogously, native SdrF and SdrG undergo rapid degradation in in vitro culture conditions in the absence of protease inhibitors (unpublished observations), and this proteolysis may provide a mechanism by which the bacteria can be detached from a substrate.

SdrF fractionates with cell-wall anchored proteins released by lysostaphin digestion, suggesting that it is present on the cell surface. In contrast, SdrG, which contains an LPXTG, cell-wall sorting motif similar to SdrF, was found only in the protoplast fraction. The apparent lack of SdrG in the cell-wall fraction may be influenced by the bacterial growth phase or by proteolytic enzymes expressed during various growth phases. For instance, SdrG was found to be absent or diminished in lysates of strain K28 in early exponential phase. In addition, a number of *S. epidermidis* strains grown to late stationary phase did contain SdrG in the cell-wall extracts while other strains (including K28 and 9491) contained only potential degradation products of SdrG (unpublished results). Further studies are warranted to detail the regulation of SdrG anchorage to the cell wall and localization at the cell surface. Similarly, additional studies are required for SdrH, which contains features of cell-wall proteins but lacks a clear LPXTG motif.

As mentioned above, a protein similar to SdrG (designated Fbe) has been identified as a *S. epidermidis* protein capable of binding fibrinogen (22). Fbe was reported to have a region A

directly adjacent to a SD-repeat region, but structures similar to region B repeats were not described. We have found that Fbe contains two region B repeats with 99% amino acids identity to the region B repeats of SdrG (unpublished results). In the reported sequence of Fbe, these repeats begin at amino acid 601 and end at the beginning of the SD-repeats. The original region A of Fbe was reported to contain a minimal fibrinogen-binding region between residues 269-599. With respect to the newly identified region B repeats, the minimal fibrinogen-binding region would be positioned at the extreme C terminus of region A. This is similar to ClfA which contains a minimal fibrinogen-binding region at its C terminus (McDevitt, 1995). The region As of Fbe and SdrG are 93% identical in amino acid sequence, and the predicted minimal-binding regions are 98% identical.

SdrH is unique among the eight described members of the Sdr protein family (from *S. aureus* and *S. epidermidis*) in that it possesses a divergent putative domain organization. The position of the SD-repeat region at the N terminus, a novel region C, and the lack of definitive cell-wall association sequences suggest that this protein functions differently than the known Sdr MSCRAMMs. Further studies on the bacterial localization and ligand-binding potential of SdrH are in progress.

The SD-repeat regions of SdrF and SdrG represent the longest and shortest SD repeats (558 and 56 residues, respectively) of the eight known Sdr proteins. Although the SD-repeats do not participate in fibrinogen binding, wild-type levels of functional ClfA expression were found to require a SD-repeat region with more than 40 residues (72 residues from the end of region A to the LPXTG motif (4). This expanse of amino acids was postulated to span the cell wall and present a functional region A. Although SdrG contains 73 residues from the end of the region B repeats to the LPXTG motif, the two region B repeats may also affect the structure and function of the ligand-binding region A. The purpose of an extremely large SD-repeat region in SdrF is unknown. Given the interaction of the SD-repeat region with the cell wall, the differences in length of the SD-repeat regions between SdrF and SdrG may be associated with the localization differences observed in cell-wall fractions of these proteins. Variations in the length of SD-repeats in SdrH have been described. The SdrH protein from strain KH11 (the smallest SdrH observed) was found by DNA sequence analysis to contain 64 residues (unpublished results). The role of the SD repeats in SdrH is unknown but we speculate that this region, like other Sdr proteins, may be partially associated with the cell wall.

Genes encoding Sdr proteins of *S. epidermidis* are present in most of the clinical isolates examined to date. These strains were isolated from a broad range of disease outcomes in patients of diverse geographic locations. In addition, patients recovering from a variety of *S. epidermidis* infections have SdrF-, SdrG-, and SdrH-reactive IgG in their antisera. Similar traits have been observed for the five reported Sdr proteins of *S. aureus* [(8, 17) and unpublished results]. These studies suggest that the Sdr proteins are important constituents in *S. epidermidis* infectivity and growth. Interestingly, loci with homology to DNA encoding SD-repeat regions are also prevalent in strains of *S. haemolyticus*, *S. lugdunensis*, and *S. intermedius*, additional staphylococci capable of producing disease in humans and other mammals (unpublished results).

#### REFERENCES CITED IN EXAMPLE 2

1. Casolini, F., L. Visai, D. Joh, P. G. Conaldi, A. Toniolo, M. Höök, and P. Speziale. 1998. Antibody response to



- fibrinectin-binding adhesin FnbpA in patients with *Staphylococcus aureus* infections. *Infect Immun.* 66:5433-5442.
2. Fleer, A., and J. Verhoef. 1989. An evaluation of the role of surface hydrophobicity and extracellular slime in the pathogenesis of foreign-body-related infections due to coagulase-negative staphylococci. *J Invest Surg.* 2:391-6.
  3. Foster, T. J., and M. Höök. 1998. Surface protein adhesins of *Staphylococcus aureus*. *Trends Microbiol.* 6:484-488.
  4. Hartford, O., P. Francois, P. Vaudaux, and T. J. Foster. 1997. The dipeptide repeat region of the fibrinogen-binding protein (clumping factor) is required for functional expression of the fibrinogen-binding domain on the *Staphylococcus aureus* cell surface. *Mol Microbiol.* 25:1065-1076.
  5. Heilmann, C., O. Schweitzer, C. Gerke, N. Vanittanakom, D. Mack, and F. Götz. 1996. Molecular basis of intercellular adhesion in the biofilm-forming *Staphylococcus epidermidis*. *Mol Microbiol.* 20:1083-1091.
  6. Herrmann, M., P. E. Vaudaux, D. Pittet, R. Auckenthaler, P. D. Lew, F. Schumacher-Perdreau, G. Peters, and F. A. Waldvogel. 1988. Fibronectin, fibrinogen, and laminin act as mediators of adherence of clinical staphylococcal isolates to foreign material. *J Infect Dis.* 158:693-701.
  7. Joh, H. J., K. House-Pompeo, J. M. Patti, S. Gurusiddappa, and M. Höök. 1994. Fibronectin receptors from Gram-positive bacteria: Comparison of active sites. *Biochem.* 33:6086-6092.
  8. Josefsson, E., K. W. McCrea, D. Ni Eidhin, D. O'Connell, Cox, J., M. Höök, and T. J. Foster. 1998. Three new members of the serine-aspartate repeat protein multigene family of *Staphylococcus aureus*. *Microbiology.* 144:3387-3395.
  9. Josefsson, E., D. O'Connell, T. J. Foster, I. Durussel, and J. A. Cox. 1998. The binding of calcium to the B-repeat segment of SdrD, a cell surface protein of *Staphylococcus aureus*. *J Biol. Chem.* 273:31145-31152.
  10. Kehoe, M. A. 1994. Cell-Wall-Associated Proteins in Gram-Positive Bacteria. In J. M. Ghuysen, and R. Hakenbeck (ed.), *Bacterial Cell Wall.* p.217-61.
  11. Kloos, W. E., and T. L. Bannerman. 1994. Update on clinical significance of coagulase-negative staphylococci. *Clin Microbiol Rev.* 7:117-140.
  12. Mack, D., M. Nedelmann, A. Krokotsch, A. Schwarzkopf, J. Heesemann, and R. Laufs. 1994. Characterization of transposon mutants of biofilm-producing *Staphylococcus epidermidis* impaired in the accumulative phase of biofilm production: genetic identification of a hexosamine-containing polysaccharide intercellular adhesin. *Infect Immun.* 62:3244-3253.
  13. Martin, M. A., M. A. Pfaller, R. M. Massanari, and R. P. Wenzel. 1989. Use of cellular hydrophobicity, slime production, and species identification markers for the clinical significance of coagulase-negative staphylococcal isolates. *Am J Infect Control.* 17:130-135.
  14. McCrea, K. W., W. J. Wats n, J. R. Gilsdorf, and C. F. Marrs. 1997. Identification of two minor subunits in the pilus of *Haemophilus influenzae*. *J. Bacteriol.* 179:4227-4231.
  15. McDevitt, D., and T. J. Foster. 1995. Variation in the size of the repeat region of the fibrinogen receptor (clumping factor) of *Staphylococcus aureus* strains. *Microbiology.* 141:937-43.
  16. McDevitt, D., P. Francois, P. Vaudaux, and T. J. Foster. 1995. Identification of the ligand-binding domain of the

- surface-located fibrinogen receptor (clumping factor) of *Staphylococcus aureus*. *Mol Microbiol.* 16:895-907.
17. McDevitt, D., P. Francois, P. Vaudaux, and T. J. Foster. 1994. Molecular characterization of the clumping factor (fibrinogen receptor) of *Staphylococcus aureus*. *Mol Microbiol.* 11:237-248.
  18. McGavin, M. J., C. Zahradka, K. Rice, and J. E. Scott. 1997. Modification of the *Staphylococcus aureus* fibrinectin binding phenotype by V8 protease. *Infect Immun.* 65:2621-2628.
  19. McKenney, D., J. Hubner, E. Muller, Y. Wang, D. A. Goldmann, and G. B. Pier. 1998. The ica locus of *Staphylococcus epidermidis* encodes production of the capsular polysaccharide/adhesin. *Infect Immun.* 66:4711-4720.
  20. Moreillon, P., J. M. Entenza, P. Francioli, D. McDevitt, T. J. Foster, P. Francois, and P. Vaudaux. 1995. Role of *Staphylococcus aureus* coagulase and clumping factor in pathogenesis of experimental endocarditis. *Infect Immun.* 63:4738-4743.
  21. Ni Eidhin, D., S. Perkins, P. Francois, P. Vaudaux, M. Höök, and T. J. Foster. 1998. Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of *Staphylococcus aureus*. *Mol Microbiol.* 30:245-257.
  22. Nilsson, M., L. Frykberg, J. I. Flock, L. Pei, M. Lindberg, and B. Guss. 1998. A fibrinogen-binding protein of *Staphylococcus epidermidis*. *Infect Immun.* 66:2666-2673.
  23. O'Connell, D. P., T. Nanavaty, D. McDevitt, S. Gurusiddappa, M. Höök, and T. J. Foster. 1998. The fibrinogen-binding MSCRAMM (clumping factor) of *Staphylococcus aureus* has a Ca<sup>2+</sup>-dependent inhibitory site. *J Biol. Chem.* 273:6821-6829.
  24. Pascual, A., A. Fleer, N. A. Westerdal, and J. Verhoef. 1986. Modulation of adherence of coagulase-negative staphylococci to Teflon catheters in vitro. *Eur J Clin Microbiol.* 5:518-22.
  25. Paulsson, M., A. Ljungh, and T. Wadström. 1992. Rapid identification of fibronectin, vitronectin, laminin, and collagen cell surface binding proteins on coagulase-negative staphylococci by particle agglutination assays. *J Clin Microbiol.* 30:2006-2012.
  26. Pitt, W. G., B. R. Young, K. Park, and S. L. Cooper. 1988. Plasma protein adsorption: in vitro and ex vivo observations. *Macromol. Chem. Macromol. Symp.* 17:435-465. (Abstract).
  27. Rapley, R., and M. Walker. 1992. PCR screening of DNA cloned into polylinker-containing vectors with M13 sequencing primers. *Biotechniques.* 12:516.
  28. Schägger, H., and G. von Jagow. 1987. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. *Anal Biochem.* 166:368-79.
  29. Switalski, L. M., C. Ryden, K. Rubin, A. Ljungh, M. Höök, and T. Wadström. 1983. Binding of fibronectin to *Staphylococcus* strains. *Infect Immun.* 42:628-633.
  30. Timmerman, C. P., A. Fleer, J. M. Besnier, L. De Graaf, F. Cremers, and J. Verhoef. 1991. Characterization of a proteinaceous adhesin of *Staphylococcus epidermidis* which mediates attachment to polystyrene. *Infect Immun.* 59:4187-4192.
  31. Vaudaux, P. E., P. Francois, R. A. Proctor, D. McDevitt, T. J. Foster, R. M. Albrecht, D. P. Lew, H. Wabers, and S. L. Cooper. 1995. Use of adhesion-defective mutants of *Staphylococcus aureus* to define the role of specific plasma proteins in promoting bacterial adhesion to canine arteriovenous shunts. *Infect Immun.* 63:585-590.

## SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 39

<210> SEQ ID NO 1

<211> LENGTH: 5406

<212> TYPE: DNA

<213> ORGANISM: Staphylococcus epidermidis

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(5406)

<223> OTHER INFORMATION:

<400> SEQUENCE: 1

tat tgg ata aat tat gct tat aaa gta ttt aca taa aaa tgt aaa tgc	48
Tyr Trp Ile Asn Tyr Ala Tyr Lys Val Phe Thr Lys Cys Lys Cys	
1 5 10 15	
aat tta caa gta aat att caa att att tcc ttg taa aat att tat ttt	96
Asn Leu Gln Val Asn Ile Gln Ile Ile Ser Leu Asn Ile Tyr Phe	
20 25 30	
aac tgg agg tat agt atg aaa aag aga aga caa gga cca att aac aag	144
Asn Trp Arg Tyr Ser Met Lys Lys Arg Arg Gln Gly Pro Ile Asn Lys	
35 40 45	
aga gtg gat ttt cta tcc aac aag gta aac aag tac tcg att agg aag	192
Arg Val Asp Phe Leu Ser Asn Lys Val Asn Lys Tyr Ser Ile Arg Lys	
50 55 60	
ttc aca gta ggt aca gct tca ata ctc gtg ggt gct acg tta atg ttt	240
Phe Thr Val Gly Thr Ala Ser Ile Leu Val Gly Ala Thr Leu Met Phe	
65 70 75	
ggt gcc gca gac aat gag gct aaa gcg gct gaa gac aat caa tta gaa	288
Gly Ala Ala Asp Asn Glu Ala Lys Ala Ala Glu Asp Asn Gln Leu Glu	
80 85 90	
tca gct tca aaa gaa gaa cag aaa ggt agt cgt gat aat gaa aac tca	336
Ser Ala Ser Lys Glu Gln Lys Gly Ser Arg Asp Asn Glu Asn Ser	
95 100 105 110	
aaa ctt aat caa gtc gat tta gac aac gga tca cat agt tct gag aaa	384
Lys Leu Asn Gln Val Asp Leu Asp Asn Gly Ser His Ser Ser Glu Lys	
115 120 125	
aca aca aat gta aac aat gca act gaa gta aaa aaa gtt gaa gca cca	432
Thr Thr Asn Val Asn Asn Ala Thr Glu Val Lys Lys Val Glu Ala Pro	
130 135 140	
acg aca agt gac gta tct aag cct aaa gct aat gaa gca gta gtg acg	480
Thr Thr Ser Asp Val Ser Lys Pro Lys Ala Asn Glu Ala Val Val Thr	
145 150 155	
aat gag tca act aaa cca aaa aca aca gaa gca cca act gtt aat gag	528
Asn Glu Ser Thr Lys Pro Lys Thr Thr Glu Ala Pro Thr Val Asn Glu	
160 165 170	
gaa tca ata gct gaa aca ccc aaa acc tca act aca caa caa gat tcg	576
Glu Ser Ile Ala Glu Thr Pro Lys Thr Ser Thr Thr Gln Gln Asp Ser	
175 180 185 190	
act gag aag aat aat cca tct tta aaa gat aat tta aat tca tcc tca	624
Thr Glu Lys Asn Asn Pro Ser Leu Lys Asp Asn Leu Asn Ser Ser Ser	
195 200 205	
acg aca tct aaa gaa agt aaa aca gac gaa cat tct act aag caa gct	672
Thr Thr Ser Lys Glu Ser Lys Thr Asp Glu His Ser Thr Lys Gln Ala	
210 215 220	
caa atg tct act aat aaa tca aat tta gac aca aat gac tct cca act	720
Gln Met Ser Thr Asn Lys Ser Asn Leu Asp Thr Asn Asp Ser Pro Thr	
225 230 235	
caa agt gag aaa act tca tca caa gca aat aac gac agt aca gat aat	768
Gln Ser Glu Lys Thr Ser Ser Ser Gln Ala Asn Asn Asp Ser Thr Asp Asn	
240 245 250	

-continued

cag tca gca cct tct aaa caa tta gat tca aaa cca tca gaa caa aaa Gln Ser Ala Pro Ser Lys Gln Leu Asp Ser Lys Pro Ser Glu Gln Lys 255 260 265 270	816
gta tat aaa aca aaa ttt aat gat gaa cct act caa gat gtt gaa cac Val Tyr Lys Thr Lys Phe Asn Asp Glu Pro Thr Gln Asp Val Glu His 275 280 285	864
acg aca act aaa tta aaa aca cct tct gtt tca aca gat agt tca gtc Thr Thr Thr Lys Leu Lys Thr Pro Ser Val Ser Thr Asp Ser Ser Val 290 295 300	912
aat gat aag caa gat tac aca cga agt gct gta gct agt tta ggt gtt Asn Asp Lys Gln Asp Tyr Thr Arg Ser Ala Val Ala Ser Leu Gly Val 305 310 315	960
gat tct aat gaa aca gaa gca att aca aat gca gtt aga gac aat tta Asp Ser Asn Glu Thr Glu Ala Ile Thr Asn Ala Val Arg Asp Asn Leu 320 325 330	1008
gat tta aaa gct gca tct aga gaa caa atc aat gaa gca atc att gct Asp Leu Lys Ala Ala Ser Arg Glu Gln Ile Asn Glu Ala Ile Ile Ala 335 340 345 350	1056
gaa gca cta aaa aaa gac ttt tct aac cct gat tat ggt gtc gat acg Glu Ala Leu Lys Lys Asp Phe Ser Asn Pro Asp Tyr Gly Val Asp Thr 355 360 365	1104
cca tta gct cta aac aga tct caa tca aaa aat tca cca cat aag agt Pro Leu Ala Leu Asn Arg Ser Gln Ser Lys Asn Ser Pro His Lys Ser 370 375 380	1152
gca agt cca cgc atg aat tta atg agt tta gct gct gag cct aat agt Ala Ser Pro Arg Met Asn Leu Met Ser Leu Ala Ala Glu Pro Asn Ser 385 390 395	1200
ggt aaa aat gtg aat gat aaa gtt aaa atc aca aac cct acg ctt tca Gly Lys Asn Val Asn Asp Lys Val Lys Ile Thr Asn Pro Thr Leu Ser 400 405 410	1248
ctt aat aag agt aat aat cac gct aat aac gta ata tgg cca aca agt Leu Asn Lys Ser Asn Asn His Ala Asn Asn Val Ile Trp Pro Thr Ser 415 420 425 430	1296
aac gaa caa ttt aat tta aaa gca aat tat gaa tta gat gac agc ata Asn Glu Gln Phe Asn Leu Lys Ala Asn Tyr Glu Leu Asp Asp Ser Ile 435 440 445	1344
aaa gag gga gat act ttt act att aag tat ggt cag tat att aga ccg Lys Glu Gly Asp Thr Phe Thr Ile Lys Tyr Gly Gln Tyr Ile Arg Pro 450 455 460	1392
ggt ggt tta gaa ctt cct gca ata aaa act caa cta cgt agt aag gat Gly Gly Leu Glu Leu Pro Ala Ile Lys Thr Gln Leu Arg Ser Lys Asp 465 470 475	1440
ggc tct att gta gct aat ggt gta tat gat aaa act aca aat acg acg Gly Ser Ile Val Ala Asn Gly Val Tyr Asp Lys Thr Thr Asn Thr Thr 480 485 490	1488
act tat aca ttt act aac tat gtt gat caa tat caa aat att aca ggt Thr Tyr Thr Phe Thr Asn Tyr Val Asp Gln Tyr Gln Asn Ile Thr Gly 495 500 505 510	1536
agt ttt gat tta att gcg acg cct aag agg gaa aca gca att aag gat Ser Phe Asp Leu Ile Ala Thr Pro Lys Arg Glu Thr Ala Ile Lys Asp 515 520 525	1584
aat cag aat tat cct atg gaa gtg acg att gct aac gaa gta gtc aaa Asn Gln Asn Tyr Pro Met Glu Val Thr Ile Ala Asn Glu Val Val Lys 530 535 540	1632
aaa gac ttc att gtg gat tat ggt aat aaa aag gac aat aca act aca Lys Asp Phe Ile Val Asp Tyr Gly Asn Lys Lys Asp Asn Thr Thr Thr 545 550 555	1680
gca gcg gta gca aat gtg gat aat gta aat aat aaa cat aac gaa gtt Ala Ala Val Ala Asn Val Asp Asn Val Asn Asn Lys His Asn Glu Val 560 565 570	1728

-continued

560	565	570	
gtt tat cta aac caa aat aac caa aac cct aaa tat gct aaa tat ttc Val Tyr Leu Asn Gln Asn Asn Gln Asn Pro Lys Tyr Ala Lys Tyr Phe 575 580 585 590			1776
tca aca gta aaa aat ggt gaa ttt ata cca ggt gaa gtg aaa gtt tac Ser Thr Val Lys Asn Gly Glu Phe Ile Pro Gly Glu Val Lys Val Tyr 595 600 605			1824
gaa gtg acg gat acc aat gcg atg gta gat agc ttc aat cct gat tta Glu Val Thr Asp Thr Asn Ala Met Val Asp Ser Phe Asn Pro Asp Leu 610 615 620			1872
aat agt tct aat gta aaa gat gtg aca agt caa ttt gca cct aaa gta Asn Ser Ser Asn Val Lys Asp Val Thr Ser Gln Phe Ala Pro Lys Val 625 630 635			1920
agt gca gat ggt act aga gtt gat atc aat ttt gct aga agt atg gca Ser Ala Asp Gly Thr Arg Val Asp Ile Asn Phe Ala Arg Ser Met Ala 640 645 650			1968
aat ggt aaa aag tat att gta act caa gca gtg aga cca acg gga act Asn Gly Lys Lys Tyr Ile Val Thr Gln Ala Val Arg Pro Thr Gly Thr 655 660 665 670			2016
gga aat gtt tat acc gaa tat tgg tta aca aga gat ggt act acc aat Gly Asn Val Tyr Thr Glu Tyr Trp Leu Thr Arg Asp Gly Thr Thr Asn 675 680 685			2064
aca aat gat ttt tac cgt gga acg aag tct aca acg gtg act tat ctc Thr Asn Asp Phe Tyr Arg Gly Thr Lys Ser Thr Thr Val Thr Tyr Leu 690 695 700			2112
aat ggt tct tca aca gca cag ggg gat aat cct aca tat agt cta ggt Asn Gly Ser Ser Thr Ala Gln Gly Asp Asn Pro Thr Tyr Ser Leu Gly 705 710 715			2160
gac tat gta tgg tta gat aaa aat aaa aac ggt gtt caa gat gat gat Asp Tyr Val Trp Leu Asp Lys Asn Lys Asn Gly Val Gln Asp Asp Asp 720 725 730			2208
gag aaa ggt tta gca ggt gtt tat gtt act ctt aaa gac agt aac aat Glu Lys Gly Leu Ala Gly Val Tyr Val Thr Leu Lys Asp Ser Asn Asn 735 740 745 750			2256
aga gaa tta caa cgt gta act act gat caa tct gga cat tat caa ttt Arg Glu Leu Gln Arg Val Thr Thr Asp Gln Ser Gly His Tyr Gln Phe 755 760 765			2304
gat aat tta caa aat gga acg tac aca gtc gag ttt gcg att cct gat Asp Asn Leu Gln Asn Gly Thr Tyr Thr Val Glu Phe Ala Ile Pro Asp 770 775 780			2352
aat tat acg cca tct ccc gca aat aat tct aca aat gat gca ata gat Asn Tyr Thr Pro Ser Pro Ala Asn Asn Ser Thr Asn Asp Ala Ile Asp 785 790 795			2400
tca gat ggt gaa cgt gat ggt aca cgt aaa gta gtt gtt gcc aaa gga Ser Asp Gly Glu Arg Asp Gly Thr Arg Lys Val Val Val Ala Lys Gly 800 805 810			2448
aca att aat aat gct gat aat atg act gta gat act ggc ttt tat tta Thr Ile Asn Asn Ala Asp Asn Met Thr Val Asp Thr Gly Phe Tyr Leu 815 820 825 830			2496
act cct aaa tac aat gtc gga gat tat gta tgg gaa gat aca aat aaa Thr Pro Lys Tyr Asn Val Gly Asp Tyr Val Trp Glu Asp Thr Asn Lys 835 840 845			2544
gat ggt atc caa gat gac aat gaa aaa gga att tct ggt gtt aaa gta Asp Gly Ile Gln Asp Asp Asn Glu Lys Gly Ile Ser Gly Val Lys Val 850 855 860			2592
acg tta aaa aat aaa aat gga gat act att ggc aca acg aca aca gat Thr Leu Lys Asn Lys Asn Gly Asp Thr Ile Gly Thr Thr Thr Asp 865 870 875			2640
tca aat ggt aaa tat gaa ttc aca ggt tta gag aac ggg gat tac aca			2688

-continued

Ser	Asn	Gly	Lys	Tyr	Glu	Phe	Thr	Gly	Leu	Glu	Asn	Gly	Asp	Tyr	Thr		
880						885					890						
ata	gaa	ttt	gag	acg	ccg	gaa	ggc	tac	aca	ccg	act	aaa	caa	aac	tcg	2736	
Ile	Glu	Phe	Glu	Thr	Pro	Glu	Gly	Tyr	Thr	Pro	Thr	Lys	Gln	Asn	Ser		
895				900						905					910		
gga	agt	gac	gaa	ggt	aaa	gat	tca	aac	ggt	acg	aaa	aca	aca	gtc	aca	2784	
Gly	Ser	Asp	Glu	Gly	Lys	Asp	Ser	Asn	Gly	Thr	Lys	Thr	Thr	Val	Thr		
			915						920					925			
gtc	aaa	gat	gca	gat	aat	aaa	aca	ata	gac	tca	ggt	ttc	tac	aag	cca	2832	
Val	Lys	Asp	Ala	Asp	Asn	Lys	Thr	Ile	Asp	Ser	Gly	Phe	Tyr	Lys	Pro		
			930					935					940				
aca	tat	aac	tta	ggt	gac	tat	gta	tgg	gaa	gat	aca	aat	aaa	gat	ggt	2880	
Thr	Tyr	Asn	Leu	Gly	Asp	Tyr	Val	Trp	Glu	Asp	Thr	Asn	Lys	Asp	Gly		
		945					950					955					
att	caa	gac	gac	agt	gaa	aaa	ggg	att	tct	ggg	gtt	aaa	gtg	acg	tta	2928	
Ile	Gln	Asp	Asp	Ser	Glu	Lys	Gly	Ile	Ser	Gly	Val	Lys	Val	Thr	Leu		
	960					965				970							
aaa	gat	aaa	aat	gga	aat	gcc	att	ggg	aca	acg	aca	aca	gac	gca	agt	2976	
Lys	Asp	Lys	Asn	Gly	Asn	Ala	Ile	Gly	Thr	Thr	Thr	Thr	Asp	Ala	Ser		
975					980					985				990			
ggt	cat	tat	caa	ttt	aaa	gga	tta	gaa	aat	gga	agc	tac	aca	gtt	gag	3024	
Gly	His	Tyr	Gln	Phe	Lys	Gly	Leu	Glu	Asn	Gly	Ser	Tyr	Thr	Val	Glu		
				995					1000					1005			
ttt	gag	aca	cca	tca	ggt	tat	aca	ccg	aca	aaa	gcg	aat	tca	ggt		3069	
Phe	Glu	Thr	Pro	Ser	Gly	Tyr	Thr	Pro	Thr	Lys	Ala	Asn	Ser	Gly			
			1010					1015					1020				
caa	gat	ata	act	gta	gat	tcc	aac	ggt	ata	aca	aca	aca	ggt	atc		3114	
Gln	Asp	Ile	Thr	Val	Asp	Ser	Asn	Gly	Ile	Thr	Thr	Thr	Gly	Ile			
			1025					1030					1035				
att	aac	gga	gct	gat	aat	ctc	aca	att	gat	agt	ggt	ttc	tac	aaa		3159	
Ile	Asn	Gly	Ala	Asp	Asn	Leu	Thr	Ile	Asp	Ser	Gly	Phe	Tyr	Lys			
			1040					1045					1050				
aca	cca	aaa	tat	agt	gtc	gga	gat	tat	gta	tgg	gaa	gat	aca	aat		3204	
Thr	Pro	Lys	Tyr	Ser	Val	Gly	Asp	Tyr	Val	Trp	Glu	Asp	Thr	Asn			
			1055					1060					1065				
aaa	gat	ggt	atc	caa	gat	gac	aat	gaa	aag	gga	att	tct	ggt	gtt		3249	
Lys	Asp	Gly	Ile	Gln	Asp	Asp	Asn	Glu	Lys	Gly	Ile	Ser	Gly	Val			
			1070					1075					1080				
aaa	gta	acg	tta	aag	gat	gaa	aaa	gga	aat	ata	att	agc	act	aca		3294	
Lys	Val	Thr	Leu	Lys	Asp	Glu	Lys	Gly	Asn	Ile	Ile	Ser	Thr	Thr			
			1085					1090					1095				
aca	act	gat	gaa	aat	ggg	aag	tat	caa	ttt	gat	aat	tta	gat	agt		3339	
Thr	Thr	Asp	Glu	Asn	Gly	Lys	Tyr	Gln	Phe	Asp	Asn	Leu	Asp	Ser			
			1100					1105					1110				
ggt	aat	tac	att	att	cat	ttt	gag	aaa	ccg	gaa	ggc	atg	act	caa		3384	
Gly	Asn	Tyr	Ile	Ile	His	Phe	Glu	Lys	Pro	Glu	Gly	Met	Thr	Gln			
			1115					1120					1125				
act	aca	gca	aat	tct	gga	aat	gat	gat	gaa	aaa	gat	gct	gat	ggg		3429	
Thr	Thr	Ala	Asn	Ser	Gly	Asn	Asp	Asp	Glu	Lys	Asp	Ala	Asp	Gly			
			1130					1135					1140				
gaa	gat	ggt	cgt	ggt	acg	att	act	gat	cat	gat	gac	ttt	agt	ata		3474	
Glu	Asp	Val	Arg	Val	Thr	Ile	Thr	Asp	His	Asp	Asp	Phe	Ser	Ile			
			1145					1150					1155				
gat	aat	ggt	tat	ttt	gac	gat	gat	tca	gac	agt	gac	tca	gac	gca		3519	
Asp	Asn	Gly	Tyr	Phe	Asp	Asp	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ala			
			1160					1165					1170				
gat	agt	gat	tca	gac	tca	gac	agt	gac	tcg	gac	gca	gac	agc	gat		3564	
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ala	Asp	Ser	Asp			
			1175					1180					1185				

-continued

tct gac gca gac Ser Asp Ala Asp	1190	agt gac tca gac Ser Asp Ser Asp	1195	gca gat agt gat Ala Asp Ser Asp	1200	tct gac tca Ser Asp Ser	3609
gac agc gac tca Asp Ser Asp Ser	1205	gac gca gat agt Asp Ala Asp Ser	1210	tcc gat tca gac Ser Asp Ser Asp	1215	gac gac Ser Asp	3654
tcg gat tca gat Ser Asp Ser Asp	1220	agt gat tcg gat Ser Asp Ser Asp	1225	gca gac agc gac Ala Asp Ser Asp	1230	tcg gat tct Ser Asp Ser	3699
gac agt gat tct Asp Ser Asp Ser	1235	gac gca gac agt Asp Ala Asp Ser	1240	tca gat tca gac Ser Asp Ser Asp	1245	agt gac Ser Asp	3744
tcg gat tca gac Ser Asp Ser Asp	1250	agc gat tcg gat Ser Asp Ser Asp	1255	tcc gat tca gac Ser Asp Ser Asp	1260	agt gac tcg Ser Asp Ser	3789
gat tca gac agt Asp Ser Asp Ser	1265	gac tca gac tcc Asp Ser Asp Ser	1270	gac agt gat tcc Ser Asp Ser Asp	1275	tca gat Ser Asp	3834
agc gac tcc gac Ser Asp Ser Asp	1280	gca gat agt gat Ala Asp Ser Asp	1285	tcg gac gca gac Ser Asp Ala Asp	1290	agt gac tca Ser Asp Ser	3879
gat tca gac agt Asp Ser Asp Ser	1295	gat tcg gac gca Asp Ser Asp Ala	1300	gac agt gac tcg Ser Asp Ser Asp	1305	tca gat Ser Asp	3924
agt gat tca gat Ser Asp Ser Asp	1310	gca gac agc gat Ala Asp Ser Asp	1315	tca gac tca gat Ser Asp Ser Asp	1320	agc gac tcg Ser Asp Ser	3969
gat tca gac agc Asp Ser Asp Ser	1325	gac tcc gac gca Asp Ser Asp Ala	1330	gac agc gac tcg Ser Asp Ser Asp	1335	gat tca gat Ser Asp	4014
agt gat tct gac Ser Asp Ser Asp	1340	tca gac agt gac Ser Asp Ser Asp	1345	tca gat tcc gat Ser Asp Ser Asp	1350	agt gat tcg Ser Asp Ser	4059
gat tca gat agt Asp Ser Asp Ser	1355	gat tcc gac gca Asp Ser Asp Ala	1360	gac agc gat tcg Ser Asp Ser Asp	1365	gat tcc gat Ser Asp	4104
agc gat tca gac Ser Asp Ser Asp	1370	tca gac agc gat Ser Asp Ser Asp	1375	tca gat tca gac Ser Asp Ser Asp	1380	agc gac tca Ser Asp Ser	4149
gat tca gat agt Asp Ser Asp Ser	1385	gat tcc gac gca Asp Ser Asp Ala	1390	gac agc gat gca Ser Asp Ala Asp	1395	agc gac Ser Asp	4194
tca gac gca gac Ser Asp Ala Asp	1400	agt gat tca gat Ser Asp Ser Asp	1405	gca gac agc gat Ala Asp Ser Asp	1410	tct gac tca Ser Asp Ser	4239
gat agt gac tca Asp Ser Asp Ser	1415	gac gca gat agt Asp Ala Asp Ser	1420	tcc gat tcc gat Ser Asp Ser Asp	1425	agc gat Ser Asp	4284
tca gat tct gat Ser Asp Ser Asp	1430	agt gac tca gac Ser Asp Ser Asp	1435	tca gac agt gac Ser Asp Ser Asp	1440	tca gat tcc Ser Asp Ser	4329
gat agc gac tcg Asp Ser Asp Ser	1445	gat tca gat agt Asp Ser Asp Ser	1450	tcc gac gca gac Ser Asp Ala Asp	1455	agt gac Ser Asp	4374
tca gac tca gat Ser Asp Ser Asp	1460	agt gac tcg gat Ser Asp Ser Asp	1465	tcc gat agt gat Ser Asp Ser Asp	1470	tcc gac gca Ser Asp Ala	4419
gac agc gat tct Asp Ser Asp Ser	1475	gac tca gat agt Asp Ser Asp Ser	1480	tca gac gca gat Ser Asp Ala Asp	1485	agt gat Ser Asp	4464

-continued

tcc gat tcc gat Ser Asp Ser Asp 1490	agc gat tcg gat Ser Asp Ser Asp	gca gac agc gac Ala Asp Ser Asp	tcg gat tca Ser Asp Ser Asp	gca gac agc gac Ala Asp Ser Asp	tcg gat tca Ser Asp Ser Asp	tca Ser Asp	4509
gat agt gat tcc Asp Ser Asp Ser 1505	gac gca gac agt Asp Ala Asp Ser	gac tca gac tca Asp Ser Asp Ser	gat agt gac Ser Asp Ser Asp	gac tca gac tca Asp Ser Asp Ser	gat agt gac Ser Asp Ser Asp	gac Ser Asp	4554
tcg gat tcc gat Ser Asp Ser Asp 1520	agt gat tcc gac Ser Asp Ser Asp	gca gac agc gat Ala Asp Ser Asp	tcg gat tcc Ser Asp Ser Asp	gca gac agc gat Ala Asp Ser Asp	tcg gat tcc Ser Asp Ser Asp	tcc Ser Asp	4599
gat agc gat tca Asp Ser Asp Ser 1535	gac tcc gac agc Asp Ser Asp Ser	gat tca gat tca Asp Ser Asp Ser	gac agc gac Asp Ser Asp Ser	gat tca gat tca Asp Ser Asp Ser	gac agc gac Asp Ser Asp Ser	gac Ser Asp	4644
tca gat tcc gat Ser Asp Ser Asp 1550	agt gat tcc gat Ser Asp Ser Asp	tca gac agt gac Ser Asp Ser Asp	tcg gat tcc Ser Asp Ser Asp	tca gac agt gac Ser Asp Ser Asp	tcg gat tcc Ser Asp Ser Asp	tcc Ser Asp	4689
gat agt gac tca Asp Ser Asp Ser 1565	gac tca gac agt Asp Ser Asp Ser	gac tca gat tca Asp Ser Asp Ser	gat agc gac Asp Ser Asp Ser	tca gat tca gat Asp Ser Asp Ser	gat agc gac Asp Ser Asp Ser	gac Ser Asp	4734
tca gat tca gac Ser Asp Ser Asp 1580	agt gat tcg gac Ser Asp Ser Asp	tca gat agt gac Ser Asp Ser Asp	tcc gat tca Ser Asp Ser Asp	tca gat agt gac Ser Asp Ser Asp	tcc gat tca Ser Asp Ser Asp	tca Ser Asp	4779
gac agt gat tcg Asp Ser Asp Ser 1595	gat tcc gat agc Asp Ser Asp Ser	gat tcg gat tcc Asp Ser Asp Ser	gat agt gac Asp Ser Asp Ser	tcg gat tcc gat Asp Ser Asp Ser	gat agt gac Asp Ser Asp Ser	gac Asp Ser	4824
tcg gat tca gac Ser Asp Ser Asp 1610	agt gat tcg gac Ser Asp Ser Asp	tca gac agc gac Ser Asp Ser Asp	tcc gat tca Ser Asp Ser Asp	gac agc gac tcc Asp Ser Asp Ser	gat tca Asp Ser Asp Ser	tca Ser Asp	4869
gat agt gat tcc Asp Ser Asp Ser 1625	gac tca gac agc Asp Ser Asp Ser	gat tcg gat tcc Asp Ser Asp Ser	gat agt gac Asp Ser Asp Ser	tcg gat tcc gat Asp Ser Asp Ser	gat agt gac Asp Ser Asp Ser	gac Asp Ser	4914
tcg gat tca gac Ser Asp Ser Asp 1640	agt gat tcg gac Ser Asp Ser Asp	tca gac agc gac Ser Asp Ser Asp	tcc gat tca Ser Asp Ser Asp	gac agc gac tcc Asp Ser Asp Ser	gat tca Asp Ser Asp Ser	tca Ser Asp	4959
gat agt gat tcc Asp Ser Asp Ser 1655	gac gca gac agc Asp Ala Asp Ser	gac tcc gat tca Asp Ser Asp Ser	gat agt gat Asp Ser Asp Ser	tcc gat tca gat Asp Ser Asp Ser	gat agt gat Asp Ser Asp Ser	gac Asp Ser	5004
tcg gac gca gac Ser Asp Ala Asp 1670	agc gat tcc gat Ser Asp Ser Asp	agt gac tcg gat Ser Asp Ser Asp	tca gac agt gac Ser Asp Ser Asp	gac tcg gat tca Asp Ser Asp Ser	gac agt gac Asp Ser Asp Ser	agt Ser Asp	5049
gat tcg gac tca Asp Ser Asp Ser 1685	gac agc gat tcc Asp Ser Asp Ser	gat tca gac agt Asp Ser Asp Ser	gac tcg gat tca Asp Ser Asp Ser	gat agt gac tcg Asp Ser Asp Ser	gac tcg gac Asp Ser Asp Ser	gac Asp Ser	5094
tca gat agc gac Ser Asp Ser Asp 1700	tcg gat tca gac Ser Asp Ser Asp	agt gac tcg gac Ser Asp Ser Asp	tca gat agt Ser Asp Ser Asp	gac tcg gac tca Asp Ser Asp Ser	gat agt gac Asp Ser Asp Ser	agt Ser Asp	5139
gac tcc gat tca Asp Ser Asp Ser 1715	gac agc gac tcg Asp Ser Asp Ser	gat tct gat aaa Asp Ser Asp Lys	aat gca aaa Asp Ser Asp Lys	tct gat aaa aat Ser Asp Lys Asn	gca aaa Asp Ser Asp Lys	aaa Lys	5184
gat aaa tta cct Asp Lys Leu Pro 1730	gat aca gga gca Asp Thr Gly Ala	aat gaa gat cat Asn Glu Asp His	gat tct aaa Asp Ser Lys	gaa gat cat gat Asp His Asp Ser	tct aaa Asp Ser Lys	aaa Lys	5229
ggc aca tta ctt Gly Thr Leu Leu 1745	gga act tta ttt Gly Thr Leu Phe	gca ggt tta gga Ala Gly Leu Gly	gca tta tta Ala Leu Leu	ggt tta gga gca Gly Leu Gly Ala	tta tta Ala Leu Leu	tta Leu	5274
tta gga aga cgt Leu Gly Arg Arg 1760	cgt aaa aaa gat Arg Lys Lys Asp	aat aaa gaa aaa Asn Lys Glu Lys	tag cac tat Lys His Tyr	aaa gaa aaa tag Lys His Tyr	cac tat His Tyr	tat Tyr	5319
tga ttc att cat Phe Ile His Lys	aag tta ttt caa Leu Phe Gln Ala	gcc agg tct ata Ala Arg Ser Ile	tgg cct ggt Trp Pro Gly	agg tct ata tgg Arg Ser Ile Trp	cct ggt Pro Gly	ggt Gly	5364

-continued

---

```

          1775                1780
ttg  aaa tca tat taa att gaa  agg aga aaa aga tga gta  tgg          5406
Leu  Lys Ser Tyr   Ile Glu  Arg Arg Lys Arg   Val Trp
1785                1790                1795

```

```

<210> SEQ ID NO 2
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Staphylococcus epidermidis

```

```

<400> SEQUENCE: 2

```

```

Tyr Trp Ile Asn Tyr Ala Tyr Lys Val Phe Thr
1          5          10

```

```

<210> SEQ ID NO 3
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Staphylococcus epidermidis

```

```

<400> SEQUENCE: 3

```

```

Lys Cys Lys Cys Asn Leu Gln Val Asn Ile Gln Ile Ile Ser Leu
1          5          10          15

```

```

<210> SEQ ID NO 4
<211> LENGTH: 1742
<212> TYPE: PRT
<213> ORGANISM: Staphylococcus epidermidis

```

```

<400> SEQUENCE: 4

```

```

Asn Ile Tyr Phe Asn Trp Arg Tyr Ser Met Lys Lys Arg Arg Gln Gly
1          5          10          15

```

```

Pro Ile Asn Lys Arg Val Asp Phe Leu Ser Asn Lys Val Asn Lys Tyr
          20          25          30

```

```

Ser Ile Arg Lys Phe Thr Val Gly Thr Ala Ser Ile Leu Val Gly Ala
          35          40          45

```

```

Thr Leu Met Phe Gly Ala Ala Asp Asn Glu Ala Lys Ala Ala Glu Asp
          50          55          60

```

```

Asn Gln Leu Glu Ser Ala Ser Lys Glu Glu Gln Lys Gly Ser Arg Asp
          65          70          75          80

```

```

Asn Glu Asn Ser Lys Leu Asn Gln Val Asp Leu Asp Asn Gly Ser His
          85          90          95

```

```

Ser Ser Glu Lys Thr Thr Asn Val Asn Asn Ala Thr Glu Val Lys Lys
          100          105          110

```

```

Val Glu Ala Pro Thr Thr Ser Asp Val Ser Lys Pro Lys Ala Asn Glu
          115          120          125

```

```

Ala Val Val Thr Asn Glu Ser Thr Lys Pro Lys Thr Thr Glu Ala Pro
          130          135          140

```

```

Thr Val Asn Glu Glu Ser Ile Ala Glu Thr Pro Lys Thr Ser Thr Thr
          145          150          155          160

```

```

Gln Gln Asp Ser Thr Glu Lys Asn Asn Pro Ser Leu Lys Asp Asn Leu
          165          170          175

```

```

Asn Ser Ser Ser Thr Thr Ser Lys Glu Ser Lys Thr Asp Glu His Ser
          180          185          190

```

```

Thr Lys Gln Ala Gln Met Ser Thr Asn Lys Ser Asn Leu Asp Thr Asn
          195          200          205

```

```

Asp Ser Pro Thr Gln Ser Glu Lys Thr Ser Ser Gln Ala Asn Asn Asp
          210          215          220

```

```

Ser Thr Asp Asn Gln Ser Ala Pro Ser Lys Gln Leu Asp Ser Lys Pro

```



-continued

225 230 235 240  
Ser Glu Gln Lys Val Tyr Lys Thr Lys Phe Asn Asp Glu Pro Thr Gln  
245 250 255  
Asp Val Glu His Thr Thr Thr Lys Leu Lys Thr Pro Ser Val Ser Thr  
260 265 270  
Asp Ser Ser Val Asn Asp Lys Gln Asp Tyr Thr Arg Ser Ala Val Ala  
275 280 285  
Ser Leu Gly Val Asp Ser Asn Glu Thr Glu Ala Ile Thr Asn Ala Val  
290 295 300  
Arg Asp Asn Leu Asp Leu Lys Ala Ala Ser Arg Glu Gln Ile Asn Glu  
305 310 315 320  
Ala Ile Ile Ala Glu Ala Leu Lys Lys Asp Phe Ser Asn Pro Asp Tyr  
325 330 335  
Gly Val Asp Thr Pro Leu Ala Leu Asn Arg Ser Gln Ser Lys Asn Ser  
340 345 350  
Pro His Lys Ser Ala Ser Pro Arg Met Asn Leu Met Ser Leu Ala Ala  
355 360 365  
Glu Pro Asn Ser Gly Lys Asn Val Asn Asp Lys Val Lys Ile Thr Asn  
370 375 380  
Pro Thr Leu Ser Leu Asn Lys Ser Asn Asn His Ala Asn Asn Val Ile  
385 390 395 400  
Trp Pro Thr Ser Asn Glu Gln Phe Asn Leu Lys Ala Asn Tyr Glu Leu  
405 410 415  
Asp Asp Ser Ile Lys Glu Gly Asp Thr Phe Thr Ile Lys Tyr Gly Gln  
420 425 430  
Tyr Ile Arg Pro Gly Gly Leu Glu Leu Pro Ala Ile Lys Thr Gln Leu  
435 440 445  
Arg Ser Lys Asp Gly Ser Ile Val Ala Asn Gly Val Tyr Asp Lys Thr  
450 455 460  
Thr Asn Thr Thr Thr Tyr Thr Phe Thr Asn Tyr Val Asp Gln Tyr Gln  
465 470 475 480  
Asn Ile Thr Gly Ser Phe Asp Leu Ile Ala Thr Pro Lys Arg Glu Thr  
485 490 495  
Ala Ile Lys Asp Asn Gln Asn Tyr Pro Met Glu Val Thr Ile Ala Asn  
500 505 510  
Glu Val Val Lys Lys Asp Phe Ile Val Asp Tyr Gly Asn Lys Lys Asp  
515 520 525  
Asn Thr Thr Thr Ala Ala Val Ala Asn Val Asp Asn Val Asn Asn Lys  
530 535 540  
His Asn Glu Val Val Tyr Leu Asn Gln Asn Asn Gln Asn Pro Lys Tyr  
545 550 555 560  
Ala Lys Tyr Phe Ser Thr Val Lys Asn Gly Glu Phe Ile Pro Gly Glu  
565 570 575  
Val Lys Val Tyr Glu Val Thr Asp Thr Asn Ala Met Val Asp Ser Phe  
580 585 590  
Asn Pro Asp Leu Asn Ser Ser Asn Val Lys Asp Val Thr Ser Gln Phe  
595 600 605  
Ala Pro Lys Val Ser Ala Asp Gly Thr Arg Val Asp Ile Asn Phe Ala  
610 615 620  
Arg Ser Met Ala Asn Gly Lys Lys Tyr Ile Val Thr Gln Ala Val Arg  
625 630 635 640  
Pro Thr Gly Thr Gly Asn Val Tyr Thr Glu Tyr Trp Leu Thr Arg Asp  
645 650 655

-continued

---

Gly Thr Thr Asn Thr Asn Asp Phe Tyr Arg Gly Thr Lys Ser Thr Thr  
 660 665 670  
 Val Thr Tyr Leu Asn Gly Ser Ser Thr Ala Gln Gly Asp Asn Pro Thr  
 675 680 685  
 Tyr Ser Leu Gly Asp Tyr Val Trp Leu Asp Lys Asn Lys Asn Gly Val  
 690 695 700  
 Gln Asp Asp Asp Glu Lys Gly Leu Ala Gly Val Tyr Val Thr Leu Lys  
 705 710 715 720  
 Asp Ser Asn Asn Arg Glu Leu Gln Arg Val Thr Thr Asp Gln Ser Gly  
 725 730 735  
 His Tyr Gln Phe Asp Asn Leu Gln Asn Gly Thr Tyr Thr Val Glu Phe  
 740 745 750  
 Ala Ile Pro Asp Asn Tyr Thr Pro Ser Pro Ala Asn Asn Ser Thr Asn  
 755 760 765  
 Asp Ala Ile Asp Ser Asp Gly Glu Arg Asp Gly Thr Arg Lys Val Val  
 770 775 780  
 Val Ala Lys Gly Thr Ile Asn Asn Ala Asp Asn Met Thr Val Asp Thr  
 785 790 795 800  
 Gly Phe Tyr Leu Thr Pro Lys Tyr Asn Val Gly Asp Tyr Val Trp Glu  
 805 810 815  
 Asp Thr Asn Lys Asp Gly Ile Gln Asp Asp Asn Glu Lys Gly Ile Ser  
 820 825 830  
 Gly Val Lys Val Thr Leu Lys Asn Lys Asn Gly Asp Thr Ile Gly Thr  
 835 840 845  
 Thr Thr Thr Asp Ser Asn Gly Lys Tyr Glu Phe Thr Gly Leu Glu Asn  
 850 855 860  
 Gly Asp Tyr Thr Ile Glu Phe Glu Thr Pro Glu Gly Tyr Thr Pro Thr  
 865 870 875 880  
 Lys Gln Asn Ser Gly Ser Asp Glu Gly Lys Asp Ser Asn Gly Thr Lys  
 885 890 895  
 Thr Thr Val Thr Val Lys Asp Ala Asp Asn Lys Thr Ile Asp Ser Gly  
 900 905 910  
 Phe Tyr Lys Pro Thr Tyr Asn Leu Gly Asp Tyr Val Trp Glu Asp Thr  
 915 920 925  
 Asn Lys Asp Gly Ile Gln Asp Asp Ser Glu Lys Gly Ile Ser Gly Val  
 930 935 940  
 Lys Val Thr Leu Lys Asp Lys Asn Gly Asn Ala Ile Gly Thr Thr Thr  
 945 950 955 960  
 Thr Asp Ala Ser Gly His Tyr Gln Phe Lys Gly Leu Glu Asn Gly Ser  
 965 970 975  
 Tyr Thr Val Glu Phe Glu Thr Pro Ser Gly Tyr Thr Pro Thr Lys Ala  
 980 985 990  
 Asn Ser Gly Gln Asp Ile Thr Val Asp Ser Asn Gly Ile Thr Thr Thr  
 995 1000 1005  
 Gly Ile Ile Asn Gly Ala Asp Asn Leu Thr Ile Asp Ser Gly Phe  
 1010 1015 1020  
 Tyr Lys Thr Pro Lys Tyr Ser Val Gly Asp Tyr Val Trp Glu Asp  
 1025 1030 1035  
 Thr Asn Lys Asp Gly Ile Gln Asp Asp Asn Glu Lys Gly Ile Ser  
 1040 1045 1050  
 Gly Val Lys Val Thr Leu Lys Asp Glu Lys Gly Asn Ile Ile Ser  
 1055 1060 1065

-continued

Thr	Thr	Thr	Thr	Asp	Glu	Asn	Gly	Lys	Tyr	Gln	Phe	Asp	Asn	Leu
	1070					1075					1080			
Asp	Ser	Gly	Asn	Tyr	Ile	Ile	His	Phe	Glu	Lys	Pro	Glu	Gly	Met
	1085					1090					1095			
Thr	Gln	Thr	Thr	Ala	Asn	Ser	Gly	Asn	Asp	Asp	Glu	Lys	Asp	Ala
	1100					1105					1110			
Asp	Gly	Glu	Asp	Val	Arg	Val	Thr	Ile	Thr	Asp	His	Asp	Asp	Phe
	1115					1120					1125			
Ser	Ile	Asp	Asn	Gly	Tyr	Phe	Asp	Asp	Asp	Ser	Asp	Ser	Asp	Ser
	1130					1135					1140			
Asp	Ala	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ala	Asp
	1145					1150					1155			
Ser	Asp	Ser	Asp	Ala	Asp	Ser	Asp	Ser	Asp	Ala	Asp	Ser	Asp	Ser
	1160					1165					1170			
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ala	Asp	Ser	Asp	Ser	Asp	Ser	Asp
	1175					1180					1185			
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ala	Asp	Ser	Asp	Ser
	1190					1195					1200			
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ala	Asp	Ser	Asp	Ser	Asp	Ser	Asp
	1205					1210					1215			
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser
	1220					1225					1230			
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
	1235					1240					1245			
Ser	Asp	Ser	Asp	Ser	Asp	Ala	Asp	Ser	Asp	Ser	Asp	Ala	Asp	Ser
	1250					1255					1260			
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ala	Asp	Ser	Asp	Ser	Asp
	1265					1270					1275			
Ser	Asp	Ser	Asp	Ser	Asp	Ala	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser
	1280					1285					1290			
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ala	Asp	Ser	Asp	Ser	Asp
	1295					1300					1305			
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser
	1310					1315					1320			
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ala	Asp	Ser	Asp	Ser	Asp
	1325					1330					1335			
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser
	1340					1345					1350			
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ala	Asp	Ser	Asp	Ala	Asp
	1355					1360					1365			
Ser	Asp	Ser	Asp	Ala	Asp	Ser	Asp	Ser	Asp	Ala	Asp	Ser	Asp	Ser
	1370					1375					1380			
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ala	Asp	Ser	Asp	Ser	Asp	Ser	Asp
	1385					1390					1395			
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser
	1400					1405					1410			
Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ala	Asp
	1415					1420					1425			
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser
	1430					1435					1440			
Asp	Ala	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ala	Asp
	1445					1450					1455			
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ala	Asp	Ser	Asp	Ser

-continued

1460	1465	1470
Asp Ser Asp Ser Asp Ser Asp	Ala Asp Ser Asp Ser	Asp Ser Asp Ser Asp
1475	1480	1485
Ser Asp Ser Asp Ser Asp Ser	Asp Ser Asp Ala Asp	Ser Asp Ser Ser
1490	1495	1500
Asp Ser Asp Ser Asp Ser Asp	Ser Asp Ser Asp Ser	Ser Asp Ser Asp
1505	1510	1515
Ser Asp Ser Asp Ser Asp Ser	Asp Ser Asp Ser Asp	Ser Asp Ser Ser
1520	1525	1530
Asp Ser Asp Ser Asp Ser Asp	Ser Asp Ser Asp Ser	Ser Asp Ser Asp
1535	1540	1545
Ser Asp Ser Asp Ser Asp Ser	Asp Ser Asp Ser Asp	Ser Asp Ser Ser
1550	1555	1560
Asp Ser Asp Ser Asp Ser Asp	Ser Asp Ser Asp Ser	Ser Asp Ser Asp
1565	1570	1575
Ser Asp Ser Asp Ser Asp Ser	Asp Ser Asp Ser Asp	Ser Asp Ser Ser
1580	1585	1590
Asp Ser Asp Ser Asp Ser Asp	Ser Asp Ser Asp Ser	Ser Asp Ser Asp
1595	1600	1605
Ser Asp Ser Asp Ser Asp Ser	Asp Ser Asp Ser Asp	Ser Asp Ser Ser
1610	1615	1620
Asp Ser Asp Ser Asp Ser Asp	Ala Asp Ser Asp Ser	Ser Asp Ser Asp
1625	1630	1635
Ser Asp Ser Asp Ala Asp Ser	Asp Ser Asp Ser Asp	Ser Asp Ser Ser
1640	1645	1650
Asp Ser Asp Ser Asp Ser Asp	Ser Asp Ser Asp Ser	Ser Asp Ser Asp
1655	1660	1665
Ser Asp Ser Asp Ser Asp Ser	Asp Ser Asp Ser Asp	Ser Asp Ser Ser
1670	1675	1680
Asp Ser Asp Ser Asp Ser Asp	Ser Asp Ser Asp Ser	Ser Asp Lys Asn
1685	1690	1695
Ala Lys Asp Lys Leu Pro Asp	Thr Gly Ala Asn Glu	Asp His Asp
1700	1705	1710
Ser Lys Gly Thr Leu Leu Gly	Thr Leu Phe Ala Gly	Leu Gly Ala
1715	1720	1725
Leu Leu Leu Gly Arg Arg Arg	Lys Lys Asp Asn Lys	Glu Lys
1730	1735	1740

<210> SEQ ID NO 5  
 <211> LENGTH: 18  
 <212> TYPE: PRT  
 <213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 5

Phe Ile His Lys Leu Phe Gln Ala Arg Ser Ile Trp Pro Gly Leu Lys  
 1 5 10 15

Ser Tyr

<210> SEQ ID NO 6  
 <211> LENGTH: 6  
 <212> TYPE: PRT  
 <213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 6

Ile Glu Arg Arg Lys Arg  
 1 5

-continued

```

<210> SEQ ID NO 7
<211> LENGTH: 2976
<212> TYPE: DNA
<213> ORGANISM: Staphylococcus epidermidis
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (3)..(2975)
<223> OTHER INFORMATION:

<400> SEQUENCE: 7

at att gca aaa aag act tat ata cta tat tgt att tta ctc tag aaa      47
  Ile Ala Lys Lys Thr Tyr Ile Leu Tyr Cys Ile Leu Leu      Lys
    1                    5                                10

cga ttt tta ctt gaa aat tac att gaa ata gtc aaa gat aag gag ttt      95
Arg Phe Leu Leu Glu Asn Tyr Ile Glu Ile Val Lys Asp Lys Glu Phe
  15                    20                                25                                30

tta tga tta aaa aaa aat aat tta cta act aaa aag aaa cct ata gca      143
Leu      Leu Lys Lys Asn Asn Leu Leu Thr Lys Lys Lys Pro Ile Ala
  35                    40                                45

aat aaa tcc aat aaa tat gca att aga aaa ttc aca gta ggt aca gcg      191
Asn Lys Ser Asn Lys Tyr Ala Ile Arg Lys Phe Thr Val Gly Thr Ala
  50                    55                                60

tct att gta ata ggt gca gca tta ttg ttt ggt tta ggt cat aat gag      239
Ser Ile Val Ile Gly Ala Ala Leu Leu Phe Gly Leu Gly His Asn Glu
  65                    70                                75

gcc aaa gct gag gag aat aca gta caa gac gtt aaa gat tcg aat atg      287
Ala Lys Ala Glu Glu Asn Thr Val Gln Asp Val Lys Asp Ser Asn Met
  80                    85                                90

gat gat gaa tta tca gat agc aat gat cag tcc agt aat gaa gaa aag      335
Asp Asp Glu Leu Ser Asp Ser Asn Asp Gln Ser Ser Asn Glu Glu Lys
  95                    100                               105

aat gat gta atc aat aat agt cag tca ata aac acc gat gat gat aac      383
Asn Asp Val Ile Asn Asn Ser Gln Ser Ile Asn Thr Asp Asp Asp Asn
  110                    115                               120                               125

caa ata aaa aaa gaa gaa acg aat agc aac gat gcc ata gaa aat cgc      431
Gln Ile Lys Lys Glu Glu Thr Asn Ser Asn Asp Ala Ile Glu Asn Arg
  130                    135                               140

tct aaa gat ata aca cag tca aca aca aat gta gat gaa aac gaa gca      479
Ser Lys Asp Ile Thr Gln Ser Thr Thr Asn Val Asp Glu Asn Glu Ala
  145                    150                               155

aca ttt tta caa aag acc cct caa gat aat act cag ctt aaa gaa gaa      527
Thr Phe Leu Gln Lys Thr Pro Gln Asp Asn Thr Gln Leu Lys Glu Glu
  160                    165                               170

gtg gta aaa gaa ccc tca tca gtc gaa tcc tca aat tca tca atg gat      575
Val Val Lys Glu Pro Ser Ser Val Glu Ser Ser Asn Ser Ser Met Asp
  175                    180                               185

act gcc caa caa cca tct cat aca aca ata aat agt gaa gca tct att      623
Thr Ala Gln Gln Pro Ser His Thr Thr Ile Asn Ser Glu Ala Ser Ile
  190                    195                               200                               205

caa aca agt gat aat gaa gaa aat tcc cgc gta tca gat ttt gct aac      671
Gln Thr Ser Asp Asn Glu Glu Asn Ser Arg Val Ser Asp Phe Ala Asn
  210                    215                               220

tct aaa ata ata gag agt aac act gaa tcc aat aaa gaa gag aat act      719
Ser Lys Ile Ile Glu Ser Asn Thr Glu Ser Asn Lys Glu Glu Asn Thr
  225                    230                               235

ata gag caa cct aac aaa gta aga gaa gat tca ata aca agt caa ccg      767
Ile Glu Gln Pro Asn Lys Val Arg Glu Asp Ser Ile Thr Ser Gln Pro
  240                    245                               250

tct agc tat aaa aat ata gat gaa aaa att tca aat caa gat gag tta      815
Ser Ser Tyr Lys Asn Ile Asp Glu Lys Ile Ser Asn Gln Asp Glu Leu

```

-continued

255	260	265	
tta aat tta cca ata aat gaa tat gaa aat aag gtt aga ccg tta tct Leu Asn Leu Pro Ile Asn Glu Tyr Glu Asn Lys Val Arg Pro Leu Ser 270 275 280 285			863
aca aca tct gcc caa cca tcg agt aag cgt gta acc gta aat caa tta Thr Thr Ser Ala Gln Pro Ser Ser Lys Arg Val Thr Val Asn Gln Leu 290 295 300			911
gcg gca gaa caa ggt tcg aat gtt aat cat tta att aaa gtt act gat Ala Ala Glu Gln Gly Ser Asn Val Asn His Leu Ile Lys Val Thr Asp 305 310 315			959
caa agt att act gaa gga tat gat gat agt gat ggt att att aaa gca Gln Ser Ile Thr Glu Gly Tyr Asp Asp Ser Asp Gly Ile Ile Lys Ala 320 325 330			1007
cat gat gct gaa aac tta atc tat gat gta act ttt gaa gta gat gat His Asp Ala Glu Asn Leu Ile Tyr Asp Val Thr Phe Glu Val Asp Asp 335 340 345			1055
aag gtg aaa tct ggt gat acg atg aca gtg aat ata gat aag aat aca Lys Val Lys Ser Gly Asp Thr Met Thr Val Asn Ile Asp Lys Asn Thr 350 355 360 365			1103
gtt cca tca gat tta acc gat agt ttt gca ata cca aaa ata aaa gat Val Pro Ser Asp Leu Thr Asp Ser Phe Ala Ile Pro Lys Ile Lys Asp 370 375 380			1151
aat tct gga gaa atc atc gct aca ggt act tat gac aac aca aat aaa Asn Ser Gly Glu Ile Ile Ala Thr Gly Thr Tyr Asp Asn Thr Asn Lys 385 390 395			1199
caa att acc tac act ttt aca gat tat gta gat aaa tat gaa aat att Gln Ile Thr Tyr Thr Phe Thr Asp Tyr Val Asp Lys Tyr Glu Asn Ile 400 405 410			1247
aaa gcg cac ctt aaa tta aca tca tac att gat aaa tca aag gtt cca Lys Ala His Leu Lys Leu Thr Ser Tyr Ile Asp Lys Ser Lys Val Pro 415 420 425			1295
aat aat aac act aag tta gat gta gaa tat aag acg gcc ctt tca tca Asn Asn Asn Thr Lys Leu Asp Val Glu Tyr Lys Thr Ala Leu Ser Ser 430 435 440 445			1343
gta aat aaa aca att acg gtt gaa tat caa aaa cct aac gaa aat cgg Val Asn Lys Thr Ile Thr Val Glu Tyr Gln Lys Pro Asn Glu Asn Arg 450 455 460			1391
act gct aac ctt caa agt atg ttc aca aac ata gat acg aaa aac cat Thr Ala Asn Leu Gln Ser Met Phe Thr Asn Ile Asp Thr Lys Asn His 465 470 475			1439
aca gtt gag caa acg att tat att aac cct ctt cgt tat tca gcc aaa Thr Val Glu Gln Thr Ile Tyr Ile Asn Pro Leu Arg Tyr Ser Ala Lys 480 485 490			1487
gaa aca aat gta aat att tca ggg aat ggc gat gaa ggt tca aca att Glu Thr Asn Val Asn Ile Ser Gly Asn Gly Asp Glu Gly Ser Thr Ile 495 500 505			1535
atc gac gat agt aca atc att aaa gtt tat aag gtt gga gat aat caa Ile Asp Asp Ser Thr Ile Ile Lys Val Tyr Lys Val Gly Asp Asn Gln 510 515 520 525			1583
aat tta cca gat agt aac aga att tat gat tac agt gaa tat gaa gat Asn Leu Pro Asp Ser Asn Arg Ile Tyr Asp Tyr Ser Glu Tyr Glu Asp 530 535 540			1631
gtc aca aat gat gat tat gcc caa tta gga aat aat aat gac gtg aat Val Thr Asn Asp Tyr Ala Gln Leu Gly Asn Asn Asn Asp Val Asn 545 550 555			1679
att aat ttt ggt aat ata gat tca cca tat att att aaa gtt att agt Ile Asn Phe Gly Asn Ile Asp Ser Pro Tyr Ile Ile Lys Val Ile Ser 560 565 570			1727
aaa tat gac cct aat aag gac gat tac acg acg ata cag caa act gtg			1775

-continued

Lys 575	Tyr	Asp	Pro	Asn	Lys	Asp	Asp	Tyr	Thr	Thr	Ile	Gln	Gln	Thr	Val	
						580					585					
aca	atg	caa	acg	act	ata	aat	gag	tat	act	ggt	gag	ttt	aga	aca	gca	1823
Thr	Met	Gln	Thr	Thr	Ile	Asn	Glu	Tyr	Thr	Gly	Glu	Phe	Arg	Thr	Ala	
590					595					600					605	
tcc	tat	gat	aat	aca	att	gct	ttc	tct	aca	agt	tca	ggt	caa	gga	caa	1871
Ser	Tyr	Asp	Asn	Thr	Ile	Ala	Phe	Ser	Thr	Ser	Ser	Gly	Gln	Gly	Gln	
				610					615					620		
ggt	gac	ttg	cct	cct	gaa	aaa	act	tat	aaa	atc	gga	gat	tac	gta	tgg	1919
Gly	Asp	Leu	Pro	Pro	Glu	Lys	Thr	Tyr	Lys	Ile	Gly	Asp	Tyr	Val	Trp	
			625					630					635			
gaa	gat	gta	gat	aaa	gat	ggt	att	caa	aat	aca	aat	gat	aat	gaa	aaa	1967
Glu	Asp	Val	Asp	Lys	Asp	Gly	Ile	Gln	Asn	Thr	Asn	Asp	Asn	Glu	Lys	
		640				645						650				
ccg	ctt	agt	aat	gta	ttg	gta	act	ttg	acg	tat	cct	gat	gga	act	tca	2015
Pro	Leu	Ser	Asn	Val	Leu	Val	Thr	Leu	Thr	Tyr	Pro	Asp	Gly	Thr	Ser	
	655					660					665					
aaa	tca	gtc	aga	aca	gat	gaa	gag	ggg	aaa	tat	caa	ttt	gat	ggg	tta	2063
Lys	Ser	Val	Arg	Thr	Asp	Glu	Glu	Gly	Lys	Tyr	Gln	Phe	Asp	Gly	Leu	
670					675					680					685	
aaa	aac	gga	ttg	act	tat	aaa	att	aca	ttc	gaa	aca	ccg	gaa	gga	tat	2111
Lys	Asn	Gly	Leu	Thr	Tyr	Lys	Ile	Thr	Phe	Glu	Thr	Pro	Glu	Gly	Tyr	
			690						695					700		
acg	ccg	acg	ctt	aaa	cat	tca	gga	aca	aat	cct	gca	cta	gac	tca	gaa	2159
Thr	Pro	Thr	Leu	Lys	His	Ser	Gly	Thr	Asn	Pro	Ala	Leu	Asp	Ser	Glu	
			705					710					715			
ggc	aat	tct	gta	tgg	gta	act	att	aac	gga	caa	gac	gat	atg	act	att	2207
Gly	Asn	Ser	Val	Trp	Val	Thr	Ile	Asn	Gly	Gln	Asp	Asp	Met	Thr	Ile	
	720					725						730				
gat	agc	gga	ttt	tat	caa	aca	cct	aaa	tat	agc	tta	ggg	aac	tat	gta	2255
Asp	Ser	Gly	Phe	Tyr	Gln	Thr	Pro	Lys	Tyr	Ser	Leu	Gly	Asn	Tyr	Val	
	735				740						745					
tgg	tat	gac	act	aat	aaa	gat	ggt	att	caa	ggt	gat	gat	gaa	aaa	gga	2303
Trp	Tyr	Asp	Thr	Asn	Lys	Asp	Gly	Ile	Gln	Gly	Asp	Asp	Glu	Lys	Gly	
750					755					760				765		
atc	tct	gga	gta	aaa	gtg	acg	tta	aaa	gat	gaa	aac	gga	aat	atc	att	2351
Ile	Ser	Gly	Val	Lys	Val	Thr	Leu	Lys	Asp	Glu	Asn	Gly	Asn	Ile	Ile	
			770					775						780		
agt	aca	aca	aca	act	gat	gaa	aat	gga	aag	tat	caa	ttt	gat	aat	tta	2399
Ser	Thr	Thr	Thr	Thr	Asp	Glu	Asn	Gly	Lys	Tyr	Gln	Phe	Asp	Asn	Leu	
			785					790					795			
aat	agt	ggt	aat	tat	att	ggt	cat	ttt	gat	aaa	cct	tca	ggt	atg	act	2447
Asn	Ser	Gly	Asn	Tyr	Ile	Val	His	Phe	Asp	Lys	Pro	Ser	Gly	Met	Thr	
		800						805					810			
caa	aca	aca	aca	gat	tct	ggt	gat	gat	gac	gaa	cag	gat	gct	gat	ggg	2495
Gln	Thr	Thr	Thr	Asp	Ser	Gly	Asp	Asp	Asp	Glu	Gln	Asp	Ala	Asp	Gly	
	815					820						825				
gaa	gaa	gtc	cat	gta	aca	att	act	gat	cat	gat	gac	ttt	agt	ata	gat	2543
Glu	Glu	Val	His	Val	Thr	Ile	Thr	Asp	His	Asp	Asp	Phe	Ser	Ile	Asp	
830					835					840				845		
aac	gga	tac	tat	gat	gac	gac	tca	gat	tca	gat	agt	gat	tca	gac	tca	2591
Asn	Gly	Tyr	Tyr	Asp	Asp	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	
				850					855					860		
gat	agc	gac	gac	tca	gac	tcc	gat	agc	gat	tcc	gac	tca	gac	agc	gac	2639
Asp	Ser	Asp	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	
			865					870						875		
tca	gat	tcc	gat	agt	gat	tca	gat	tca	gac	agt	gac	tca	gac	tca	gat	2687
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	
		880						885						890		

-continued

```

agt gat tca gat tca gac agc gat tcc gac tca gac agt gac tca gga 2735
Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Gly
895 900 905

tta gac aat agc tca gat aag aat aca aaa gat aaa tta ccg gat aca 2783
Leu Asp Asn Ser Ser Asp Lys Asn Thr Lys Asp Lys Leu Pro Asp Thr
910 915 920 925

gga gct aat gaa gat cat gat tct aaa ggc aca tta ctt gga gct tta 2831
Gly Ala Asn Glu Asp His Asp Ser Lys Gly Thr Leu Leu Gly Ala Leu
930 935 940

ttt gca ggt tta gga gcg tta tta tta ggg aag cgt cgc aaa aat aga 2879
Phe Ala Gly Leu Gly Ala Leu Leu Leu Gly Lys Arg Arg Lys Asn Arg
945 950 955

aaa aat aaa aat taa att att caa atg aaa tta gtg aaa gaa gca gat 2927
Lys Asn Lys Asn Ile Ile Gln Met Lys Leu Val Lys Glu Ala Asp
960 965 970

acg aca ttt gaa tag aaa gta tat tta gtc caa caa ata taa ggt gtt g 2976
Thr Thr Phe Glu Lys Val Tyr Leu Val Gln Gln Ile Gly Val
975 980 985

```

```

<210> SEQ ID NO 8
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Staphylococcus epidermidis

```

<400> SEQUENCE: 8

```

Ile Ala Lys Lys Thr Tyr Ile Leu Tyr Cys Ile Leu Leu
1 5 10

```

```

<210> SEQ ID NO 9
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Staphylococcus epidermidis

```

<400> SEQUENCE: 9

```

Lys Arg Phe Leu Leu Glu Asn Tyr Ile Glu Ile Val Lys Asp Lys Glu
1 5 10 15
Phe Leu

```

```

<210> SEQ ID NO 10
<211> LENGTH: 930
<212> TYPE: PRT
<213> ORGANISM: Staphylococcus epidermidis

```

<400> SEQUENCE: 10

```

Leu Lys Lys Asn Asn Leu Leu Thr Lys Lys Lys Pro Ile Ala Asn Lys
1 5 10 15
Ser Asn Lys Tyr Ala Ile Arg Lys Phe Thr Val Gly Thr Ala Ser Ile
20 25 30
Val Ile Gly Ala Ala Leu Leu Phe Gly Leu Gly His Asn Glu Ala Lys
35 40 45
Ala Glu Glu Asn Thr Val Gln Asp Val Lys Asp Ser Asn Met Asp Asp
50 55 60
Glu Leu Ser Asp Ser Asn Asp Gln Ser Ser Asn Glu Glu Lys Asn Asp
65 70 75 80
Val Ile Asn Asn Ser Gln Ser Ile Asn Thr Asp Asp Asp Asn Gln Ile
85 90 95
Lys Lys Glu Glu Thr Asn Ser Asn Asp Ala Ile Glu Asn Arg Ser Lys
100 105 110
Asp Ile Thr Gln Ser Thr Thr Asn Val Asp Glu Asn Glu Ala Thr Phe
115 120 125

```



-continued

---

Leu Gln Lys Thr Pro Gln Asp Asn Thr Gln Leu Lys Glu Glu Val Val  
 130 135 140  
 Lys Glu Pro Ser Ser Val Glu Ser Ser Asn Ser Ser Met Asp Thr Ala  
 145 150 155  
 Gln Gln Pro Ser His Thr Thr Ile Asn Ser Glu Ala Ser Ile Gln Thr  
 165 170 175  
 Ser Asp Asn Glu Glu Asn Ser Arg Val Ser Asp Phe Ala Asn Ser Lys  
 180 185 190  
 Ile Ile Glu Ser Asn Thr Glu Ser Asn Lys Glu Glu Asn Thr Ile Glu  
 195 200 205  
 Gln Pro Asn Lys Val Arg Glu Asp Ser Ile Thr Ser Gln Pro Ser Ser  
 210 215 220  
 Tyr Lys Asn Ile Asp Glu Lys Ile Ser Asn Gln Asp Glu Leu Leu Asn  
 225 230 235 240  
 Leu Pro Ile Asn Glu Tyr Glu Asn Lys Val Arg Pro Leu Ser Thr Thr  
 245 250 255  
 Ser Ala Gln Pro Ser Ser Lys Arg Val Thr Val Asn Gln Leu Ala Ala  
 260 265 270  
 Glu Gln Gly Ser Asn Val Asn His Leu Ile Lys Val Thr Asp Gln Ser  
 275 280 285  
 Ile Thr Glu Gly Tyr Asp Asp Ser Asp Gly Ile Ile Lys Ala His Asp  
 290 295 300  
 Ala Glu Asn Leu Ile Tyr Asp Val Thr Phe Glu Val Asp Asp Lys Val  
 305 310 315 320  
 Lys Ser Gly Asp Thr Met Thr Val Asn Ile Asp Lys Asn Thr Val Pro  
 325 330 335  
 Ser Asp Leu Thr Asp Ser Phe Ala Ile Pro Lys Ile Lys Asp Asn Ser  
 340 345 350  
 Gly Glu Ile Thr Ala Thr Gly Thr Tyr Asp Asn Thr Asn Lys Gln Ile  
 355 360 365  
 Thr Tyr Thr Phe Thr Asp Tyr Val Asp Lys Tyr Glu Asn Ile Lys Ala  
 370 375 380  
 His Leu Lys Leu Thr Ser Tyr Ile Asp Lys Ser Lys Val Pro Asn Asn  
 385 390 395 400  
 Asn Thr Lys Leu Asp Val Glu Tyr Lys Thr Ala Leu Ser Ser Val Asn  
 405 410 415  
 Lys Thr Ile Thr Val Glu Tyr Gln Lys Pro Asn Glu Asn Arg Thr Ala  
 420 425 430  
 Asn Leu Gln Ser Met Phe Thr Asn Ile Asp Thr Lys Asn His Thr Val  
 435 440 445  
 Glu Gln Thr Ile Tyr Ile Asn Pro Leu Arg Tyr Ser Ala Lys Glu Thr  
 450 455 460  
 Asn Val Asn Ile Ser Gly Asn Gly Asp Glu Gly Ser Thr Ile Ile Asp  
 465 470 475 480  
 Asp Ser Thr Ile Ile Lys Val Tyr Lys Val Gly Asp Asn Gln Asn Leu  
 485 490 495  
 Pro Asp Ser Asn Arg Ile Tyr Asp Tyr Ser Glu Tyr Glu Asp Val Thr  
 500 505 510  
 Asn Asp Asp Tyr Ala Gln Leu Gly Asn Asn Asn Asp Val Asn Ile Asn  
 515 520 525  
 Phe Gly Asn Ile Asp Ser Pro Tyr Ile Ile Lys Val Ile Ser Lys Tyr  
 530 535 540

-continued

Asp	Pro	Asn	Lys	Asp	Asp	Tyr	Thr	Thr	Ile	Gln	Gln	Thr	Val	Thr	Met
545					550					555					560
Gln	Thr	Thr	Ile	Asn	Glu	Tyr	Thr	Gly	Glu	Phe	Arg	Thr	Ala	Ser	Tyr
			565						570					575	
Asp	Asn	Thr	Ile	Ala	Phe	Ser	Thr	Ser	Ser	Gly	Gln	Gly	Gln	Gly	Asp
			580					585					590		
Leu	Pro	Pro	Glu	Lys	Thr	Tyr	Lys	Ile	Gly	Asp	Tyr	Val	Trp	Glu	Asp
		595					600					605			
Val	Asp	Lys	Asp	Gly	Ile	Gln	Asn	Thr	Asn	Asp	Asn	Glu	Lys	Pro	Leu
	610					615					620				
Ser	Asn	Val	Leu	Val	Thr	Leu	Thr	Tyr	Pro	Asp	Gly	Thr	Ser	Lys	Ser
	625				630					635					640
Val	Arg	Thr	Asp	Glu	Glu	Gly	Lys	Tyr	Gln	Phe	Asp	Gly	Leu	Lys	Asn
			645						650					655	
Gly	Leu	Thr	Tyr	Lys	Ile	Thr	Phe	Glu	Thr	Pro	Glu	Gly	Tyr	Thr	Pro
			660					665						670	
Thr	Leu	Lys	His	Ser	Gly	Thr	Asn	Pro	Ala	Leu	Asp	Ser	Glu	Gly	Asn
		675					680					685			
Ser	Val	Trp	Val	Thr	Ile	Asn	Gly	Gln	Asp	Asp	Met	Thr	Ile	Asp	Ser
	690					695					700				
Gly	Phe	Tyr	Gln	Thr	Pro	Lys	Tyr	Ser	Leu	Gly	Asn	Tyr	Val	Trp	Tyr
	705				710					715					720
Asp	Thr	Asn	Lys	Asp	Gly	Ile	Gln	Gly	Asp	Asp	Glu	Lys	Gly	Ile	Ser
			725						730					735	
Gly	Val	Lys	Val	Thr	Leu	Lys	Asp	Glu	Asn	Gly	Asn	Ile	Ile	Ser	Thr
			740					745					750		
Thr	Thr	Thr	Asp	Glu	Asn	Gly	Lys	Tyr	Gln	Phe	Asp	Asn	Leu	Asn	Ser
			755				760					765			
Gly	Asn	Tyr	Ile	Val	His	Phe	Asp	Lys	Pro	Ser	Gly	Met	Thr	Gln	Thr
	770					775					780				
Thr	Thr	Asp	Ser	Gly	Asp	Asp	Asp	Glu	Gln	Asp	Ala	Asp	Gly	Glu	Glu
					790					795					800
Val	His	Val	Thr	Ile	Thr	Asp	His	Asp	Asp	Phe	Ser	Ile	Asp	Asn	Gly
				805					810					815	
Tyr	Tyr	Asp	Asp	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser
			820					825					830		
Asp	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
		835					840					845			
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp
	850					855					860				
Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Asp	Ser	Gly	Leu	Asp
	865				870					875				880	
Asn	Ser	Ser	Asp	Lys	Asn	Thr	Lys	Asp	Lys	Leu	Pro	Asp	Thr	Gly	Ala
				885					890					895	
Asn	Glu	Asp	His	Asp	Ser	Lys	Gly	Thr	Leu	Leu	Gly	Ala	Leu	Phe	Ala
			900					905					910		
Gly	Leu	Gly	Ala	Leu	Leu	Leu	Gly	Lys	Arg	Arg	Lys	Asn	Arg	Lys	Asn
		915					920					925			
Lys	Asn														
	930														

<210> SEQ ID NO 11  
 <211> LENGTH: 15  
 <212> TYPE: PRT

-continued

&lt;213&gt; ORGANISM: Staphylococcus epidermidis

&lt;400&gt; SEQUENCE: 11

Ile Ile Gln Met Lys Leu Val Lys Glu Ala Asp Thr Thr Phe Glu  
 1 5 10 15

&lt;210&gt; SEQ ID NO 12

&lt;211&gt; LENGTH: 8

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Staphylococcus epidermidis

&lt;400&gt; SEQUENCE: 12

Lys Val Tyr Leu Val Gln Gln Ile  
 1 5

&lt;210&gt; SEQ ID NO 13

&lt;211&gt; LENGTH: 1464

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Staphylococcus epidermidis

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: CDS

&lt;222&gt; LOCATION: (1)..(1464)

&lt;223&gt; OTHER INFORMATION:

&lt;400&gt; SEQUENCE: 13

atg aaa aag ttt aac att aaa cat tca ttt atg ctt acg ggc ttt gct 48  
 Met Lys Lys Phe Asn Ile Lys His Ser Phe Met Leu Thr Gly Phe Ala  
 1 5 10 15

ttc atg gta act aca tca tta ttc agt cac caa gca cat gct gaa ggt 96  
 Phe Met Val Thr Thr Ser Leu Phe Ser His Gln Ala His Ala Glu Gly  
 20 25 30

aat cat cct att gac att aat ttt tct aaa gat caa att gat aga aat 144  
 Asn His Pro Ile Asp Ile Asn Phe Ser Lys Asp Gln Ile Asp Arg Asn  
 35 40 45

aca gct aag agc aat att atc aat cga gtg aat gac act agt cgc aca 192  
 Thr Ala Lys Ser Asn Ile Ile Asn Arg Val Asn Asp Thr Ser Arg Thr  
 50 55 60

gga att agt atg aat tcg gat aat gat tta gat aca gat atc gtt tca 240  
 Gly Ile Ser Met Asn Ser Asp Asn Asp Leu Asp Thr Asp Ile Val Ser  
 65 70 75 80

aat agt gac tca gaa aat gac aca tat tta gat agt gat tca gat tca 288  
 Asn Ser Asp Ser Glu Asn Asp Thr Tyr Leu Asp Ser Asp Ser Asp Ser  
 85 90 95

gac agt gac tca gat tca gat agt gac tca gat tca gat agt gac tca 336  
 Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser  
 100 105 110

gat tca gat agt gac tca gat tca gac agt gat tca gac tca gat agt 384  
 Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser  
 115 120 125

gac tca gat tca gac agt gat tca gac tca gat agt gat tca gat tca 432  
 Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser  
 130 135 140

gac agt gat tca gat tca gac agt gac tca gac tca gac agt gat tca 480  
 Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser  
 145 150 155 160

gat tca gat agt gat tca gat tca gat agt gat tca gat tca gat agt 528  
 Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser  
 165 170 175

gat tca gat tca gac agt gac tca gac tca gac agt gat tca gat tca 576  
 Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser  
 180 185 190

gat agt gat tca gac tca gat agt gac tca gat tca gat agt gat tca 624



-continued

&lt;213&gt; ORGANISM: Staphylococcus epidermidis

&lt;400&gt; SEQUENCE: 14

```

Met Lys Lys Phe Asn Ile Lys His Ser Phe Met Leu Thr Gly Phe Ala
1          5          10          15
Phe Met Val Thr Thr Ser Leu Phe Ser His Gln Ala His Ala Glu Gly
20          25          30
Asn His Pro Ile Asp Ile Asn Phe Ser Lys Asp Gln Ile Asp Arg Asn
35          40          45
Thr Ala Lys Ser Asn Ile Ile Asn Arg Val Asn Asp Thr Ser Arg Thr
50          55          60
Gly Ile Ser Met Asn Ser Asp Asn Asp Leu Asp Thr Asp Ile Val Ser
65          70          75          80
Asn Ser Asp Ser Glu Asn Asp Thr Tyr Leu Asp Ser Asp Ser Asp Ser
85          90          95
Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser
100         105         110
Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser
115         120         125
Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser
130         135         140
Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser
145         150         155         160
Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser
165         170         175
Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser
180         185         190
Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser
195         200         205
Asp Ser Gly Thr Ser Ser Gly Lys Gly Ser His Thr Gly Lys Lys Pro
210         215         220
Gly Asn Pro Lys Gly Asn Thr Asn Arg Pro Ser Gln Arg His Thr Asn
225         230         235         240
Gln Pro Gln Arg Pro Lys Tyr Asn Gln Thr Asn Gln Asn Asn Ile Asn
245         250         255
Asn Ile Asn His Asn Ile Asn His Thr Arg Thr Ser Gly Asp Gly Ala
260         265         270
Pro Phe Lys Arg Gln Gln Asn Ile Ile Asn Ser Asn Ser Gly His Arg
275         280         285
Asn Gln Asn Asn Ile Asn Gln Phe Ile Trp Asn Lys Asn Gly Phe Phe
290         295         300
Lys Ser Gln Asn Asn Thr Glu His Arg Met Asn Ser Ser Asp Asn Thr
305         310         315         320
Asn Ser Leu Ile Ser Arg Phe Arg Gln Leu Ala Thr Gly Ala Tyr Lys
325         330         335
Tyr Asn Pro Phe Leu Ile Asn Gln Val Lys Asn Leu Asn Gln Leu Asp
340         345         350
Gly Lys Val Thr Asp Ser Asp Ile Tyr Ser Leu Phe Arg Lys Gln Ser
355         360         365
Phe Arg Gly Asn Glu Tyr Leu Asn Ser Leu Gln Lys Gly Thr Ser Tyr
370         375         380
Phe Arg Phe Gln Tyr Phe Asn Pro Leu Asn Ser Ser Lys Tyr Tyr Glu
385         390         395         400

```

-continued

---

```

Asn Leu Asp Asp Gln Val Leu Ala Leu Ile Thr Gly Glu Ile Gly Ser
      405                      410                      415
Met Pro Glu Leu Lys Lys Pro Thr Asp Lys Glu Asp Lys Asn His Ser
      420                      425                      430
Ala Phe Lys Asn His Ser Ala Asp Glu Ile Thr Thr Asn Asn Asp Gly
      435                      440                      445
His Ser Lys Asp Tyr Asp Lys Lys Lys Lys Ile His Arg Ser Leu Leu
      450                      455                      460
Ser Leu Ser Ile Ala Ile Ile Gly Ile Phe Leu Gly Val Thr Gly Leu
      465                      470                      475                      480
Tyr Ile Phe Arg Arg Lys Lys
      485

```

```

<210> SEQ ID NO 15
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Staphylococcus epidermidis
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (12)..(12)
<223> OTHER INFORMATION: n=(a or c or t or g)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (6)..(6)
<223> OTHER INFORMATION: n=(a or c or t or g)

```

```

<400> SEQUENCE: 15

```

```

gaytcngayt cngayagy

```

18

```

<210> SEQ ID NO 16
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Staphylococcus epidermidis

```

```

<400> SEQUENCE: 16

```

```

Thr Tyr Thr Phe Thr Asp Tyr Val Asp
1          5

```

```

<210> SEQ ID NO 17
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Staphylococcus epidermidis
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (3)..(3)
<223> OTHER INFORMATION: Xaa can be any amino acid

```

```

<400> SEQUENCE: 17

```

```

Leu Pro Xaa Thr Gly
1          5

```

```

<210> SEQ ID NO 18
<211> LENGTH: 60
<212> TYPE: PRT
<213> ORGANISM: Staphylococcus epidermidis

```

```

<400> SEQUENCE: 18

```

```

Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Lys Asn
1          5                      10                      15

```

```

Ala Lys Asp Lys Leu Pro Asp Thr Gly Ala Asn Glu Asp His Asp Ser
      20                      25                      30

```

```

Lys Gly Thr Leu Leu Gly Thr Leu Phe Ala Gly Leu Gly Ala Leu Leu
      35                      40                      45

```

-continued

---

Leu Gly Arg Arg Arg Lys Lys Asp Asn Lys Glu Lys  
50 55 60

<210> SEQ ID NO 19  
<211> LENGTH: 60  
<212> TYPE: PRT  
<213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 19

Ser Asp Ser Asp Ser Asp Ser Gly Leu Asp Asn Ser Ser Asp Lys Asn  
1 5 10 15

Thr Lys Asp Lys Leu Pro Asp Thr Gly Ala Asn Glu Asp His Asp Ser  
20 25 30

Lys Gly Thr Leu Leu Gly Ala Leu Phe Ala Gly Leu Gly Ala Leu Leu  
35 40 45

Leu Gly Lys Arg Arg Lys Asn Arg Lys Asn Lys Asn  
50 55 60

<210> SEQ ID NO 20  
<211> LENGTH: 60  
<212> TYPE: PRT  
<213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 20

Asp Lys Asn His Ser Ala Phe Lys Asn His Ser Ala Asp Glu Ile Thr  
1 5 10 15

Thr Asn Asn Asp Gly His Ser Lys Asp Tyr Asp Lys Lys Lys Ile  
20 25 30

His Arg Ser Leu Leu Ser Leu Ser Ile Ala Ile Ile Gly Ile Phe Leu  
35 40 45

Gly Val Thr Gly Leu Tyr Ile Phe Arg Arg Lys Lys  
50 55 60

<210> SEQ ID NO 21  
<211> LENGTH: 18  
<212> TYPE: DNA  
<213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 21

gatgatgaat tatcagac 18

<210> SEQ ID NO 22  
<211> LENGTH: 19  
<212> TYPE: DNA  
<213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 22

caggaggcaa gtcaccttg 19

<210> SEQ ID NO 23  
<211> LENGTH: 27  
<212> TYPE: DNA  
<213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 23

gccgatccc caattccaga ggattca 27

<210> SEQ ID NO 24  
<211> LENGTH: 27  
<212> TYPE: DNA  
<213> ORGANISM: Staphylococcus epidermidis

-continued

---

<400> SEQUENCE: 24  
gccaagctta ttgttagaac ctgactc 27

<210> SEQ ID NO 25  
<211> LENGTH: 17  
<212> TYPE: DNA  
<213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 25  
gattcagata gccattc 17

<210> SEQ ID NO 26  
<211> LENGTH: 17  
<212> TYPE: DNA  
<213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 26  
ctgagtcact gtctgag 17

<210> SEQ ID NO 27  
<211> LENGTH: 28  
<212> TYPE: DNA  
<213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 27  
cccggatccg ctgaagacaa tcaattag 28

<210> SEQ ID NO 28  
<211> LENGTH: 27  
<212> TYPE: DNA  
<213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 28  
cccaagctta attatccccc tgtgctg 27

<210> SEQ ID NO 29  
<211> LENGTH: 31  
<212> TYPE: DNA  
<213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 29  
cccggatccg aggagaatac agtacaagac g 31

<210> SEQ ID NO 30  
<211> LENGTH: 33  
<212> TYPE: DNA  
<213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 30  
cccgtacct agtttttcag gaggaagtc acc 33

<210> SEQ ID NO 31  
<211> LENGTH: 30  
<212> TYPE: DNA  
<213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 31  
cccggatccg aaggtaatca tcctattgac 30

<210> SEQ ID NO 32  
<211> LENGTH: 37  
<212> TYPE: DNA  
<213> ORGANISM: Staphylococcus epidermidis



-continued

---

<400> SEQUENCE: 32  
 cccaagctta cttttttctt ctaaagatat atagtcc 37

<210> SEQ ID NO 33  
 <211> LENGTH: 30  
 <212> TYPE: DNA  
 <213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 33  
 cccgaattca attatcccc tgtgctgttg 30

<210> SEQ ID NO 34  
 <211> LENGTH: 33  
 <212> TYPE: DNA  
 <213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 34  
 cccgaattct agtttttcag gaggcaagtc acc 33

<210> SEQ ID NO 35  
 <211> LENGTH: 28  
 <212> TYPE: DNA  
 <213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 35  
 ggcgatccg aagtaatca tcctattg 28

<210> SEQ ID NO 36  
 <211> LENGTH: 28  
 <212> TYPE: DNA  
 <213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 36  
 ggcaagcttc taaatatgtg tcattttc 28

<210> SEQ ID NO 37  
 <211> LENGTH: 4  
 <212> TYPE: PRT  
 <213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 37  
 Gly Gly Ala Gly  
 1

<210> SEQ ID NO 38  
 <211> LENGTH: 13  
 <212> TYPE: PRT  
 <213> ORGANISM: Staphylococcus epidermidis

<400> SEQUENCE: 38  
 Asp Tyr Ser Glu Tyr Glu Asp Val Thr Asn Asp Asp Tyr  
 1 5 10

<210> SEQ ID NO 39  
 <211> LENGTH: 5  
 <212> TYPE: PRT  
 <213> ORGANISM: Staphylococcus aureus

<400> SEQUENCE: 39  
 Leu Pro Asp Thr Gly  
 1 5

---

89

What is claimed is:

- 1. An isolated protein having the amino acid sequence SEQ ID NO:10.
- 2. An isolated protein encoded by a nucleic acid having the sequence SEQ ID NO: 7.
- 3. The protein of claim 1, wherein the protein is expressed from a vector in a living organism.
- 4. A pharmaceutical composition comprising the protein of claim 1, in a pharmaceutically acceptable carrier.
- 5. The protein of claim 1 immobilized on a solid phase.
- 6. An isolated protein encoded by a nucleic acid having the sequence of nucleotides 102 to 2894 in SEQ ID NO:7.
- 7. An isolated polypeptide having the amino acid sequence of amino acids 32 to 961 of SEQ ID NO:10.
- 8. The isolated protein of claim 6 wherein said protein has fibrinogen binding activity.

90

- 9. The isolated protein of claim 1 wherein said protein has fibrinogen binding activity.
- 10. The isolated protein of claim 2 wherein said protein has fibrinogen binding activity.
- 11. An isolated polypeptide consisting essentially of the amino acid sequence of amino acids 51-598 of SEQ ID NO:10.
- 12. The isolated polypeptide of claim 11 wherein said polypeptide has fibrinogen binding activity.
- 13. An isolated polypeptide encoded by a nucleic acid consisting essentially of the sequence of nucleotides 252-1895 of SEQ ID NO: 7.
- 14. The isolated polypeptide of claim 13 wherein said polypeptide has fibrinogen binding activity.

\* \* \* \* \*

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,473,762 B2  
APPLICATION NO. : 10/689082  
DATED : January 6, 2009  
INVENTOR(S) : Foster et al.

Page 1 of 1


It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page Item (54):

please change --**PROTEINS AND POLYPEPTIDES FROM COAGULASLASE-  
NEGATIVE STAPHYLOCOCCI**-- to "**PROTEINS AND POLYPEPTIDES  
FROM COAGULASE-NEGATIVE STAPHYLOCOCCI**".

Signed and Sealed this

Third Day of March, 2009



JOHN DOLL  
*Acting Director of the United States Patent and Trademark Office*

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,473,762 B2  
APPLICATION NO. : 10/689082  
DATED : January 6, 2009  
INVENTOR(S) : Foster et al.

Page 1 of 1


It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page Item (54) and Column 1, lines 1-3:  
please change --**PROTEINS AND POLYPEPTIDES FROM  
COAGULASLASE-NEGATIVE STAPHYLOCOCCI**-- to "**PROTEINS AND  
POLYPEPTIDES FROM COAGULASE-NEGATIVE STAPHYLOCOCCI**".

This certificate supersedes the Certificate of Correction issued March 3, 2009.

Signed and Sealed this

Thirty-first Day of March, 2009



JOHN DOLL  
*Acting Director of the United States Patent and Trademark Office*